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Introduction 
I. The pancreas 
 A.  Anatomy and histology 
The mature pancreas is an abdominal gland lying behind the stomach and belonging to 
the digestive tract and endocrine system found in all vertebrates. It plays an important role in 
maintaining the nutritional homeostasis through the secretion of enzymes and hormones. This 
organ is anatomically subdivided into the head, that lies near the duodenum, the body, found 
behind the base of the stomach, and the tail, which extends to the hilum of the spleen (Figure 
1). The mammalian pancreas is composed of two morphologically distinct compartments: the 
exocrine tissue and the endocrine compartment (Slack, 1995).  
 
Figure 1: Anatomy and histology of the human pancreas (adapted from different sources). 
The adult pancreas is a glandular organ connected to the duodenum, the stomach and the spleen. It can be 
subdivided into two distinct compartments: the exocrine tissue, comprising acinar cells and ducts, and the 
endocrine compartment which consists of small cell clusters termed islets of Langerhans making up only 2% of the 
pancreatic mass.  
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 B.  Physiology of the pancreas  
 The exocrine pancreas 1.
The exocrine compartment of the pancreas is composed of acinar and duct cells and 
represents approximately 98% of the total organ mass. Arranged in clusters of cells termed 
acini, acinar cells produce and secrete the digestive enzymes of the pancreatic juice. These 
digestives enzymes, such as lipase, trypsin and α-amylase, are released into a branched network 
of tubules composed of epithelial ductal cells and travel through the main pancreatic duct to the 
bile duct in an inactive form (zymogen). These enzymes are then activated by a duodenal 
enzyme termed enteropeptidase, and eventually reach the intestinal tract though connections to 
the duodenum (Figure 1). They subsequently aid in the metabolism of nutrients to generate 
simple substances from more complex ones, such as carbohydrates, proteins and lipids, which 
can be then absorbed by the intestine. 
 
 The endocrine pancreas 2.
The endocrine compartment represents less than 2% of the pancreatic mass and regulate 
nutrient metabolism and maintain glucose homeostasis. This tissue is composed of cells 
organized into highly vascularized functional units termed islets of Langerhans, scattered 
throughout the pancreatic tissue. These islets consist of five cell subtypes, each secreting a 
particular endocrine hormone (that will be further described in the paragraphs below): the 
insulin
+
 beta (β)-cells, the glucagon
+
 alpha (α)-cells, the somatostatin
+
 delta (δ)-cells, pancreatic 
polypeptide (PP)
+
-cells and the ghrelin
+
 epsilon (ε)-cells (Figure 2) (Adrian et al., 1978; 
Collombat et al., 2006; Csaba and Dournaud, 2001; Heller et al., 2005; Prado et al., 2004; 
Roncoroni et al., 1983). Endocrine hormones are secreted in the circulatory system through an 
intricate blood vessel network, their release from the different islet cell types being regulated by 
autocrine and paracrine interactions. 
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The five hormone-producing cell types are arranged differently depending on the 
species. In rodents, islets are characterized by a predominant proportion of -cells in the core of 
the cluster with a heterogeneous layer of -, -, PP-cells and ε-cells in the periphery (Figure 
2A). Human islets display no particular order or arrangement but -, - and -cells, in close 
relationship with each other, are aligned along the blood vessels irrigating the whole structure 
(Figure 2B) (Cabrera et al., 2006). Moreover, human islet composition varies from rodents with 
a larger amount of -cells and a decreased content of -cells.  
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Figure 2: Islet architecture with respective hormone-expressing cell proportions in mice 
and in humans. 
 
 
a) Alpha-cells 
 The α-cells represent about 15% of the total endocrine cells in rodents while they make 
up 33-46% of the human islet cells (Figure 2). These cells are responsible for synthesizing and 
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secreting the peptide hormone glucagon. This hormone is released in response to hypoglycemia 
and acts to elevate blood sugar levels by promoting glucose release and/or neogenesis.  
Glucagon interacts with receptors localized on hepatocytes resulting in the activation of 
the glycogen phosphorylase enzyme. This enzyme hydrolyses liver-stored glycogen into 
individual glucose molecules, which are subsequently released into the bloodstream in a process 
known as glycogenolysis.  
As the stores become depleted, glucagon then promotes the liver to synthesize additional 
glucose from pyruvate and glycerol by gluconeogenesis, in a series of eleven enzyme-catalyzed 
reactions. This hormone also stimulates glucose synthesis by inducing lipolysis in the 
adipocytes, freeing glycerol that will be metabolized into glucose (Liljenquist et al., 1974). 
 
b) Beta-cells 
The β-cells correspond to the major population of the pancreatic islets, representing 
about 65 to 80% of the total endocrine cells in mice (Figure 2). The primary function of these 
cells is to store and release insulin upon increased blood glucose levels following food intake. β-
cells can respond quickly to spikes in blood glucose concentrations by releasing some of its 
stored insulin while simultaneously producing more.  
Insulin is a hormone composed of two polypeptide chains (A and B), linked together by 
disulfide bonds and a connecting (C)-peptide bridge. It is first synthesized as a single 
polypeptide called pre-proinsulin in pancreatic β-cells, then processed to proinsulin. The latter 
undergoes maturation into active insulin through the action of cellular endopeptidases known as 
prohormone convertases (PC1 and PC2). These endopeptidases cleave at 2 positions, releasing 
the C-peptide fragment, and leaving 2 peptide chains (A and B) linked by 2 disulfide bonds. The 
resulting mature insulin is packaged into secretory granules waiting stimuli to be released.  
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Insulin acts in order to reduce glycemic levels by promoting the storage and/or 
metabolism of glucose in the liver, muscle and/or adipose tissues. This hormone is secreted in 
two phases:  
 The first phase release is triggered rapidly in response to increased blood glucose 
levels (Figure 3), 
 The second phase corresponds to a sustained, slow release of newly formed 
vesicles.  
Glucose is transported into β-cells by a glucose transporter: GLUT 1 for humans and 
Glut 2 for rodents. Glucose is then metabolized into Glucose-6-phosphate (G-6-P) by a specific 
hexokinase, the glucokinase, which produces multiple, high-energy ATP molecules leading to a 
rise in the ATP/ADP ratio within the cell. This increase in intracellular ATP/ADP ratio causes 
the closure of the ATP sensitive potassium (K
+
) transporter channels. This in turn prevents K
+
 
ions from leaving the cell by facilitated diffusion leading to a build up of K
+
 ions. As a result, 
the inner part of the cell becomes positively charger with respect to the outside, causing cell 
membrane depolarization. This change in membrane potential difference opens the calcium 
(Ca
2+
) voltage-dependent channels allowing an influx of Ca
2+
 ions by facilitated diffusion 
(Mueckler, 1994). The resulting increase in intracellular Ca
2+
 ions triggers the fusion of insulin-
containing vesicles to the plasma membrane and thereby release of the insulin by exocytosis 
(Figure 3).  
Insulin exerts its hypoglycemic role through different processes (Figure 3):  
 Increase of glycogen synthesis: storage of the glucose in hepatocytes in the form 
of glycogen.  
 Decrease of glucose production (neoglucogenesis) by the liver (Michael et al., 
2000). 
 Increase of glucose uptake by adipocytes and skeletal muscle cells (Bergman and 
Ader, 2000) 
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Figure 3: Insulin production and action (adapted from betacellbiology.org) 
In the mouse, glucose enters the β-cell via the glucose transporter Glut2 and is transformed into G-6-P by 
glucokinase (Gck) during glycolysis. Glycolysis generates multiple ATP molecules leading to an increase of the 
ATP/ADP ratio in the cell and the closing the ATP-sensitive K
+
 channel. This results in the depolarization of the 
plasma membrane and the opening of the voltage-gated Ca
2+
 channels. Extracellular Ca
2+
 flows into the cell 
triggering the fusion of the insulin granules with the plasma membrane and the release of insulin into the 
bloodstream by exocytosis. Insulin will then induce glycogen synthesis in the liver and stimulate glucose uptake by 
adipocytes and muscle cells. 
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c) Delta-cells 
-cells represent less than 5% of the entire endocrine cell population. They secrete 
somatostatin, a hormone implicated in the local control of - and -cells acting by inhibiting 
insulin and glucagon release and thereby allowing a fine tuning of the glycaemia (Hauge-Evans 
et al., 2009). These endocrine cells harbor the cholecystokinin B receptor (CCKBR, which 
respond to gastrin) and the M3 receptors (which respond to acetylcholine). Respectively, these 
receptors will increase and decrease somatostatin output from the -cells. Somatostatin release 
can be also increased by vasoactive intestinal peptide (VIP). 
 
d) PP-cells 
PP-cells are very few in number as they represent less than 1% of the total islet cell 
population. These endocrine cells are responsible for the production and the secretion of 
pancreatic polypeptide, a peptide involved in the regulation of pancreatic secretion activities 
(Lee et al., 2001b). Although its physiological role in the pancreas remains relatively unclear, it 
has been shown to have effects on digestion by reducing pancreatic exocrine enzyme secretions, 
gastrointestinal secretions and intestinal motility (Adrian et al., 1978; Artner et al., 2006; 
Murphy and Bloom, 2004; Roncoroni et al., 1983; Slack, 1995) 
 
e) Epsilon-cells 
-cells were recently discovered in the mouse pancreas as the fifth endocrine cell type, 
producing ghrelin (Date et al., 2002; Heller et al., 2005; Prado et al., 2004). These cells are 
present from late embryogenesis until 2 days postpartum. Ghrelin is a hunger-stimulating 
peptide and hormone also produced by the stomach, the intestine and the α-cells of the pancreas. 
This hormone stimulates gastric emptying and is involved in appetite and hormone secretion but 
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its function remains unclear regarding glucidic homeostasis (Dezaki et al., 2004; Murphy and 
Bloom, 2006; Prado et al., 2004; Wierup et al., 2014). 
II. Mouse Pancreatic Development 
In the following section, I will describe the different steps of pancreas development from 
its induction to its specification (Figure 4) and I will cover the main genetic determinants acting 
during these processes focusing mainly on the well-studied mouse pancreas. 
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Figure 4: Schematic representation of the chronological progression of the embryonic 
mouse pancreatic morphogenesis. (Adapted from different sources) 
(A) Patterning of the pancreatic field within the foregut tube. This region is composed of cells that will bulge from 
the foregut to give rise to the pancreas. (B) At E9.5, the dorsal and ventral foregut endoderm thicken and evaginate 
into the surrounding mesenchyme. (C) Active proliferation of pancreatic progenitors, formation of microlumens 
and compartmentalization of pancreatic epithelium into « (Ptf1A
+
 pre-acinar) tip » and « (Nkx6
+
 pre-
endocrine/duct) trunk » domains  (D) Gut rotation starts at E14.5 bringing the ventral and dorsal counterparts into 
close contact prior to their fusion into a single organ. Subsequently, the first islet aggregates are detected. (E) 
Ventral and dorsal parts of the pancreas subsequently fuse in a single organ assuming the final and mature organ 
structure. Concurrently, well-formed islets are detected within the exocrine population. 
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Mature pancreas 
Nkx6+ pre-endocrine/duct trunk 
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 A. Endoderm patterning and pancreas induction 
During mouse embryogenesis, the pancreas develops from a pre-patterned region of the 
primitive gut endoderm. The earliest histological evidences of the pancreas development are 
recognizable by approximately 9 days of development (embryonic day (E) 9.0-9.5). Two 
pancreatic buds arise as thickenings along the dorsal and ventral surfaces of the posterior 
foregut, near the prospective hepatic endoderm. The development of these two pancreatic 
outgrowths is temporally distinct, the dorsal bud being first observed at E9.0, while its ventral 
counterpart emerges at E9.5 (Figure 4) (Pictet et al., 1972; Slack, 1995; Spooner et al., 1970). 
Such a difference is due to different signals originating from neighboring mesoderm-derived 
tissues which secretes soluble factors, such as Fibroblast Growth Factor (FGF), activin and 
retinoid acid (RA) (Dessimoz et al., 2006; Kumar et al., 2003). The dorsal bud is being 
surrounded by the notochord and the dorsal aorta while the ventral bud is in contact with the 
cardiac mesenchyme (Oliver-Krasinski and Stoffers, 2008). Over the next day, from E9.0 to 
E10.5, the dorsal pancreatic epithelium continues to thicken to form a proper bud (Figure 4) 
(Pictet et al., 1972; Spooner et al., 1970). FGF4 acts directly on the endoderm by suppressing 
the transcription factor (TF) genes Nkx2.1 and Hhex, required for foregut endoderm formation, 
and by promoting the expression of the TF gene pancreatic and duodenal homeobox 1 (Pdx1) 
required for pancreas formation (Dessimoz et al., 2006; Wells and Melton, 2000). RA 
posteriorizes the gut endoderm (thereby promoting pancreas-organ allocation during 
gastrulation) and represents a critical factor for pancreatic development as it was shown that 
blocking RA signaling inhibits pancreas specification (Alanentalo et al., 2007; Bayha et al., 
2009; Kumar et al., 2003; Stafford et al., 2004; Stafford and Prince, 2002; Stafford et al., 2006). 
In addition, the dorsal pancreas fails to bud in mice lacking a critical RA-synthesizing enzyme 
(in RALDH2 null mice) (Akiyama et al., 2005; Molotkov et al., 2005).  
Subsequent pancreas morphogenesis can be subdivided into two overlapping waves of 
development: the primary and secondary transitions (Pictet et al., 1972).  
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 B. Primary transition (E9.5-E12.5): pancreas budding and multipotent 
pancreatic progenitor cell (MPC) proliferation 
The primary regulatory transition is related to organ determination and corresponds to 
phase of active proliferation of pancreatic progenitors in the protodifferentiated state, these 
being committed to the pancreatic fate (Pictet et al., 1972) and characterized by a minimal 
expression of pancreatic-specific proteins. 
Pancreatic fate allocation is reinforced by interactions between a network of TFs: Pdx1, 
Hb9, Ptf1a, Sox9, and HNF1β are widely expressed in the MPCs of the dorsal and ventral buds 
(Gu et al., 2002; Haumaitre et al., 2005; Henseleit et al., 2005; Kawaguchi et al., 2002; Seymour 
et al., 2007) and play multiple roles during pancreas development.  
Early pancreatic transcriptional program 
a) Pdx1 
The first important TF to be identified regarding pancreas development in mice and 
humans was Pdx1 (Jonsson et al., 1994; Ohlsson et al., 1993; Stoffers et al., 1997). Indeed, in 
both mice and humans, Pdx1 deficiency results in complete pancreas agenesis at birth due to an 
arrested growth of the pancreatic primordia at a very early stage (Jonsson et al., 1994; Offield et 
al., 1996; Schwitzgebel et al., 2003; Stoffers et al., 1997). In addition, upon Pdx1 loss-of-
function, a highly under-developed dorsal bud is observed, whereas ventral bud cells appear to 
be either re-routed to the common bile duct or arrested in a non-proliferative pancreas-specified 
state (Jonsson et al., 1994; Offield et al., 1996). Taken together, these results demonstrated that 
the specification of the endoderm toward a pancreatic fate does not rely on Pdx1 expression, but 
it is necessary for development beyond initial bud formation. Interestingly, a number of “first 
wave” immature endocrine cells can develop in the absence of a functional Pdx1 allele, 
suggesting that some of these can be specified in a Pdx1-independant fashion (Ahlgren et al., 
1996; Offield et al., 1996). Strong levels of Pdx1 are detected as early as E8.5 in the dorsal and 
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ventral pancreatic endoderm (Apelqvist et al., 1999; Guz et al., 1995), such an expression being 
maintained at later stages in β-cells and in a subset of δ-cells (Chu et al., 2001; Jensen et al., 
2000). Interestingly, Pdx1 was found to be required for β-cell proliferation and survival as its 
ablation induces a dramatic decrease in β-cell numbers (Crawford et al., 2009). The conditional 
inactivation of this TF at different developmental stages, as well as in mature β-cells, further 
outlined its requirement to specify and maintain the β-cell phenotype (Ahlgren et al., 1998; 
Holland et al., 2005). In the adult pancreas, Pdx1 plays a critical role in the regulation of the 
transcription of genes associated with the β-cell identity, such as the expression of Glut2, islet 
amyloid polypeptide (IAPP), and glucokinase (Chakrabarti et al., 2002; Leonard et al., 1993; 
Macfarlane et al., 2000; Miller et al., 1994; Ohlsson et al., 1993; Waeber et al., 1996; Watada et 
al., 1996). 
b) Ptf1a 
The pancreas-specific transcription factor 1a (Ptf1a) is a bHLH factor acting in the 
regulation of exocrine gene transcription (Krapp et al., 1996; Rose et al., 2001). Ptf1a is co-
expressed with Pdx1 in both the dorsal and ventral pancreatic epithelia, from E9.0 to E9.5, and 
is essential for pancreas organogenesis in mice and humans (Kawaguchi et al., 2002; Krapp et 
al., 1998; Sellick et al., 2004). At E12.5, Ptf1a expression segregates to the growing tips of the 
branching epithelium and ultimately to acinar cells. Ptf1a null mice lack the ventral pancreas 
with an arrested growth and differentiation of the dorsal bud, however, like Pdx1, Ptf1a is not 
necessary for initial pancreas formation (Kawaguchi et al., 2002; Krapp et al., 1998). In 
addition, there is a complete absence of exocrine development in these mutant mice, but one can 
detect a small number of relatively mature β- and α-cells (Kawaguchi et al., 2002). Tracing the 
cells that normally contribute to the ventral pancreas in Ptf1-deficient mice revealed that these 
cells experience a different outcome by adopting an intestinal fate within the duodenum or the 
common bile duct (Kawaguchi et al., 2002). This led to the conclusion that Ptf1a acts as an 
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MPC organ-allocation switch factor. In addition, double KO animals for Pdx1 and Ptf1a 
displayed a similar phenotype to the Pdx1 single KO, suggesting that Ptf1a acts downstream of 
Pdx1 (Burlison et al., 2008). However, recent studies have shown that Ptf1a interacts with the 
Pdx1 promoter region thus potentiating Pdx1 expression in early pancreatic progenitors and 
later in acinar cells (Wiebe et al., 2007). 
c) Hb9 
Hb9 (also Hlxb9 or Mnx1) is expressed prior Pdx1 at E8 within the notochord and the 
dorsal endoderm and at E9.5, within the ventral endoderm (Apelqvist et al., 1999; Harrison et 
al., 1999). At E12.5, Hb9 expression declines in the periphery but remains in some cells in the 
central pancreatic epithelium before, at later stages, becoming restricted to β-cells (Li et al., 
1999; Li and Edlund, 2001). Hb9 null mice display a complete agenesis of the dorsal pancreas, 
possibly due to a defective notochord function. However, ventral pancreas development 
proceeds normally most likely due to Hb9 expression being activated after Pdx1 (unlike in the 
dorsal pancreas), thus all pancreatic cell types develop, although the β-cells are immature and 
their number is reduced along with a disorganized islet structure (Apelqvist et al., 1999; 
Harrison et al., 1999).  
d) Sox9 
Sox9, a member of the SRY/HMG box family is expressed at E10.5 in the primary 
MPCs (Akiyama et al., 2005). Sox9 expression persists in the endocrine/duct bipotent progenitor 
pool during the secondary transition (further detailed hereafter in Section II.D of the 
Introduction) (Lynn et al., 2007; Seymour et al., 2007) and is maintained in the adult pancreas in 
a subpopulation of the duct epithelium. Ablating Sox9 specifically in early pancreatic MPCs 
results in progenitor depletion and hypoplasia of both the dorsal and ventral pancreas, through 
decreased proliferation, increased cell death, and precocious differentiation. This work therefore 
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demonstrated that Sox9 is essential to maintain MPC proliferation, survival and their 
undifferentiated state (Seymour et al., 2007).  
e) HNF1β 
HNF1β represents another important factor in pancreas progenitor expansion. Its 
expression is detected at E9.5 in the liver and in both pancreatic buds (Haumaitre et al., 2005). It 
becomes confined to the duct/endocrine bipotent progenitor domain during the secondary 
transition and restricted to ductal cells in the postnatal and adult organ (Solar et al., 2009). 
HNF1β ablation leads to the loss of Ptf1a expression and results in a similar phenotype to Ptf1a 
deficiency, namely the absence of a ventral bud and a transient dorsal bud (Haumaitre et al., 
2005). In addition to Ptf1a, HNF1β forms a transcription regulatory cascade with HNF6, a 
regulator of pancreas specification, to control pancreatic progenitor generation and endocrine 
progenitor induction (Maestro et al., 2003; Poll et al., 2006).  
 
 As previously mentioned, the primary transition phase encompasses a proliferative 
epithelial expansion of MPCs and this event is followed by formation of multiple microlumens 
in order to turn the entire pancreatic primordium into a growing epithelial arbor (Figure 4). 
These processes lead to the growth and formation of a correctly sized organ, determined by the 
total number of primary MPCs allocated to the buds (Stanger et al., 2007). This suggests that the 
primary transition suppresses differentiation to allow sufficient proliferation in the 
protodifferentitated state, the Notch pathway being critical for the maintenance and proliferation 
of primary MPCs in association with ongoing epithelial expansion (Norgaard et al., 2003). 
Ablation of various components of the Notch pathway, such as RBPJ, Dll1 and Hes1, indeed 
results in a decrease in organ size due to precocious endocrine differentiation that causes MPC 
pool depletion (Apelqvist et al., 1999; Fujikura et al., 2006; Jensen et al., 2000). 
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Concomitantly, some differentiated endocrine cells can be observed during the primary 
transition. Indeed, glucagon-producing cells begin to appear in the early pancreatic epithelium 
(Herrera, 2000; Kesavan et al., 2009; Pictet et al., 1972; Villasenor et al., 2010). Although 
evidences of insulin, somatostatin, pancreatic polypeptide or ghrelin can be found at the 
transcriptional (Chiang and Melton, 2003) and protein (Jorgensen et al., 2007) levels, insulin
+
 
and glucagon
+
/insulin
+
 cells represent the main cell subtypes detected at this stage (Herrera, 
2000). At E12.5, evagination of the pancreatic epithelium into the surrounding mesenchyme and 
compartmentalization of this epithelium into different domains represent important steps for the 
differentiation of pancreatic cells at later stages. 
 
 C. Tubulogenesis and compartimentalization (E12-E15) 
Tubulogenesis is a critical event during pancreas organogenesis since the tubular 
network will set up the initial tip-trunk compartmentalization (Figure 5). 
 
 
Figure 5: Tip/trunk compartmentalization and tubulogenesis (adapted from (Pan and 
Wright, 2011) 
Only the dorsal bud is shown for clarity. E9-E9.5: A region of gut tube epithelium becomes pancreas-specified, 
forming a bulge of MPC (red), which expands to form a stratified bud of several layers. At E11, one notes the 
formation of multiple microlumens. Subsequently, lumen coalescence, concomitant to tip/trunk segregation (E12.5) 
and proliferation produce an epithelial plexus that is extensive at (E14.5), and now includes proper epithelial tubes. 
The plexus is further remodeled and grows further towards a final hierarchically organized, single tubular arbor. 
Tip regions are in red and contain acinar progenitors while trunk domains are in blue/green with bipotentiality for 
endocrine (blue) or duct (green) fates.   
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The developing epithelial arbor can be considered as two functionally distinct 
compartments termed as tip and trunk domains (Figure 5). The MPCs in the pancreatic buds 
become heterogeneous during developments: tip MPC proliferation extends the arbor and drives 
remodeling of the epithelium, pushing the tip cells outward and leaving behind trunk MPCs with 
a slower division rate (Figure 5) (Masui et al., 2007; Masui et al., 2010; Zhou et al., 2007). The 
tip domain contains acinar progenitors while the trunk region is composed of endocrine-duct 
bipotential progenitors (Figure 5) (Solar et al., 2009; Zhou et al., 2007). Moreover, it was 
shown that Ptf1a is required for tip formation and Nkx6.1 for trunk formation, each factor 
sufficient to transcriptionally cross-repress the alternate lineage program (Figure 4) (Schaffer et 
al., 2010). Fate allocation can be affected if the balance between the tip and trunk domains is 
disturbed. Indeed, increasing the tip domain (should Ptf1a be favored) induces the 
differentiation of more acinar cells, whereas expanding the trunk domain (should Nkx6.1 
predominate) results in more duct/endocrine cells (Schaffer et al., 2010). In addition, Notch 
signaling activation leads to a strong induction of Nkx6.1 expression resulting in a pancreatic 
anlage filled with trunk cells, the opposite phenotype being observed upon Notch signaling 
repression (Afelik and Jensen, 2013; Esni et al., 2004).  
Tip and trunk MPCs will differentiate at later stages during the second wave of pancreas 
development, called secondary transition.  
 
 D. Secondary transition (E13.5-E16.5): endocrine specification and exocrine cell 
development 
 Onset of islet, duct and acinar differentiation 1.
The secondary regulatory transition refers to the conversion of the protodifferentiated 
tissue to fully differentiated cells and is characterized by an increase in pancreas-specific protein 
synthesis.  
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a) Acinar differentiation 
Pro-acinar cells differentiate from distal tip cells synthesizing high levels of acinar 
digestive enzymes (Pictet et al., 1972) by downregulating progenitor-specific TFs and 
upregulating expression of Ptf1a and various digestive enzymes (Esni et al., 2004; Schaffer et 
al., 2010; Seymour et al., 2007; Solar et al., 2009). It was demonstrated that such switch occurs 
at E14.5 by the lineage tracing of CpaI-expressing cells (the enzyme gene Cpa1 could be 
considered a surrogate for Ptf1a, since Ptf1a regulates its expression), which were shown to 
only give rise to acinar cells at E14.5 and not duct or endocrine cells (Masui et al., 2007; Masui 
et al., 2010; Zhou et al., 2007). Few TFs have been shown to be involved in acinar development. 
Ptf1a is crucial for acinar cell differentiation and its loss causes acinar cell agenesis. Another 
factor required for full acinar cell differentiation is Mist1, a bHLH factor. In Mist1-deficient 
mice, acinar development is initiated but the acini do not acquire the rosette-like morphology. 
The differentiation process also involves LRH-1/Nr5a2, a direct target gene of Ptf1a that 
regulates acinar-specific genes (Holmstrom et al., 2011; Thompson et al., 2012) and promotes 
acinar cell proliferation (Benod et al., 2011). This proliferation will then carry on until birth, 
allowing acinar cells to fill the mature pancreas.  
 
b) Islet and duct differentiation 
Concomitantly, « second wave » endocrine cells emerge from within the trunk 
epithelium due to high transient expression of the pro-endocrine TF Ngn3 (Gradwohl et al., 
2000; Gu et al., 2002; Jensen et al., 2000; Schwitzgebel et al., 2000). Indeed, endocrine 
precursors delaminate from the central epithelial cord, further differentiate, and migrate to form 
the islets of Langerhans (Figure 4). Delamination has been suggested to be initiated by Ngn3 
(Gouzi et al., 2011) by triggering a cascade leading to the degradation of E-cadherin and 
delamination, the non-delaminated trunk cells being fated to become duct cells (Schaffer et al., 
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2010; Seymour et al., 2007; Solar et al., 2009). Interestingly, mice lacking Ngn3 fail to develop 
endocrine cells, whereas the exocrine and ductal counterparts appear to develop normally 
(Gradwohl et al., 2000). Of note, Ngn3 expression driven by the Pdx1 promoter induces the 
differentiation of pancreatic bud progenitor cells into endocrine cells, mostly glucagon-
producing cells (Apelqvist et al., 1999; Schwitzgebel et al., 2000).  
The decision between endocrine and ductal lineages involves the regulation of Ngn3 
levels. Scattered cells within the trunk domain activate a low level of Ngn3 (Ngn3LO) and then 
undergo asymmetric cell division to generate one daughter cell with higher Ngn3 expression 
(Ngn3HI), which becomes endocrine-committed. The high level of Ngn3 expression in trunk 
progenitors is necessary and sufficient to trigger delamination away from the epithelium - 
probably involving epithelial to mesenchymal transition (EMT) (Gouzi et al., 2011; Magenheim 
et al., 2011) thanks to the activation of Snai2 (a well known inducer of EMT and cell motility) - 
and to activate the expression of additional transcription factors, which allow endocrine 
precursor cells to move towards a mono-hormone-expressing cell fate (further explained in the 
section II.D.2 of the Introduction) (Gouzi et al., 2011; Naya et al., 1997).  
The distribution of Ngn3 within the trunk domain can be explain by a model called the 
lateral inhibition model (Figure 6) for Notch signaling in which endocrine progenitors prevent 
adjacent cells from adopting an endocrine fate (Lee et al., 2001a). In this model, Ngn3 
expression in endocrine progenitor cells leads to the secretion of the extra-cellular ligand Delta-
like (Dll). The subsequent binding of the ligand to the Notch receptor leads to the intracellular 
activation of Hairy and enhancer of split (Hes), which in turn, inhibits Ngn3 signaling. Hes1 
plays a crucial role in the maintenance of an undifferentiated precursor cell state by negatively 
regulating Ngn3 (Kageyama et al., 2000). 
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Figure 6: Model of lateral inhibition by the Notch signaling pathway.  
The selection process of a pro-endocrine precursor is accomplished by cell–cell signaling between epithelial 
neighbors. This signaling occurs through a progressive strengthening of the expression levels of Ngn3 in the 
differentiating cell (right) (1), with a weakening in neighbors (left). The lateral signaling is mediated through the 
activation of a notch ligand (Delta) controlled by Ngn3 (2). Ligand expression on the differentiating cell activates 
the notch receptor in the neighbor (3), in turn activating the bHLH-type Hes1 repressor gene (4). Hes1 effectively 
reduces Ngn3 expression in these cells (5), silencing other pro- endocrine inputs that the cell may receive (6). The 
absence of Notch stimuli in the cell expressing Ngn3 allows for endocrine differentiation (7). 
 
Ngn3 expression is detected from E8.5 to E15.5, before being reduced to extremely low 
levels. While lineage tracing studies revealed that all endocrine cell types derive from Ngn3-
expressing endocrine precursors (Gu et al., 2002), an elegant study combining the induction of 
Ngn3 at different developmental stages in Ngn3-deficient embryos with lineage tracing 
demonstrated that a window of competence underlies Ngn3 activities (Johansson et al., 2007). 
The stage and the context within which Ngn3-expressing cells arise dictate their endocrine 
progenitor competence (Johansson et al., 2007). Indeed, early Ngn3
+
 cells were found to 
exclusively give rise to α-cells, whereas the activation of Ngn3 at later stages successively led to 
the generation of β- (at E11.5), PP- (at E12.5) and finally δ-cells (after E14.5) (Johansson et al., 
2007). Further analyses confirmed that endocrine cell fate allocation clearly depends on the 
timing and dose of Ngn3 (McKnight et al., 2010).  
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The endocrine cells are still associated with the trunk epithelium after delamination and 
form later these aggregates that will become organized into the future islets of Langerhans 
(Miller et al., 2009). At E18.5, islets are formed where α-cells engulf the β-cells clusters, 
initiating the formation of the mature mantle/core structure. The maturing islets leave then the 
ductal epithelium and acquire their definitive shape shortly after birth (Miller et al., 2009). 
 
 Genes involved in endocrine subtype selection, differentiation and 2.
maturation  
It is important to note that it is not possible to define accurately when commitment 
towards a specific islet subtype is finalized due to the limited methods of tracing transient cell 
populations. NeuroD1, Islet1 and IA-1, represent a group of transcription factors that control the 
number of endocrine cells by promoting progenitor cell survival and/or proliferation. 
Concomitantly, additional factors called lineage allocation factors, such as Nkx2.2, Nkx6.1, 
Nkx6.2, Arx and Pax4, drive the differentiation of endocrine progenitors towards a specific 
lineage. Perturbing the action of these factors leads to alterations in the overall allocation of 
endocrine subtypes within the pancreas, although endocrine cell numbers are almost unaffected. 
Finally, others factors such as Pax6, MafA, MafB, Foxa1 and Foxa2 are required to control later 
aspects of endocrine maturation and physiological functionality. 
 
a) General endocrine differentiation factors 
Neurogenic differentiation 1 (NeuroD1) is a bHLH TF expressed during early pancreatic 
development (E9.5) in the pancreatic epithelium (Naya et al., 1997). At E17.5, its expression is 
restricted to endocrine cells and remains so in adults (Chu et al., 2001; Itkin-Ansari et al., 2005; 
Naya et al., 1995). Mice homozygous for a deletion of NeuroD1 display a great reduction in 
endocrine cell numbers (Naya et al., 1997). Full NeuroD1 KO mice survive until birth, but die 
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within three to five days postpartum due to severe hyperglycemia. In addition, NeuroD1 is 
required for β-cell maturity and glucose responsiveness (Artner et al., 2010).  
Islet1 (Isl1) is a TF involved in early pancreatic differentiation and the full knockout of 
this gene is lethal. Isl1 is expressed in all endocrine cells subtypes (Ahlgren et al., 1997). The 
conditional loss of Isl1 at E13.5 leads to a decreased differentiation of -, -, - and PP cells 
without any effect on -cells (Acloque et al., 2009). 
Insulinoma-associated 1 (IA-1) is a zinc-finger-containing TF that was found to be a 
direct target of Ngn3 and is necessary for endocrine differentiation (Mellitzer et al., 2006). IA-1 
KO mice display endocrine cells that fail to express any hormone (Gierl et al., 2006).  
These general endocrine factors facilitate the formation of proper endocrine cell numbers 
and also permit endocrine cells to move into the single-hormone-expressing cell state. 
 
b) Lineage allocation factors 
Lineage-specific factors control the flux of endocrine progenitors towards a specific 
endocrine cell type. 
 Nkx2.2 (1)
Nkx2.2, a homeodomain-containing factor belonging to the NK family, was found to 
play a predominant role in the specification of endocrine progenitors toward the β-cell lineage. 
Its expression is initiated at E9.5 in the dorsal pancreatic epithelium (Sussel et al., 1998) and 
persists in mature α-, β- and PP-cell types but remains excluded from δ-cells. In Nkx2.2 mutant 
mice, β-, α-, and PP-cells are replaced by ghrelin-producing cells, whereas the number of δ-cells 
remains unaffected (Prado et al., 2004; Sussel et al., 1998). In addition, the absence of Nkx2.2 
prevents β-cells from differentiating into fully functional insulin-producing cells. Thus, Nkx2.2 
appears to both control the late differentiation of β-cells and the formation of α- and PP-cells.  
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 Nkx6.1 and Nkx6.2 (2)
Nkx6.1, another member of the NK family, is also initially detected at E9.5 but in both 
pancreatic buds where it persists until E13 when its expression becomes restricted to β-cells and 
where it was found to be required for proper insulin secretion (Oster et al., 1998; Sander et al., 
2000). Mice lacking Nkx6.1 display a diminished number of β-cells while other cell subtypes 
develop normally, suggesting that Nkx6.1 is necessary for β-cell development (Sander et al., 
2000). Nkx6.2 displays a similar expression pattern compared to Nkx6.1 but it is not detected in 
adult β-cells (Nelson et al., 2007; Pedersen et al., 2006). The deletion of Nkx6.2 does not lead to 
any obvious phenotype and the double knockout of Nkx6.1 and Nkx6.2 induces similar 
alterations as seen in Nkx6.1 mutant mice (Henseleit et al., 2005; Sander et al., 2000). However, 
the misexpression of Nkx6.2 under the control of the Pdx1 promoter was found to be able to 
rescue the phenotype of Nkx6.1 null mice, indicating that both factors possess redundant 
activities for β-cell differentiation (Nelson et al., 2007).    
 Arx and Pax4 (3)
Arx and Pax4 were found to be instrumental for the specification towards the α-/PP- and 
β-/δ-cell fates, respectively. The expression of Pax4, a paired box-encoding gene, is initiated 
around E9.5 in both pancreatic buds and becomes progressively restricted to β-cells (Dohrmann 
et al., 2000; Smith et al., 1999; Sosa-Pineda et al., 1997). Arx, a member of the homeodomain-
encoding gene family and the Aristaless subfamily is also expressed around E9.5 and becomes 
restricted to -cells. Mice depleted of Pax4 are born normally but develop severe 
hyperglycemia. These animals exhibit a loss of - and -cells accompanied by a proportional 
increase in -cells. Conversely, Arx-deficient mutant mice develop severe hypoglycaemia, 
weakness, dehydration, and display a phenotype opposite to the one noted in Pax4 mutants with 
a loss of -cells and an augmented content of - and -cells (Collombat et al., 2003; Sosa-
Pineda et al., 1997). Interestingly, in both mutant mice, it is worth noting that the total number 
 
 
 
24 
 
  
of islet cells remained unchanged compared to wild-type pancreata. Further studies revealed that 
Arx and Pax4 display antagonistic activities with respect to the allocation of the endocrine 
precursors through an inhibitory cross-regulatory circuit that controls the transcriptional state of 
these two genes (Collombat et al., 2005). Indeed, Arx and Pax4 were found to mutually inhibit 
each other’s transcription through direct physical interaction with the pertinent promoter 
(Collombat et al., 2005). Accordingly, the amount of Pax4 mRNA is upregulated in Arx mutant 
mice, whereas an augmentation in the Arx transcript content was demonstrated in the absence of 
a functional Pax4 allele. It is interesting to note that, during pancreas development, Arx and 
Pax4 are initially found co-expressed, most likely in an inactive form, the activation of one or 
the other (probably through selective conformational changes or post-translational 
modifications) leading to the allocation to a given cell lineage: should Arx predominate, the α-
cell fate will be specified at the expense of the -/-cell lineage; should Pax4 be activated, the β- 
and δ-cell lineages will be preferred. Interestingly, the co-ablation of Arx and Pax4 results in a 
massive increase in δ-cells at the expense of α and β-cells, suggesting that δ-cell terminal 
differentiation is independent of Pax4 and Arx (Collombat et al., 2005).  
 
c) Maturation factors 
Maturation factors control later aspects of the final move towards physiological 
readiness. Loss of these factors causes little or no defect during endocrine cell lineage 
diversification, but the cells begin to show aberrant function postnatally or in adulthood.  
 Pax6 (1)
Pax6, another member of the Pax gene family, is expressed in all endocrine cells and its 
deficiency leads to a reduction in the entire islet cell population, indicating its requirement for 
the development of all endocrine cell subtypes. Pax6 is also required for the structure of islets 
during the development (Ahlgren et al., 1997; Sander et al., 1997; St-Onge et al., 1997). Pax6 
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plays a crucial role during islet differentiation by regulating glucagon, insulin and somatostatin 
gene transcription (Sander et al., 1997). In addition, Pax6 is also important for maintaining the 
mature β-cell phenotype. Indeed, the conditional knock-out of Pax6 results in diabetic pups 
severely lacking insulin expression (Ashery-Padan et al., 2004). 
 MafA and MafB (2)
The expression of the basic leucine-zipper TFs MafA and MafB is critical for α and β-
cell maturation. MafB is required for both α-cell and β-cell differentiation/maturation but is later 
restricted to α-cells, whereas MafA remains β-cell specific (Artner et al., 2010; Artner et al., 
2006; Kroon et al., 2008; Nishimura et al., 2006). MafA mutant mice display an unaltered 
endocrine cell development but are hyperglycemic and display a major decrease in blood insulin 
levels. These mice develop glucose intolerance after birth and exhibit a β-cell defect in glucose-
induced insulin secretion (Akiyama et al., 2005). On the contrary, MafB-deficient mice exhibit 
reduced α- and β-cell numbers, both endocrine cell types failing to reach complete maturation 
(Artner et al., 2010; Artner et al., 2006).  
 FoxA1 and FoxA2 (3)
The winged-helix TF Forkhead box A1 and A2 (FoxA1 and FoxA2) are required for the 
terminal differentiation of endocrine cells. FoxA1-deficient mice die soon after birth due to a 
severe hypoglycemia accompanied by a decreased expression of several islet genes, including 
glucagon (Kaestner et al., 1999; Shih et al., 1999). FoxA1 was found to bind an element of the 
preproglucagon promoter (Kaestner et al., 1999) indicating his involvement in the maintenance 
of α-cell function. The specific deletion of FoxA2 in the endoderm causes severe hypoglycemia 
and early lethality. Similar to what was described in FoxA1 mutants, a reduction in plasmatic 
glucagon levels and in number of mature α-cells was observed with a decreased postnatal 
preproglucagon mRNA levels (Lee et al., 2005). Initial specification of α-precursor cells was 
found to be normal in FoxA2 mutants but subsequent differentiation appeared blocked with a 
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90% reduction of glucagon expression and complete lack of prohormone convertase 2 (PC2) 
production (Lee et al., 2005), suggesting the important role of FoxA2 during terminal, but not 
initial, α-cell differentiation.  
 
This non-exhaustive description outlines the complexity of the mechanisms underlying 
endocrine cell differentiation, which involve the interplay of different factors often displaying 
stage-specific functions and requiring the function of additional factors or signaling molecules. 
An overview of the key players involved in pancreatic development is depicted in Figure 7. 
 
 
 
27 
 
  
 
 
Figure 7: Activities of selected transcription factors acting on endocrine cell lineage 
allocation.  
Several signaling pathways are activated for the specification of the pancreatic fate. A specific program of TF gene 
expression is also activated and defines the fate of pancreatic progenitors. Among these, Pdx1 is required for 
pancreatic epithelium determination and subsequently Ngn3 for endocrine lineage specification. Following Ngn3 
activation, a complex network of TF promotes the different endocrine fate, including Arx and Pax4. Pax4 favors 
the β- and δ-cell fates whereas Arx promotes the α- and PP-cell lineages. Additional TFs permit the maintenance of 
the different endocrine cell phenotypes. 
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III. Diabetes Mellitus 
Diabetes mellitus represents one of the most common endocrine diseases in all 
populations and all age groups with 347 million people affected worldwide. The World Health 
Organization (WHO) projects that diabetes will become the 7
th
 leading cause of death by 2030. 
This metabolic disorder of multiple etiologies is characterized by chronic hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both. The development of diabetes 
involves several pathogenetic processes that either destroy the β-cells of the pancreas with a 
consequent insulin deficiency, or result in resistance to insulin action. The long-term increase in 
blood glucose levels leads to long-term damage, dysfunction and/or failure of various organs. 
Higher glucose concentration causes an increased of blood viscosity and a thickening of blood 
vessels. It is also important to note that in diabetic patients, glucagon concentrations remain 
unsuppressed, which may contribute to their hyperglycemia (Greenbaum et al., 2002; Thule, 
2012).  
Without proper management, diabetes, and its associated chronic hyperglycemia, could 
result into dramatic complications, mainly involving micro- and macro-vascular symptoms, 
including: 
- Retinopathy with potential blindness that occurs as a result of long-term accumulated 
damage to the small blood vessels in the retina,  
- Micro- and macro-vascular symptoms, 
- Nephropathy that may lead to renal failure because of reduced blood flow,  
- Neuropathy with risk of foot ulcers,  
- Amputations due to circulation problems, etc (Nathan, 1993).  
Despite the most recent advances in diabetes care, patients suffering from diabetes still 
display a shortened life expectancy (about R years reduced on average) in regard to healthy 
people (International Diabetes Federation, Diabetes Atlas) (Franco et al., 2007). Diabetes can be 
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sub-divided into different types listed hereafter, each form exhibiting a different etiology and 
thereby requiring different treatments.   
 
 A. Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus (T1DM) results from the autoimmune-mediated destruction of 
the pancreatic β-cells and comprises approximately 10% of diabetic patients. It can affect people 
at any age although it is predominantly found in children and young adults (Eizirik, 2009). 
There is a genetic predisposition to T1DM but it is also related to environmental factors that are 
still poorly defined but could involve early events during pregnancy, diet, or viral infections. 
The rate of cell destruction is quite variable, being rapid in some individuals and slow in others 
(Zimmet et al., 1994). The rapidly progressing form is commonly observed in children, but may 
also occur in adults (Humphrey et al., 1998). Although the diagnosis of T1DM is often sudden 
for the patient, many years can pass between the beginning of the auto-immune attack and the 
clinical onset of symptoms (Molbak et al., 1994).  
An improper immune response mediated by T lymphocytes and directed against 
pancreatic β-cells results from the presentation of one or several -cell proteins as antigens. 
T1DM is usually diagnosed by the presence of glutamic acid decarboxylase (GAD67 and 
GAD65), insulin, insulinoma-associated 2 (IA2), islet amyloid polypeptide and/or islet cell 
(ICA) autoantibodies that are markers of immune destruction of the -cells mass (Roep and 
Peakman, 2012). Symptoms that may occur suddenly include excessive excretion of urine 
(polyuria), thirst (polydipsia), constant hunger, weight loss, vision changes and fatigue. 
In order to counter the loss of insulin-producing cells, the administration of exogenous 
insulin (either by pump or by injections) represents the mainstay of T1DM treatment. However, 
environmental variations, such as exercise, diet, pregnancy, or age may lead to a deregulation of 
the glycaemia and thereby result in the complications mentioned previously. Alternatively, the 
transplantation of islets of Langerhans can alleviate insulin dependence in type 1 diabetic 
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patients. However, due to the associated immunosuppression therapies and the scarcity of organ 
donors (three to five donors are required to treat a single patient), this approach remains 
seldomly used. 
 
 B. Type 2 Diabetes Mellitus  
Type 2 diabetes mellitus (T2DM) mainly results from the body’s ineffective use of 
insulin. T2DM comprises 90% of people with diabetes around the world (WHO). Until recently, 
this type of diabetes was diagnosed primarily in adults but it is now also affecting children and 
adolescents due to changes in lifestyle. This most common form of diabetes is characterized by 
alterations in insulin action and insulin secretion. Indeed, in type 2 diabetic patients, the 
pancreas is able to produce insulin, but either not in sufficient amounts or the body is not 
responding to its effects, which in turn leads to an increase in the amount of glucose in the 
blood.  
T2DM is largely the result of excess body weight and physical inactivity (Zimmet et al., 
1994). The majority of patients with this form of diabetes are overweight or obese, which can 
induce or aggravate insulin resistance (Bogardus et al., 1985; Campbell and Carlson, 1993). 
Indeed, insulin resistance is largely the consequence of increased levels of circulating fatty acids 
(that are being used by the muscles to produce energy preventing glucose uptake), which affects 
the action of insulin on its target organs, but can also be the consequence of various alterations 
in insulin transduction pathways (Boden, 1999). This results in insulin secretion being increased 
in an attempt to force glucose absorption and ultimately leads to -cell exhaustion and even 
apoptosis followed by a consequential impairment in insulin secretion (Butler et al., 2003; Doria 
et al., 2008). Other risk factors have been also identified including: poor diet, aging, ethnicity 
and genetic predisposition (Knowler et al., 1993), although the genetics of this form of diabetes 
are complex and not clearly defined. It also occurs more frequently in women with prior 
gestational diabetes mellitus (GDM) and in individuals with hypertension or dyslipidemia.  
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Symptoms may be similar to those of T1DM, but are often less marked. Subsequently, 
type 2 diabetic patients frequently remain unaware of their disease for a long time because the 
symptoms are not recognized and the associated hyperglycemia is often not severe enough to 
provoke noticeable symptoms of diabetes (Harris, 1993; Mooy et al., 1995). Nevertheless, such 
patients are at increased risk of developing macrovascular and microvascular complications as 
the body is being irreversibly damaged by excess blood glucose (Harris, 1993; Mooy et al., 
1995). As a result, the disease may be diagnosed several years after onset, once complications 
have already arisen.  
In contrast to people with T1DM, the majority of patients with T2DM do not need 
insulin treatment to survive as these individuals are resistant to the action of insulin throughout 
their lifetime. Insulin sensitivity may be increased by weight loss, lifestyle changes, increased 
physical activity, and/or pharmacological treatment of hyperglycemia but is not restored to 
normal (Simonson et al., 1984; Wing et al., 1994).  
 
 C. Gestational Diabetes Mellitus 
Gestational diabetes mellitus (GDM) is a carbohydrate intolerance resulting in 
hyperglycemia of variable severity with onset or first recognition during pregnancy. The 
metabolic demand for insulin is increased during this period and the disease arises at later stages 
when the body fails to ensure a normal regulation of blood glucose levels due to impaired 
insulin secretion.  
This form of diabetes is diagnosed through prenatal screening, rather than reported 
symptoms. Individuals at high risk for gestational diabetes include older women, those with 
previous history of glucose intolerance, women from certain high-risk ethnic groups, and any 
pregnant woman who has elevated fasting, or casual, blood glucose levels.  
As this form of diabetes presents itself relatively late during pregnancy when the fetus is 
well developed, the risk of malformation or even death is low. Since gestational diabetes 
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disappears after delivery, there is no proper treatment, however, the patients have to control 
their glycaemia by monitoring food intake as they are at increased risk of developing T2DM in 
the future.  
 
 D. Monogenic forms of Diabetes  
Several forms of the diabetic state may be associated with monogenic defects of the 
insulin-secreting -cell (inherited in an autosomal dominant pattern) and are frequently 
characterized by onset of mild hyperglycemia. Monogenic diabetes represent only 1 to 2% of all 
cases of diabetes (Eide et al., 2008) and depending on when the disease arises, have been 
classified into neonatal diabetes (ND) and maturity-onset diabetes of the young (MODY), which 
generally appears before the age of 25 years. Abnormalities at 20 genetic loci on different 
chromosomes have now been characterized and affect pancreas development/differentiation or 
normal -cell physiology (Molven and Njolstad, 2011).  
IV. Axes of research for improved treatments of TD1M 
Despite the most recent advances in diabetes care, the regulation of glycemic levels 
using exogenous insulin in these patients is not as precise as compared to its endogenous 
counterpart and daily variations are inevitable, which ultimately have an impact on the vascular 
system. Therefore, in the search for alternative treatments, most current efforts aim at finding 
alternative sources of β-cells. The generation of functional insulin-producing cells from 
stem/precursor cells by mimicking -cell development in vitro represents one of the most 
promising research avenues together with the reprogramming/trans-differentiation of other 
pancreatic cells into β-cells.  
 
The use of embryonic stem (ES) cells or induced pluripotent stem (iPS) cells may lend 
themselves well as an unlimited source of replacement β-cells. However, to date, despite a 
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number of established and straightforward protocols, including procedures using chemical 
compounds, both the efficiency of in vitro differentiation/programming and the function of the 
resulting β-like cells remain controversial. Besides, safety concerns due to inherent risks of 
teratoma formation originating from residual stem cells remain a major hurdle (Borowiak and 
Melton, 2009; Bruin et al., 2014; Hrvatin et al., 2014; McKnight et al., 2010; Pagliuca et al., 
2014; Ricordi and Edlund, 2008; Van Hoof et al., 2009). 
 
During pregnancy (Rieck and Kaestner, 2010) or in obese individuals (Lingohr et al., 
2002), a -cell mass expansion was outlined to compensate for the increased needs. Self-
duplication of preexisting -cell unquestionably represents an important process to increase islet 
size. Accordingly, Cre recombinase-mediated lineage tracing analyses provided compelling 
evidences for -cell replication as the main source of -cell neogenesis under normal 
physiological conditions, but also following 70% partial pancreatectomy (which is a surgical 
removal of a part of the pancreas) (Dor et al., 2004). Another in vivo pulse-chase study 
supported a model where insulin-expressing cells equally participate to the replication-mediated 
expansion of the -cell (Brennand et al., 2007). These findings were confirmed by studies in 
transgenic mice with -cell depletion induced by tetracycline-controlled diphtheria toxin 
expression or by c-myc activated overexpression leading to -cell apoptosis (Cano et al., 2008; 
Nir et al., 2007). In addition, under normal physiological conditions, β-cell turnover is slow and 
decreases progressively with age (Teta et al., 2005; Teta et al., 2007). However, upon injury, it 
appears that at least some β-cells can re-enter the cell cycle. Indeed, under partial 
pancreatectomy, it has been demonstrated that replication of pre-existing β-cells represents the 
predominant mechanism for generating new β-cells(Dor et al., 2004; Teta et al., 2007). 
However, these studies did not rule out the possible contribution of other sources to the β-cell 
compartment. 
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Recent findings have opened new research avenues in the context of diabetes research by 
demonstrating the plasticity of pancreatic cells, these being able to change their epigenome and 
to acquire a functionally distinct phenotype. Current researches avenues provide several 
examples of dedifferentiation of mature cells into a progenitor-like state allowing for 
redifferentiation into alternative cell subtypes. Additional reports have demonstrated the 
possibility to directly convert differentiated cells into a number of other cell subtypes, most 
importantly, pancreatic -like cells. Indeed, it has been shown that newly-formed -cells could 
originate from the ductal epithelium, other endocrine cells, or acinar cells (Figure 8).  
 
 
Figure 8: Overview of potential sources of new insulin-producing cells.  
Scheme representing the different reported approaches allowing the generation of functional insulin-secreting cells 
from alternative pancreatic cell subtypes. For the purpose of clarity, δ-, ε- and PP-cells are not figured. Of note, 
during embryonic development, β-cells are generated from Ngn3
+
 progenitors (see section II of the introduction). 
Moreover, β-cells have the capacity to undergo self-replication to expand the β-cell mass. This occurs during 
development, pregnancy, and following injury.  
 
Mature duct cells, or a subset of this population, are able to reacquire the ability to 
generate endocrine progenitors after injury, such as pancreatic duct ligation (PDL). PDL 
consists of a ligature of the main pancreatic duct resulting in distal damage, acinar involution, 
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and an associated inflammatory response. PDL is considered to be an injury model that 
generates tissue damage and cellular responses similar to those observed in acute pancreatitis. In 
rats, PDL-induced islet cell hypertrophy is the result of an insulin
+
 cell hyperplasia. The 
augmentation in duct cell numbers and the low proliferation of pre-existing β-cells led to the 
hypothesis that β-cells may have a ductal origin. Pancreatic islet regeneration following PDL 
was later shown to involve duct-lining precursor cells that re-express the proendocrine gene 
Ngn3. These Ngn3
+
 duct cells were found capable of giving rise to all endocrine cell subtypes 
when cultured with Ngn3 null pancreatic bud explants in vitro (Xu et al., 2008).  
Endocrine α-to-β-cell conversion represents another potential therapeutic strategy in the 
treatment of diabetes. It seems that combining PDL with β-cell ablation induced by alloxan (a 
chemical compound which enters the -cells through the Glut2 transporter and induces the 
generation of toxic reactive oxygen species, eventually leading to the apoptosis of insulin-
secreting cells) leads to an α-to-β cell transdifferentiation, although lineage tracing experiments 
would be required for definitive confirmation (Chung et al., 2010). Along the same line, another 
report has convincingly showed α-to-β-like cell conversion in response to severe pancreatic 
injury. By expressing the diphtheria toxin (DT) receptor in insulin-expressing cells and using 
DT administration to induce ablation of the β-cell mass, Thorel et al. (Thorel and Herrera, 2010) 
have demonstrated a contribution of -cells to β-cell regeneration processes. Following 99% β-
cell loss, α-cells were found to pass through a bi-hormonal state, such cells expressing both 
insulin and glucagon prior to acquiring a single-hormone insulin-producing cell identity. Such a 
transdifferentiation was only observed following severe pancreatic lesion as, if the efficiency of 
-cell destruction was under 95%, α-to-β-cell conversion was not detected. Understanding the 
molecular mechanisms of α-to-β-cell transdifferentiation in this model could elucidate the 
endogenous signaling pathways that could be activated/deactivated to convert α-cells into β-
cells under normal physiological or in vitro culture conditions.  
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Owing to our current knowledge of the main genetic determinants acting during β-cell 
development, the reprogramming of adult cells via the forced expression of key developmental 
transcriptional factors has made huge progresses. Although such a method does not currently 
hold any therapeutic feasibility in humans, these experiments can provide information on the 
mechanisms of cellular plasticity required to impact cell fate. Acinar cells are the most abundant 
cell type in pancreas and represent a potential supply for reprogramming strategies toward β-
cells (Heimberg, 2008). Zhou et al. demonstrated that forcing the expression of Ngn3 (to acquire 
general endocrine competence), Pdx1 (to establish a β-cell fate) and MafA (to increase Pdx1 
function and to achieve β-cell maturation and functionality) in acinar cells resulted in the 
conversion of these cells into insulin-producing β-cells in vivo (Zhou et al., 2008). The 
induction of β-cells was sporadic, apparently occurring directly from acinar cells without 
replication or acquisition of a dedifferentiated state. The acini-derived β-cells did not cluster, 
perhaps due to only a few cells receiving all factors at appropriate relative doses or only certain 
acinar cells being competent to respond to these factors. These acini-derived β-cells were able to 
improve glucose homeostasis in diabetic mice, but the full physiological function was not 
analyzed. 
 
Reprogramming has also been observed when forcing the expression of endocrine 
lineage transcription factors. This approach gives rise to the conversion of closely linked cell 
types, such as an α-to-β or the opposite β-to-α identity switch. Arx and Pax4 play opposing and 
critical roles in endocrine lineage allocation as previously described. Arx was shown to be 
sufficient to promote the α- and PP-cell lineages using a conditional approach to misexpress this 
gene during the course of development (Collombat et al., 2005). Importantly, it was later 
discovered that the sole misexpression of Arx in adult β-cells could induce the conversion of 
such mature β-cells into cells displaying an α-cell identity (Collombat et al., 2007). This implied 
that the complementary conversion might be achieved, that is, to generate β-cells from -cells. 
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Indeed, the conditional misexpression of Pax4 in immature glucagon
+
 cells was found to induce 
their conversion into cells displaying a β-cell phenotype (Collombat et al., 2009). In these mice, 
hypertrophic islets composed mainly of insulin-producing cells were observed. The α-to-β-like 
cell conversion not being able to fully account for the vast increase in the number of β-like cells 
and the continuous detection of α-cells suggested a putative regeneration of glucagon-
expressing cells. This regeneration was indeed demonstrated and found to originate from cells 
of the ductal lining, such cells re-expressing the developmental gene Ngn3 prior to acquiring an 
-cell identity and subsequently a -like cell phenotype upon Pax4 misexpression (Collombat et 
al., 2009). Notably, these processes of neogenesis followed by conversion were found sufficient 
to induce the restoration of a functional β-cell mass following -cell mass destruction induced 
by streptozotocin (a chemical compound able to enter -cells via the Glut2 transporter due to his 
structural similarity to glucose and causing DNA damage followed by apoptosis of the insulin-
producing cells). Aiming to determine whether adult α-cells, that have been exposed to 
environmental signaling, maturation and ageing, retain the ability to be converted into β-cells 
upon Pax4 misexpression, an inducible Pax4-misexpressing mouse line was generated (Al-
Hasani et al., 2013). Combining the TET-ON system with lineage tracing, the misexpression of 
Pax4 in α-cells of any age was shown to induce their neogenesis and conversion into β-like 
cells, such cells expressing the bona fide β-cell markers and being fully functional upon glucose 
challenge. Importantly, these cells were found able to repopulate the islets of streptozotocin-
treated mice and restore euglycemia even after several cycles of chemically-induced diabetes. 
This system will be further explained and discussed in the Results section of this work. 
Despite the recent advances in our understanding of the potential of conversion and/or 
regeneration of specific pancreatic cell types, gaining more insight into the mechanisms 
involved will represent one of the main challenges for the coming years. However, cellular 
reprogramming could clearly pave the way towards new therapeutic approaches in the context 
of T1DM.  
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Materials and Methods 
I. Mouse manipulations  
Mice were maintained on a 12-hour light/dark cycle and were provided with standard 
diet food and water ad libitum. Animal care and experimental procedures were conducted 
according to the French ethical regulations. Wild-type (WT) 129/sv mice were obtained from 
Charles River Laboratories and from Taconic. 
 
 A. Transgenic mouse lines 
The bitransgenic Glu-rtTA::TetO-Pax4 mouse line was generated by crossing two single 
transgenic lines, Glu-rtTA and TetO-Pax4 that were produced by classical pronuclear injection. 
The principle of the Tet-On System will be described in the Results section. 
 Linage tracing experiments were achieved by crossing Glucagon-Cre (Ashery-Padan et 
al., 2004; Gu et al., 2002; Herrera, 2000), Ngn3-CreER (Gu et al., 2002) and HNF-CreER (Gu 
et al., 2002) animals with ROSA26-β-Gal mouse line (Soriano, 1999).  
Additional quadruple transgenic lines were established by crossing the bitransgenic Glu-
rtTA::TetO-Pax4 animals with the double transgenic Glucagon-Cre::ROSA26-β-Gal, Ngn3-
CreER::ROSA26-β-Gal and HNF-CreER::ROSA26-β-Gal animals. The resulted quadruple 
transgenic mice (Figure 9) allowed us to trace cells in our Pax4-inducible Tet-On transgenic 
system cells that at any time point: 
- Expressed glucagon (Glu-rtTA::TetO-Pax4 ::Glu-Cre::ROSA26-β-Gal). 
- Expressed Ngn3 (Glu-rtTA::TetO-Pax4 ::Ngn3-Cre::ROSA26-β-Gal). 
- Expressed HNF1β (Glu-rtTA::TetO-Pax4 ::HNF-Cre::ROSA26-β-Gal). 
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Figure 9: Quadruple transgenic mice used for lineage tracing experiments.  
The transgenic lines were established by crossing the bitransgenic Glu-rtTA::TetO-Pax4 animals with the double 
transgenic Glucagon-Cre::ROSA26-β-Gal (A), Ngn3-CreER::ROSA26-β-Gal and HNF-CreER::ROSA26-β-Gal 
animals (B). The CreER inducible system requires the administration of tamoxifen (B).  
 
 B. Administration of chemical compounds 
Doxycycline (Dox; Sigma) was administered via drinking water to the mice to allow 
Pax4 expression in the glucagon-expressing cells. The Dox solution was freshly prepared once a 
week at a concentration of 2g/L.  
To assess the effects of glucagon on islet size, Glu-rtTA::TetO-Pax4 animals were 
injected intra-peritoneally (IP) every 12h with 5μg of glucagon (Sigma) in PBS and sacrificed 
after 3 weeks of treatment. 
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The CreER inducible system requires the administration of tamoxifen (Tam, Sigma). 
Tam was dissolved in corn oil at a concentration of 20mg/ml and administered by gavage. When 
free of a binding ligand, the CreER complex remains segregated in the cytoplasm. Once Tam 
binds to the corresponding estrogen receptor (ER) in the cytoplasm, the CreER complex 
translocates to the nucleus where it can recombine the loxP sites flanking a STOP-codon 
upstream of the β-gal-coding sequence enabling the expression of the enzyme β-galactosidase 
(Figure 10). 
 
 
Figure 10: CreER inducible system.  
Cre recombinase expression can be spatially restricted by its expression under the control of a cell-specific 
promoter (PROM). Temporal restriction is achieved by fusing it to the Tam-responsive hormone-binding domain of 
the estrogen receptor (ER). These Cre constructs are used in conjunction with reporter genes, such as LacZ, 
ubiquitously expressed under the control of the ROSA26 (R26) promoter, and placed downstream of a STOP codon 
flanked by Cre recombinase recognition (loxP) sites allowing their expression in specific cell types at defined time-
points. (A) In the absence of Tam, no expression of the LacZ gene is observed because the Cre enzyme is in an 
inactive state in the absence of the ligand Tam (and stays in the cytoplasm). (B) When Tam is administered, the Cre 
is activated, translocates to the nucleus and mediates recombination between the loxP sites in cells. As a 
consequence, the STOP codon is excised and LacZ permanently marks the cells.  
 
 
To assess cell proliferation, mice were treated with the thymidine analogue 
Bromodeoxyuridine (BrdU, Invitrogen) in drinking water at a concentration of 1mg/ml for 10 
LacZ R26 
STOP 
CreER 
CreER 
TAM 
TAM 
Nucleus 
+ 
Tamoxifen (TAM) 
CreER Cell-specific PROM 
LacZ R26 STOP 
CreER 
Nucleus 
CreER 
R26 Rosa 26 promoter 
LoxP site 
CreER Cre inactive 
CreER Cre active 
A          - Tamoxifen (cytoplasmic Cre) B              + Tamoxifen (nuclear Cre) 
 
 
 
41 
 
  
days prior to examination. Cells that had incorporated BrdU during DNA replication (Figure 
11A) were detected by immunohistochemistry (Figure 11B).  
 
 
Figure 11: BrdU incorporation and detection.  
(A) BrdU can be incorporated into the newly synthesized DNA of replicating cells (during the S phase of the cell 
cycle), substituting for thymidine during DNA replication. 
(B) Antibodies (AB) specific for BrdU can then be used to detect the incorporated chemical. Binding of the 
antibody requires denaturation of the DNA, usually by exposing the cells to heat. Labeled secondary antibodies 
react with the primary antibodies. The fluorescence is then detected by microscopy. 
 
GABA (Sigma) was administered in WT and transgenic animals by intraperitoneal 
injections of a 50μM solution prepared freshly once a week. 
 
 C. Lentivirus experiments 
Lentivirus production and injection were performed as previously described (Collombat 
and Mansouri, 2009; Xu et al., 2008). GABA was provided to mice for 2 days prior to lentivirus 
administration. Ductal tree virus injections (Le-Ngn3KD or Le-(pMR’)-eGFP) were then 
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Antigen from tissue 
Primary AB anti-BrdU 
Secondary AB anti-species 
with a fluorescent tag 
A 
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performed via the Papilla duodeni major followed by daily IP administration of GABA for 30 
days.  
 
 D. Tolerance tests and blood glucose level measurement 
To assess the capacity of our mice to appropriately respond to glucose, and thus to test 
the efficiency of their insulin secretion, animals were fasted for 16h, before IP injection with a 
solution of D-Glucose (Sigma; 2g/kg in H2O). Insulin tolerance tests were carried out on mice 
fasted for 6h; a solution of 0,75 units/kg human insulin diluted in PBS was administered by IP 
injection. Glycemia was measured at the indicated time points post-injection with a 
ONETOUCH Vita Glucometer (Life Scan, Inc, CA).  
 
 E. Induction of streptozotocin-mediated diabetes 
To induce hyperglycemia, STZ (Sigma) was dissolved in 0.1M sodium citrate buffer (pH 
4.5), and a single dose was administered IP (100 mg/kg) within 10 min of dissolution. Diabetes 
progression was assessed by the monitoring of blood glucose levels of the mice and/or survival 
rates of mice.  The mode of action of streptozotocin is depicted in Figure 12. 
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Figure 12: Mode of action of streptozotocin.  
Streptozotocin (STZ) is a nitrosourea analogue whose chemical structure is similar to glucose. STZ is selectively 
accumulated in pancreatic β-cells via the low-affinity Glut2 glucose transporter in the plasma membrane 
(Karunanayake et al., 1976; Tjalve et al., 1976). Other glucose transporters do not recognize STZ, explaining its 
specific toxicity to β-cells, since these cells have relatively high levels of Glut2 (Schnedl et al., 1994; Wang and 
Gleichmann, 1998). The toxicity of STZ is dependant on the DNA alkylation inducing DNA damage and β-cell 
death via necrosis. Due to its chemical properties, in particular its stability, streptozotocin is the agent of choice for 
reproducible induction of a diabetic metabolic state in experimental animals. 
II. Mouse Genotyping 
Genotyping was performed on small biopsies of mouse tail, after digestion of each 
sample with 500µL Lysis Buffer (80 mL 1M Tris/HCl, 32 mL 5M NaCl, 8mL 0.5M EDTA, 
16mL 10% SDS and fill to 800mL with ddH2O) and 10µL Proteinase K (Roche) at 58°C with 
shaking for 2 hours. To precipitate the DNA, 500µL isopropanol was added to each sample, 
which were then mixed by inverting the tubes and centrifuged for 5 min at 14000 rpm using a 
bench-top mini-centrifuge. The supernatant was discarded and the DNA pellet was washed with 
1mL of 70% ethanol before repeating the process of centrifugation (2min at 14000 rpm) and 
removing the supernatant. A quick spin allowed us to remove any remaining ethanol and the 
pellet was subsequently air-dried for 10min at room temperature (RT). The DNA was re-
suspended in 70µL Milli-Q water and incubated at 37°C for about 1 hour.  
Nucleus 
Cytoplasm 
Alkylation 
DNA damage 
Cell death 
Streptozotocin Glucose 
GLUT2 transporter 
β-cell 
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Polymerase Chain Reaction (PCR) was then used to assess the genotype of our mice, by 
combining in each reaction tube 6µL of 5x Taq Polymerase Buffer, 0.4µL dNTPs, 0.08µL of 
both forward and reverse primers (Table 1), 0.15µL Taq Polymerase and 29.81µL H2O.  
PCR results were analyzed either by gel electrophoresis or by using the QIAxcel 
Advanced System (Qiagen). The presence of the GFP gene was assessed by observing our mice 
under blue light while wearing goggles equipped with green filters. 
 
Gene Forward primer Reverse primer   Programm 
tTA GGC ATC ATA CCC 
ACT TCT GCC CCC 
TGG AAG GCG AG 
ACA GTG CGT TCT 
CCA GGG AGA 
AGC CTT GCT GAC 
AC 
94°C 5min 
40 cycles: 94°C 30sec 
57°C 30 sec 
72°C 30 sec 
72°C 10 min 
TetO GGT AGG CGT 
GTA CGG TGG 
GAG GCC TAT ATA 
AGC AG 
CCT AGC TGA TTC 
ACA CTG CTG AGT 
CCG TCC TGC TG 
94°C 5min 
40 cycles: 94°C 30sec 
57°C 30 sec 
72°C 30 sec 
72°C 10 min 
Cre ATG CTT CTG TCC 
GTT TGC CG 
CCT GTT TTG CAC 
GTT CAC CG 
94°C 5min 
40 cycles: 94°C 30sec 
57°C 30 sec 
72°C 30 sec 
72°C 10 min 
Lac TTG GCG TAA GTG 
AAG CGA C 
AGC GGC TGA TGT 
TGA ACT G 
94°C 5min 
40 cycles: 94°C 30sec 
57°C 30 sec 
72°C 30 sec 
72°C 10 min 
Neo GTC TTG TCG ATC 
AGG ATG ATC TG 
CAA TAT CAC 
GGG TAG CCA 
ACG C 
 
 
Table 1: Primers used for mouse genotyping 
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III. RNA isolation and quantification 
 A. RNA isolation  
Pancreas tissue was isolated immediately after sacrificing the mice and quickly 
transferred into liquid nitrogen. After isolation, pancreases were manually disrupted and RNA 
was extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. 
For specific experiments, RNA from the islets of Langerhans was required, thus to 
isolate them from the exocrine tissue, we injected collagenase directly into the main pancreatic 
duct quickly after animal death to digest the pancreatic tissue followed by a protein gradient to 
separate the islets from the rest of the tissue. Islet RNA was extracted as described above. 
 
 B. cDNA synthesis 
We assessed RNA quantity and quality with a NanovuePlus Spectrophotometer 
(HealthCare Biosciences AB) and then proceeded to first strand synthesis by mixing, per 
sample, 1µg RNA (in 8µL H2O), 1µL 10mM dNTP and 1µL 50mM oligodT and placing the 
reaction tube at 65°C for 5min and on ice for 1min. 
For cDNA synthesis, to each sample was added a 10µL of DNA synthesis mix (2µL 
10xRT buffer, 4µL 25mM MgCl2, 2µL 0.1 DTT, 1µL RNase out and 1µL Superscript III® 
Invitrogen), before incubating the samples for 50min at 55°C, then 5min at 85°C and finally 
4°C.  
 
 C. qPCR analysis 
Quantitative RT-PCR analyses were undertaken using the QuantiTect SYBR Green RT-
PCR kit (Roche) and Qiagen primers on a LightCycler 480 ® instrument (Roche Life Science) 
using the housekeeping gene GAPDH as internal control for normalization purposes. The qPCR 
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reaction tubes contained 5µL 2x SYBR Green Supermix, 0.5µL Primer Assay, 3µL H2O and 
1.5µL of cDNA (diluted 1/10 after previous step).  
The program used for the RT-PCR was the following, with a fluorescence acquisition 
step at the end of each cycle: 
  
IV. Pancreatic tissue processing  
 A. Paraffin embedding 
Pancreatic tissue was isolated from euthanized mice and placed in cold PBS before 
incubation for 30min at 4°C in Antigenfix (paraformaldehyde solution pH 7,2-7,4; Microm 
Microtech France) for fixation. Following 6 x 20min PBS washes at 4°C, the samples were 
incubated for 1h in 0.86% saline and dehydrated through a series of ethanol solutions with 
increasing concentrations  (50%, 70%, 80%, 90% and 100%), before incubation in isopropanol. 
The tissues were then treated with toluene to remove all alcohol from the tissue and then 
transferred into a paraffin bath for 1h, a second paraffin bath for 5-6h and finally overnight in a 
third bath of clean paraffin. The tissue was then placed in metal molds and embedded in paraffin 
on a cold plate.   
Paraffin blocks were stored at 4°C and cut into 8µm sections using a rotary microtome 
(Leica). Tissues sections were dried on a heating block at 42°C for 45min, before overnight 
drying at 37°C. Paraffin sections are stored at 4°C until staining.   
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 B. Preparation of cryo-sections 
Tissue samples were isolated from euthanized mice and placed in cold PBS before being 
fixed for 30 min at 4°C with slight rotation in a freshly prepared fixing medium containing 1% 
formaldehyde, 0.2% glutaraldehyde, 0.02% NP40, in order to preserve the tissue from 
degradation and to maintain the structure of the cell and sub-cellular components. After 6 
washes in PBS for 20min at 4°C, the tissues were incubated overnight in a high concentration 
sucrose solution (25% in PBS) to remove water and protect it from ensuing damages due to 
freezing. The pancreatic tissue was finally washed with Jung freezing medium (Leica 
Biosystems) twice for 1 hour, placed in plastic molds filled with Jung freezing medium and 
frozen on dry ice to solidify before being placed at -80°C. 
Cryoblocks were cut into 8 or 16µm sections using a Cryostat (Leica) with an object 
temperature of -14°C and an average chamber temperature of -19°C. Tissue sections were dried 
on a heating plate at 42°C for 45min and stored until staining at -80°C. 
V. Pancreatic tissue staining 
 A. Immunohistochemistry (IHC) 
To perform IHC staining on paraffin sections, the tissue sections are first incubated 
under a fume hood in xylene (3x 3min) to remove the paraffin before step-wise incubation 
(5min) in decreasing concentrations of ethanol to rehydrate the tissue (2x 95%, 80%, 60%, 
30%), before two final baths in ddH2O.  
When necessary, we used antigen retrieval to reveal nuclear proteins; indeed, 
formaldehyde induces molecular modifications of proteins during fixation, sometimes 
preventing the proper detection of antigens by the antibodies. This is reversible by heating 
above 100°C and/or basic or alkaline treatment (Griesel et al., 2006), thus rehydrated tissues 
sections were boiled in a pressure cooker for 1min at 140°C in 1,6L ddH2O with 15mL Antigen 
Unmasking solution pH6 (Vector Labs), before cooling in tap water for 40sec.  
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This boiling step also results in the denaturation of GFP, which quenched the 
endogenous fluorescence present in the samples, thus, when antigen retrieval was not 
performed, the endogenous GFP was quenched with a solution of 50µM Cu
2+
, 10mM Ascorbic 
Acid and 1% H2O2 for 10min (Isarankura-Na-Ayudhya C, 2009).  
Following either of these steps, the tissue sections were washed 3x 5min in PBS and 
incubated in 10% FCS (Gibco) in PBS for 1 hour at RT to block unspecific binding sites. The 
selected primary antibodies (Table 2) were then applied to each section after appropriate 
dilution in 10% FCS in PBS and incubated overnight in a humid chamber at 4°C. The tissue 
sections were then washed in PBS (3x 5min) and incubated with the appropriate secondary 
antibodies (Table 3) for 1h at RT in a humid chamber. After this final incubation step, the slides 
were washed again 3x 5min in PBS baths, dried and mounted with coverslips (Roth) with an 
anti-fade mounting medium (Vectashield
®
; Vector Labs) containing 4’, 6-diamidino-2-
phenylindole (DAPI) as a nuclear counterstain (Table 4).  
 
 B. IHC on cryosections 
Cryosections were incubated in PBS (3x15min) to remove the cryopreservation medium 
before blocking with 10% FCS in PBS. The staining procedure was then as described 
previously: overnight incubation with primary antibodies (diluted in 10% FCS in PBS; Table 
2), washes in PBS, 1h incubation at RT with secondary antibodies (Table 3) the following day 
and finally mounting with coverslips using DAPI-containing mounting medium (Vectashield
®
; 
Vector Labs) (Table 4). 
 
 C. DAB staining 
Paraffin sections were rehydrated using the same protocol as described above (Section V, 
A.). After the ddH2O step, the tissue sections were transferred into 0.3% H2O2 in methanol for 
20 minutes before antigen retrieval (detailed in Section V, A.) and incubation with NHS (Normal 
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horse serum) from the ABC Kit (Vectastatin) for 45min at RT. The primary antibodies (detailed 
in Table 2) were diluted in NHS and incubated overnight at 4°C. The following day, the slides 
were washed 3x 5min in PBS and incubated with the biotinylated secondary antibody from the 
ABC Kit (Vectastatin) for 45minat RT. The sections were again washed in 3x 5min in PBS, and 
then incubated with the Ready-to-use ABC Reagent (Avidin-HRP-complex) for 30min at RT. 
The corresponding DAB substrate was prepared and stored in the dark at 4°C. The slides were 
washed 3x 5min in PBS and then the DAB substrate was added directly to the tissue. DAB 
revelation was monitored by light microscopy in order to stop the reaction as soon as color had 
sufficiently developed. To stop the reaction, the slides were placed in tap water and 
subsequently washed 2x 15min in tap water before being mounted with coverslips using DAPI-
containing mounting medium (Vectashield
®
; Vector Labs).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
  
Antibody Concentration Manufacturer/source 
Mouse monoclonal anti-
glucagon 
1/500 Sigma 
Rabbit anti-Glucagon 1/500 R&D Systems 
Guinea pig anti-Glucagon 1/500 Millipore 
Guinea pig anti-Insulin 1/500 Linco 
Mouse monoclonal anti-
Insulin 
1/500 Sigma 
Rat monoclonal anti-
Somatostatin 
1/250 Chemical International 
Mouse anti-Neurog3 1/10000 Novo Nordisk 
Mouse anti-BrdU 1/40 Roche 
Rabbit anti-Pax4 1/4000 Kindly provided by B. Sosa-
Pineda 
Rabbit anti-Arx 1/500  
Rabbit anti-Nkx6.1 1/3000 Novonordisk 
Guinea pig anti-Pdx1 1/1000 Kindly provided by C. Wright 
Rabbit anti-NeuroD1 1/500 Millipore 
Rabbit anti-PC1/3 1/500 Millipore 
Rabbit anti-Glut2 1/5000 Chemical International 
Rabbit anti-MafA 1/500 Abcam 
Mouse monoclonal anti-E-
Cadherin 
1/200 BD Transduction Lab 
Mouse monoclonal anti-
Nestin 
1/1000 Millipore 
Mouse monoclonal anti-
SNAI2 
1/100 Santa Cruz Biotechnology 
Rabbit anti-Sox11 1/200 Santa Cruz Biotechnology 
Rabbit anti-GLP1R 1/1000 Kindly provided by J. 
Habener 
Goat anti-osteopontin 1/100 R&D Systems 
Goat anti-Vimentin 1/50 Santa Cruz Biotechnology 
Rabbit anti-β-Gal 1/8000 Cappel 
 
Table 2: Primary antibodies used 
 
Antibody Concentration Manufacturer/source 
647-, 594- and 488-alexa anti-
mouse 
1/1000 Molecular Probes and Jackson 
ImmunoResearch 
647-, 594- and 488-alexa anti-
rabbit 
1/1000 Molecular Probes and Jackson 
ImmunoResearch 
647-, 594- and 488-alexa anti-
guinea pig 
1/1000 Molecular Probes and Jackson 
ImmunoResearch 
594- and 488-alexa anti-goat 1/1000 Molecular Probes and Jackson 
ImmunoResearch 
594- and 488-alexa anti-
chicken 
1/1000 Molecular Probes and Jackson 
ImmunoResearch 
 
Table 3: Secondary antibodies used 
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 Colour of nuclei Max absorption (nm) Max emission (nm) 
DAPI (Vectashield) Blue 358 461 
Propidium Iodide Red 535 617 
 
Table 4: Nuclear counterstains used 
 
 D. X-gal staining 
X-Gal staining is a technique allowing the visualization of the activity of the enzyme β-
Galactosidase, as X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) is a colorless 
compound and will generate an intense blue product when cleaved by this enzyme. This reaction 
is used to trace the fate of cells having been genetically modified to express β-Galactosidase. 
Cryosections were washed 3x 15min in PBS and incubated with a X-Gal staining 
solution (500mM K3Fe(CN)6 (Sigma), 250mM K4Fe(CN)6 (Sigma), 0,5M MgCl2, 40mg/ml X-
gal  (Invitrogen)  in DMF) in a humid chamber at 37°C overnight.  
The sections were then washed 3x 10min in PBS and mounted with coverslips using DAPI-
containing mounting medium (Vectashield
®
; Vector Labs). 
VI. Electron microscopy  
For ultrastructural analyses of the pancreas, anesthetized mice were perfused 
transcardially with physiological serum in order to wash out the blood, then with 2% 
glutaraldehyde in 0.1 M cacodylate buffer. This buffer was prepared according to the following 
protocol: 
- 0,4M cacodylate buffer stock: 42,8g of cacodylic acid-sodium salts and fill up to 
500mL with ddH2O. 
- 0,1M cacodylate buffer working solution: 120mL of 0,4M stock solution + 360mL 
ddH2O with pH 7,2 – 7,4. 
The pancreas were dissected, immerged in fixative for hours, rinsed in the same buffer, post-
fixed for 2h in 1% osmium tetroxide in 0.1 M cacodylate buffer. Samples were then rinsed in 
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distilled water, dehydrated in alcohols and lastly embedded in epoxy resin. Contrasted ultrathin 
sections (70 nm) were analyzed under a JEOL 1400 transmission electron microscope mounted 
with a Morada Olympus CCD camera. 
For immunogold stainings, approximately 200 islets, isolated by collagenase (1mg/ml) 
digestion, were fixed with 4% paraformaldehyde, 0.2% glutaraldehyde in 0.1 M phosphate 
buffer (PB) (pH 7.4) overnight at 4°C and were processed for ultracryomicrotomy according to 
a slightly modified Tokuyasu method (Tokuyasu, 1973). In brief, islets were spun down in 10% 
gelatin. After immersion in 2.3 M sucrose (in [pH 7.4], 0.1 M PB) overnight at 4°C, the samples 
were rapidly frozen in liquid nitrogen. Ultrathin (70 nm thick) cryosections were prepared with 
an ultracryomicrotome (Leica EMFCS, Austria) and mounted on formvar-coated nickel grids 
(Electron Microscopy Sciences, Fort Washington, PA, USA). Immunostainings were processed 
with an automated immunogold labeling system Leica EM IGL as following: the grids were 
incubated successively in PBS containing 50 mM NH4Cl, PBS containing 1% BSA, PBS 
containing both anti-insulin and anti-glucagon primary antibodies diluted 1:1000 in 1% BSA for 
1 h, PBS containing 0.1% BSA, PBS containing 1% BSA and both 10 nm and 15 nm colloidal 
gold conjugated anti-guinea pig IgG and anti-mouse IgG, respectively, (BBInternational, 
Cardiff, UK), PBS containing 0.1% BSA for 5 min, PBS for 5 min twice. Finally, the samples 
were fixed for 10 min with 1% glutaraldehyde, rinsed in distilled water and were contrasted 
with a mixture of 1.8% methylcellulose and 0.3% uranyl acetate on ice (Al-Hasani et al., 2013; 
Courtney et al., 2013).  
VII. Optical projection tomography 
OPT analysis was performed as previously described (Alanentalo et al., 2007; Sand et 
al., 2011). Each specimen was scanned using the Bioptonics 3001 OPT scanner with a 
resolution of 1024×1024 pixels and reconstructed with the NRecon version 1.6.1. (Skyscan) 
software. Quantification of the insulin-producing cell mass was undertaken using Imaris 
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software (Biplane). Volumes were calculated by applying a “find objects by intensity” task to 
select voxels above a specified intensity. The intensity threshold value was manually determined 
for each image stack. All pancreata were scanned and analyzed blind. 
VIII. Microarray analysis 
Bitransgenic GluartTA::TetO-Pax4 animals were treated for 3 or 7 weeks with 
Doxycycline in order to force the expression of Pax4 in glucagon-expressing α-cells. The 
pancreas of these transgenic mice was isolated and immediately stored in 1ml RNA Later at a 
80°C or directly used for RNA isolation as previously described. There are 3 fundamental steps 
in a cDNA microarray experiment:  
 The first step is cDNA amplification and printing which deals with making the 
cDNA microarray itself by collecting an inventory of cDNA bacterial clones that 
represent the gene whose message abundance you wish to survey.  
 A second step requires the RNA extraction from the isolated pancreatic tissue and its 
purification as mentioned above. The purified RNA is then used as a substrate for 
reverse transcription in the presence of fluo-derived nucleotides; this process is 
needed to label the cDNA in the samples.  
 In the last step, the labeled cDNAs are hybridized to their complements on the 
microarray and the resulting localized concentration of fluorescent molecules on the 
microarray are detected and quantified.  
Data analysis was undertaken using the GeneSifter MicroArray analysis software, data sets were 
normalized to their median and statistically analyzed applying the student’s t-test.  
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IX. Counting and data analysis  
Islet size and composition were measured in silico by the counting of colored pixels on 
immunostained sections of pancreas using the Photoshop software. Every 10
th 
section was 
processed using the same settings for all animals and genotypes. 
All values in this study are depicted as mean ± SEM and considered significant if 
p<0.05. Data were statistically analyzed using Student’s t-distribution or ANOVA.    
X. Microscopes and Software 
The following microscopes and software were used to acquire pictures: 
 Bright Field pictures (X-Gal and DAB staining): LEICA DM 6000B with the 
Leica LAS AF software. 
 Fluorescent pictures (Immunostainings on cryosections and paraffin sections, 
mosaic pictures of a whole section): ZEISS AxioImager Z1 and ZEISS 
AxioImager M2 with motorized plate. The software used to acquire images was 
Axiovision from ZEISS. 
 Electron microscopy pictures: JEOL 1400 transmission electron microscope. 
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Resultats 
I. Induction of Pax4 misexpression in adult α-cells 
As previously mentioned in the Introduction section, the forced expression of Pax4 in 
embryonic glucagon
+
 cells was found to induce their neogenesis and subsequent conversion into 
cells displaying a β-cell phenotype (Collombat and Mansouri, 2009). Interestingly, the 
overexpression of Pax4 in β-cells was also shown to prevent their toxin-mediated loss (Hu He et 
al., 2011). 
Although these findings allowed us to gain insight into the regenerative potential and 
plasticity of embryonic/newborn glucagon
+
 cells misexpressing Pax4, several issues of 
fundamental importance to T1DM remain hitherto unresolved:  
 Do adult α-cells that have been subjected to environmental signaling, maturation, 
and aging retain the ability to be converted into β-like cells upon Pax4 expression?  
 Could these glucagon+ cells restore a functional β-like cell mass after β-cell ablation?  
 Is the number of precursor cells limited and does it restrict β-like cell regeneration in 
aging mice?  
 Can β-cell neogenesis be controlled?  
 What are the mechanisms underlying glucagon+ cell-mediated β-like cell neogene- 
sis?  
To address these pivotal questions and thereby potentially open avenues in the context of 
T1DM research, we generated double-transgenic mice allowing the inducible, ectopic, and 
reversible expression of Pax4 in glucagon-producing cells. Our results provide conclusive 
evidence that adult α-cells can also be converted into functional β-like cells at any age upon 
Pax4 misexpression, and that a cycle of endocrine cell/islet neogenesis is subsequently 
activated. Specifically, a Ngn3-dependent reawakening of the epithelial-to-mesenchymal 
transition in this adult context promotes duct-lining precursor cells to adopt a glucagon
+
 cell 
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identity and, subsequently, a β-like cell phenotype, these being responsive to physiological 
stimuli. Importantly, such controllable regeneration processes allow for several cycles of 
replenishment of a complete β-like cell mass that counters toxin-induced diabetes. 
 
 A. Analysis of mice conditionally misexpressing Pax4 in glucagon-expressing α-
cells 
 The generation of the bitransgenic Glu-rtTA::TetO-Pax4 mice 1.
Taking advantage of the Tet-ON system (Clontech Laboratories), we generated two mouse lines 
using pronuclear injection of recombinant transgenes (Figure 13): Glu-rtTA contained the rat 
glucagon promoter (Herrera et al., 1994) upstream of the reverse tetracycline-dependent 
transactivator (rtTA), allowing its exclusive expression in glucagon-expressing-α-cells and 
TetO-Pax4 included the Tet operator (TetO) upstream of Pax4 cDNA. 
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Figure 13: Generation of Glu-rtTA and TetO-Pax4 mouse lines.  
The constructs used for the generation of both mouse lines were assembled using the backbones contained in the 
pTet-On Advanced System (Clontech). Briefly, the CMV promoter contained within the pTet-On Advanced vector 
was replaced by the 1.1kb glucagon promoter region characterized by Herrera (Herrera, 2000). In a second set of 
experiments, the Pax4 cDNA was cloned into the multi-cloning site (MCS) found within the pTRE-Tight vector 
(TetO-Pax4). All constructs were sequenced and used for classical transgenic animal generation (pronuclear 
injection). Four founders were thereby obtained for Glu-rtTA and five for TetO-Pax4 (Neo
r
: Neomycin resistance 
gene, PSV40: SV40 promoter, PCMV, CMV promoter, Ori: Col E1 origin of replication, Amp
r
: Ampicilin 
resistance gene, rtTA-Advanced: reverse tetracycline-dependent transactivator, PGlu: glucagon promoter region, 
PTight: Tet operator, MCS: Multi-cloning site). 
 
For each, four or more founder lines were generated. To assess the specificity of the 
regulatory sequences and any putative leakiness of transgene expression, Glu-rtTA mice were 
crossed with the well-established TetO-β-gal mouse line (Hennighausen et al., 1995). Pancreata 
of 4-week-old Glu-rtTA:: TetO-β-gal mice were assayed for β-galactosidase expression in 
glucagon
+
 cells after 2 weeks of doxycycline (Dox) treatment (Figure 14). Transgene 
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expression was found specifically regulated by Glu-rtTA as β-galactosidase activity was 
detected in 80%–90% of glucagon
+
 cells but not in any other cell type of the pancreas. 
 
 
 
Figure 14: Analysis of Glu-rtTA:: TetO-β-gal mice.  
To assess the specificity of the regulatory sequences and any putative leakiness of transgene expression, Glu-rtTA 
mice were crossed with the well-established TetO-β-gal mouse line (Hennighausen et al., 1995), and the resulting 
double transgenics were assayed (after the indicated treatments) for β-galactosidase expression in glucagon-
expressing cells by combining X-gal staining and immunohistochemical detection of the glucagon hormone. 
Transgene expression was found specifically regulated by Glu-rtTA as β-galactosidase activity was detected in 80 
to 90% of glucagon
+
 cells but not in any other cell types of the pancreas, indicating no leakage of the system. 
 
Next, the double transgenic Glu-rtTA::TetO-Pax4 mice generated. In those animals, 
rtTA is expressed in glucagon-expressing cells but cannot bind to its corresponding Tet operator 
sequence due to conformational restrictions. However, upon Dox administration (provided in 
drinking water), rtTA undergoes a conformational change enabling the protein to bind to the Tet 
operator region. Once rtTA is bound, it promotes the expression of Pax4 in glucagon-expressing 
α-cells. The principle of the inducible TetOn Advanced System (Clontech) is depicted in Figure 
15. 
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Figure 15: The inducible TetOn Advanced System (Clontech).  
Strategy used for the inducible/reversible misexpression of Pax4. In Glu-rtTA::TetO-Pax4 double-transgenic mice, 
upon glucagon expression, the reverse tetracycline-dependent transactivator (rtTA) is produced but remains 
inactive. Following doxycycline treatment, rtTA is activated, specifically interacts with the Tet operator sequence 
and transactivates Pax4 transcription as long as doxycycline is present. (Glu. Pro) Glucagon promoter, (TET op.) 
Tet operator, (Dox) Doxycycline. 
 
These bitransgenic animals were thus treated with Dox at 4 weeks of age, and assayed 
for Pax4 mRNA at 12 weeks of age. From here on, mice treated with doxycycline/ tamoxifen 
for x months will be referred to as xmDox
+
/xmTam
+
. In all cases, untreated animals were found 
phenotypically similar to their wild-type (WT) counterparts, and they will be referred to as Dox
-
/Tam
-
 or controls. Accordingly, wild-type and Dox
-
Glu-rtTA::TetO-Pax4 control mice 
displayed similarly low levels of Pax4 mRNA (WT not shown and Figure 16). However, in 
pancreata of 2mDox
+
 Glu-rtTA::TetO-Pax4 mice, the content in Pax4 transcripts was found 
considerably increased from 2.6- to 27-fold as compared to control mice, depending on the 
mouse line analyzed (and most likely on the loci of integration of the transgenes). In the 
following studies, the mouse line with 2.6-fold increase (line m2, Figure 16) was used. 
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Bitransgenic Glu-rtTA::TetO-Pax4 mice were found to be viable, fertile, and healthy. 
Their basal glycaemia and life span were within normal range, independent of Dox 
administration (Table 5).  
 
 
 
Figure 16: Pax4 expression levels in non-treated versus Dox-induced Glu-rtTA::TetO-
Pax4 mice.  
Glu-rtTA::TetO-Pax4 animals were generated, treated with Dox at 1 month of age for 2 months prior to 
examination by qPCR. Note the dramatic increase in pancreatic Pax4 transcript contents from 2.6 to 27 times 
depending on the founder lines analyzed (and therefore on the different integration sites of the transgenes). While 
both lines were used and gave a similar phenotype, the photographs provided herein correspond to the former. This 
choice was motivated by the fact that an overall 2.6-fold increase in Pax4 transcripts in the pancreata of induced 
transgenics matches the expected augmentation in expression of Pax4 following a 2-month Dox-treatment. Indeed, 
such a treatment leads to a ~2.5- fold increase in the Pax4
+
 β-like cell content (Table 5 and data not shown). This 
means that in this mouse line, Pax4 is not overexpressed but rather ectopically expressed in glucagon
+
 cells, at a 
dose matching the dose normally noted in β-cells. 
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Table 5: Assessment of basal glycaemia and life span od Dox treated Glu-rtTA::TetO-
Pax4 animals treated with Dox at different ages and for different durations.  
Glu-rtTA::TetO-Pax4 mice were treated with Dox at the indicated ages for the mentioned durations. Life 
expectancy and basal glycaemia (monitored weekly) are found within normal ranges, as compared to 
controls, in all conditions analyzed. 
 
 
 Adult α-cells can be converted into β-like cells upon Pax4 2.
misexpression 
The phenotypical analysis Glu-rtTA::TetO-Pax4 animals revealed a striking increase in 
the average islet size compared to WT or non-treated animals. A thorough investigation of islet 
size in Glu-rtTA::TetO-Pax4 mice of 1–11 months of age, treated with Dox from 10 days up to 
20 months, outlined a massive increase in average islet size in all cases (Table 6; Figures 17A 
and 17B). This hypertrophy was associated with a massive insulin
+
 cell hyperplasia and was 
found not to depend on the age at Dox administration but rather on its duration (Table 6). For 
instance, 1.5-, 7-, or 11-month-old Glu-rtTA::TetO-Pax4 mice treated for 5 months with Dox all 
displayed an approximate 3.5-fold increase in average islet size compared to their untreated 
counterparts (Table 6). As remarkable was the 2.7-fold increase in the overall islet number after 
only 10 days of Dox administration (Table 6). Such neo-formed islets were initially found 
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relatively smaller in size (Figures 18A and 18B). However, unlike the aforementioned 
continuous expansion of islet size, the increase in islet number plateaued at approximately 2.8 
times the numbers observed in controls (Table 6). Islet hypertrophy/multiplication were further 
demonstrated by means of optical projection tomography allowing visualization of the entire 
pancreatic insulin
+
 cell content (Figures 18C–18J). Both head and tail of the pancreas were 
thereby found to contain significantly more islets, a majority being much larger than their 
control counterparts. Altogether, our data indicate that the conditional misexpression of Pax4 in 
a cells of any age results in a progressive islet hypertrophy as well as in the generation of islets 
that are mainly composed of insulin-expressing cells. 
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Figure 17: The ectopic expression of Pax4 in adult α-cells induces an insulin
+
 β-like cell 
hyperplasia, resulting in hypertrophic islets and also in increased islet numbers.  
Representative pictures of immunohistochemical analyses performed on pancreas sections of 4-, 6-, and 10-month-
old WT/Dox
_
 (controls, A, C and D, G and H, K and L, O and P, S and T) and on age-/sex-matched Glu-
rtTA::TetO-Pax4 mice treated with Dox for 2, 4, or 8 months (Dox
+
 Glu-rtTA::TetO-Pax4, B, E and F, I and J, M 
and N, Q and R, U and V). Represented 6-month-old 4mDox
+
 pancreas sections outline a dramatic islet 
hypertrophy caused by an insulin
+
 cell hyperplasia as well as a massive increase in islet numbers (A and B). 
Importantly, insulin
+
 cells uniformly express the bona fide β-cell markers Pdx1 (C–F), Nkx6.1 (G–J), Pax4 (K–N), 
PC1/3 (O–R), Glut2 (S–V), but also MafA, NeuroD1, and Pax6 (Figure 19).  
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Table 6: Assessment of islet size, and islet number of Glu-rtTA::TetO-Pax4 animals 
treated with Dox at different ages and for different durations. 
To illustrate the impact of Dox treatment duration on islet hyperplasia, the data are rearranged based on Dox 
treatment duration. The results show a clear correlation between the length of Dox administration and islet size 
increase. Note that age has no impact on islet hyperplasia.  
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Figure 18: Analysis of Glu-rtTA and TetO-Pax4 mouse lines. 
(A-B) Mosaic pictures composed of 64 aligned photographs taken with a 10-time magnification of controls and 
induced Glu-rtTA:::TetO-Pax4 (2-month old treated 10 days with Dox) pancreata, demonstrating islet neogenesis 
denoted by the increase in the number of small-sized islets (inlet). (C-J) By means of optical projection 
tomography, pancreata of 5-month old controls (WT and Dox
-
 Glu-rtTA::TetO-Pax4, C-F) and age-matched 
3mDox
+
 Glu-rtTA::TetO-Pax4 animals (G-J) were assayed for insulin expression. A quantification of the insulin
+
 
cell volume reveals a 2.7-fold increase in both islet number and insulin
+
 cell content. n>3, all values are depicted as 
mean ± SEM, **p<0.01 using ANOVA comparison. (K-N) Electron microscopy examination was combined to 
insulin detection using immuno-gold staining to examine pancreata of 6 month-old WT/Dox
-
 and 3mDox
+
 Glu-
rtTA:::TetO-Pax4 animals. In induced pancreata, all cells displaying a β-cell ultrastructure express insulin (inlets). 
Similarly, all cells labeled with insulin exhibit a typical β-cell ultrastructure (n=3, 200 photographs analyzed per 
sample). 
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 Phenotypic analysis of mice conditionally misexpressing Pax4 in 3.
adult α-cells 
To determine whether the supplementary insulin-labeled cells displayed a β-cell 
signature, the expression of endocrine labels was determined in pancreata of 4-, 6-, and 10-
month-old Glu-rtTA::TetO-Pax4 mice treated (or not) with Dox for 2–8 months (Figure 17) 
displaying 6-month-old 4mDox
+
 pancreata; data not shown). In all cases, insulin-expressing 
cells uniformly expressed the bona fide β-cell markers, including Pdx1 (Figures 17C–17F), 
Nkx6.1 (Figures 17G–17J), Pax4 (Figures 17K–17N), PC1/PC3 (Figures 17O–17R), Glut-2 
(Figures 17S–17V), MafA (Figures 19A–19D), and NeuroD1 (Figures 19E–19H). These cells 
also expressed the pan-endocrine marker, Pax6 (Figures 19I–19L), but were predominantly 
negative for non-β-cell determinants, such as Arx, Brn4, glucagon, somatostatin, and PP 
(Figures 19M–19P; data not shown). To further ascertain the identity of the insulin-producing 
cells observed in Dox
+
 Glu-rtTA::TetO-Pax4 pancreata, electron microscopy examination was 
combined with insulin detection by immunogold labeling: a thorough analyses of more than 200 
photo- graphs per pancreas (n = 3) indicated that the ultrastructure of insulin-producing cells 
found in Pax4-misexpressing pancreata was comparable to that of WT β-cells (Figures 18K–
18N). 
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Figure 19: Quantification and characterization of the endocrine cells in Glu-rtTA::TetO-
Pax4 pancreata.  
 (A-P) Representative pictures of immunohistochemical analyses performed on islets of 4-, 6-, 10-month old 
WT/Dox- (Controls, A-B, E-F, I-J, M-N) and age-/sex-matched Glu-rtTA::TetO-Pax4 animals treated for 2, 4, 8 
months with Dox (Dox
+
 Glu-rtTA::TetO-Pax4, C-D, G-H, K-L, O-P) using the indicated antibody combinations. 
In addition to the data presented in Figure 17, in both genotypes, insulin-labeled cells express the β-cell labels 
MafA (A-D) and NeuroD1 (E-H), endocrine cells uniformly expressing Pax6 (I-L). Arx is solely found in 
glucagon
+
 cells in controls and induced transgenic animals (M-P). (Q-V) Quantitative comparison of the numbers 
of glucagon- (Q), insulin- (R), somatostatin- (S), or PP- (T) expressing cells as well as of the number of islet (U) 
between 7-month old Dox-treated transgenic mice (treatment for 5 months) and aged-matched WT/Dox
-
 mice (n=3 
for each group). Note the dramatic increase in the numbers of hormone-expressing cells or islets in induced double-
transgenic animals compared to controls. (V) Histogram illustrating the increase in the number of proliferating cells 
in the adult pancreas. A quantitative comparison of the number of proliferating cells between 3.7-month old Dox
+
 
transgenic mice and aged-matched WT mice, following 10 days of BrdU treatment, outlines a statistically 
significant increase in the count of BrdU-labeled cells upon Pax4 misexpression. n>4, all values are depicted as 
mean ± SEM. * p<0.05, ** p<0.01 using ANOVA comparison. 
 
 
 
68 
 
  
In addition to the increased number of islets and insulin
+
 cells, Dox
+
 Glu-rtTA::TetO-
Pax4 mice also showed augmented contents of glucagon
+
 (Figures 20A–20C and 19Q), PP
+
 
(Figures 20A, 20D, and 19T), and somatostatin
+
 (Figures 20E, 20F, and 19S) cells (5.5, 2.7, 
or 14.6 times, respectively, in 7-month-old 5mDox
+
 Glu-rtTA::TetO-Pax4 animals as compared 
to their Dox counterparts). Interestingly, these were not found uniformly distributed within the 
islet mantle but clustered at one pole of the islet, adjacent to neighboring ducts (Figures 20A–
20F). Intriguingly, and solely in Dox
+
 Glu-rtTA::TetO-Pax4 pancreata, ducts appeared 
consistently surrounded by a cell-dense zone reminiscent of the mesenchyme phenotype (Figure 
21 and below). Altogether, these data indicate that induced misexpression of Pax4 in α-cells of 
any age results in progressive β-like cell hyperplasia and islet number increase. An atypical 
location and augmented numbers of non-β cells are outlined near the ducts that are surrounded 
by a cell-dense area. 
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Figure 20: Pax4 misexpression in adult glucagon
+
 cells can be controlled and results in 
islet hypertrophy and in the misallocation of non-β-cells within the Islet. 
(A–F) Not only do 6-month-old 4mDox
+
 pancreata display a substantial β-like cell hyperplasia (islets outlined in 
white), an abnormal localization of glucagon
+ 
(A–C), PP (A and D), and d cells (E and F) is also noted, these being 
mostly detected at a pole of the islet adjacent to neighboring ducts (lumen outlined in yellow) or within the ductal 
lining. In subsequent figures, non-β cells may not appear at a pole of the islet because ducts can be located 
above/below the section: only a three-dimensional examination allows proper visualization. 
(G) To determine whether Pax4 misexpression could be arrested, 1.5-month-old WT and Glu-rtTA::TetO-Pax4 
animals were initially treated (or not) with Dox for 1 month. Subsequently, Dox administration was either 
discontinued or prolonged for 3 additional months. Examination and islet size quantification were performed at 1.5, 
2.5, and 5.5 months of age. Although islet size appears similar in all conditions at the time of Dox induction (1.5 
month of age), a significant increase is noted at 2.5 months of age solely in Dox-treated mice. Islet size is found to 
be further increased in Glu-rtTA::TetO-Pax4 mice treated with Dox for 4 months (in red). Importantly, such 
reincrease is not seen in 5.5-month-old Glu-rtTA::TetO-Pax4 mice for which Dox administration has been stopped 
at 2.5 months of age (in pink). An interesting observation is that there is no return to a normal size once Dox 
treatment is arrested, suggesting that the neo-generated β-like cells are maintained even when Pax4 misexpression 
has been discontinued. The amount of Pax4 transcripts, quantified in 5.5-month-old animals, is found to match the 
increase in insulin
+
/Pax4
+
 cell numbers: a drastic increase is noted in 4mDox
+
 mice (as compared to controls, p < 
0.001), which is not seen in animals for which Dox administration was interrupted. The latter still display a slightly 
elevated Pax4 transcript content reflecting the increased insulin
+
/Pax4
+
 cell population. n > 3. All values are 
depicted as mean ± SEM. ***p < 0.001, **p < 0.01 using ANOVA comparison. See also Figure 21. 
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Figure 21: Detection of a nuclei-dense/mesenchyme-like structure surrounding ducts of 
induced Glu-rtTA::TetO-Pax4 pancreata. 
A thorough anatomical examination of 12.5-month old 5mDox
+
 Glu-rtTA::TetO-Pax4 pancreases (E-L) as 
compared to WT/Dox
-
 age-/sex-matched controls (A-D) outlines an important thickening of the ductal lining upon 
Pax4 misexpression, such structure resembling mesenchyme. Several examples are provided using the indicated 
(immuno-) staining (A, C, E, G, I, J, K) or classical bright field examination (B, D, F, H, L). For bright field 
pictures, the lumen of duct is outlined in blue, the ductal lining in red and islets in green, a rendering of the ductal 
and its lining areas being provided in selected photographs.  
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 Controlling insulin-producing cell regeneration 4.
To determine whether the misexpression of Pax4 in adult α-cells and the resulting 
hyperplasia of insulin
+
 cells could be controlled, 1.5-month-old controls or Glu-rtTA::TetO-
Pax4 mice were administered (or not) with Dox for 1 month, Dox treatment was subsequently 
continued (or not) for 3 additional months. Quantitative analyses revealed a 2.1-fold increase in 
average islet size in 1mDox
+
 Glu-rtTA::TetO-Pax4 animals, as compared to their untreated 
counterparts (Figure 20G). Islet size and insulin
+
 cell counts were found further increased in 
4mDox+ mice (up to 6.3 times). Importantly, in 1mDox
+
 animals examined 3 months after the 
interruption of Dox treatment, islets did not continue to expand but they did remain enlarged as 
compared to controls (2.3 times), indicating that the supplementary insulin
+
 cells generated 
between 1.5 and 2.5 months of age were maintained after the arrest of Pax4 misexpression 
(Figure 20G). Interestingly, compared to controls, the amount of Pax4 transcripts was 6.7-fold 
increased in 4mDox
+
 Glu-rtTA:: TetO-Pax4 mice and only 2.5-fold in 1mDox
+
 3mDox mice 
(Figure 20G). Concerning the latter, it is important to note that Pax4 is normally expressed in 
adult β-cells (Figures 17K and 17L; (Collombat and Mansouri, 2009; Lu et al., 2010): our 
results therefore confirm an arrest of Pax4 misexpression, the 2.5-fold increase in the Pax4 
transcripts corresponding to the 2.3-fold augmentation in islet size (and thereby in Pax4
+
 
insulin
+
 cells), as compared to controls. The ectopic expression of Pax4 in adult glucagon
+
 cells 
and the subsequent islet hypertrophy can thus be tightly controlled in this experimental model. 
 
 
 Mobilization of Ngn3-re-expressing duct-lining precursor cells to 5.
adopt a glucagon
+ 
cell identity and, subsequently, a β-cell phenotype 
To determine the origin of newly formed insulin+ cells in Glu- rtTA::TetO-Pax4 mice, 
further immunohistochemical analyses and lineage-tracing experiments were undertaken. A 
small number of insulin+/glucagon+ cells were consistently observed (Figures 22A–22D), 
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suggestive for a putative transitional stage during β-like cell neogenesis. To validate this 
hypothesis, Glu- rtTA::TetO-Pax4 mice were crossed with Glu-Cre::ROSA26-β-gal animals 
allowing permanent labeling of ~78% ± 8% of cells that had ever expressed glucagon (Figures 
23A–23C and 23G). Using a quantitative analysis of 4-month-old 2mDox
+
 Glu-rtTA::TetO-
Pax4::Glu-Cre::ROSA26-β-gal pancreata, insulin+ β-galactosidase+ cells (formerly glucagon+ 
cells) were found to represent ~45% ± 11% of the total insulin+  cell count, that is ~74% ± 9% 
of the calculated supplementary insulin+ cell count (Figures 22E–22I and 23D–23G). These 
results suggest that adult glucagon+ cells can be regenerated and converted into insulin+ β-like 
cells upon Pax4 induction. Indeed, given the limitation in labeling of glucagon+ cells (~78% ± 
8%), these data indicate that most of the supplementary insulin+ cells derived from glucagon+  
cells (~74% ± 9% of these insulin+  cells were found labeled). 
In Glu-rtTA::TetO-Pax4::Glu-Cre::ROSA26-β-gal animals, glucagon+ cells are labeled 
independently of Pax4 misexpression. Therefore, since Pax4 is not induced in all glucagon+  
cells, due to the inherent imperfection of these transgenic systems, it could have a paracrine 
effect on Pax4
_
 β-galactosidase+ glucagon+cells and induce their conversion into β-
galactosidase+ β-like cells. To exclude this possibility, Glu-rtTA::TetO-Pax4 mice were also 
crossed to TetO-Cre::ROSA26-β-gal animals, the resulting quadruple transgenics allowing the 
sole labeling of glucagon+ cells having misexpressed Pax4. Two-month-old animals were also 
treated with Dox for 2 months (or 4 months), and results similar to that found in Glu-
rtTA::TetO-Pax4::Glu-Cre::ROSA26-β-gal mice were obtained with a labeling of ~74%–76% 
of neogenerated β-like cells (Figure 23G). Thus, the proportion of β-galactosidase+ β-like cells 
was found unchanged across models or with different induction times, indicating that Pax4 does 
not have a paracrine activity on Pax4
_
 glucagon+ cells. 
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Of further interest was the detection of very few cells simultaneously expressing 
endocrine hormones and the duct-specific biomarker osteopontin in islets and/or adjacent to 
ducts (Figures 22J–22L). To examine a putative ductal ontogeny of these cells, HNF1β-CreER 
mice (Solar et al., 2009), allowing the labeling and tracing of ~40% ± 8% of HNF1β+ duct cells 
(Figures 23H– 23K), were crossed with Glu-rtTA::TetO-Pax4::ROSA26-β-gal mice. When 
Glu-rtTA::TetO-Pax4::HNF1β-CreER::ROSA26-β-gal mice were treated with Dox
+
Tam, ~42% 
± 8% of duct cells showed β-galactosidase activity (Figures 22M–22U and 23H–23K). 
Importantly, ~38% ± 7% of neogenerated (or newly formed) endocrine cells were found to be β-
galactosidase+, supporting the concept that a majority of these endocrine cells passed through a 
HNF1b+ transitional phase. Thus, tracing of different cell lineages provide conclusive evidence 
that the ectopic expression of Pax4 in adult a cells can stimulate a subset of HNF1β+duct-lining 
cells to adopt an endocrine cell identity and that, at least the glucagon+ cells thereby generated, 
can subsequently be converted into β-like cells. 
To gain further insight into the mechanisms underlying the insulin+ cell hyperplasia 
observed in this model, a 10-day bromo-deoxyuridine (BrdU) pulse-chase was performed. A 
5.2-fold increase in BrdU-labeled cell number was thereby observed (Figures 24A–24D and 
19V). Surprisingly, most BrdU+ cells were found predominantly localized in the ductal lining 
(Figures 24B– 24D). Under these conditions, the expression of the developmental proendocrine 
gene, Ngn3, was investigated. Ngn3 has previously been found re-expressed in duct-lining cells 
after severe injury (Pan et al., 2013; Xu et al., 2008) or constitutive, ectopic expression of Pax4 
(Collombat and Mansouri, 2009). Ngn3 expression in adult islet cells was previously reported 
by others (Wang et al., 2009), but it appeared extremely weak in our control mice (Figure 25A) 
due to a very low expression level. Nevertheless, in 12-month-old Dox
+
 Glu-rtTA::TetO-Pax4 
mice, Ngn3 expression was found robustly reactivated within the ductal lining (Figures 24D, 
24G, 24H, and 25B) and, transitorily, in a subset of islet cells located adjacent to ducts 
 
 
 
74 
 
  
(Figures 24E– 24H). The contribution of Ngn3-re-expressing duct-lining cells to the islet 
hypertrophy was determined by lineage tracing in Glu-rtTA::TetO-Pax4::ROSA26-β-gal mice 
crossed with Ngn3-CreER animals (Gu et al., 2002). Although islet cells of Tam
-
 treated 
quadruple transgenics or of Ngn3-CreER::Rosa26-β-gal controls appeared mostly negative for 
β-galactosidase (~2.3% of endocrine cells labeled after 2 months of Tam treatment, suggestive 
of scattered/low expression of Ngn3 in adult cells; Figures 24I and 24J), ~35% ± 7% of 
periductal cells were found to be positive for β-galactosidase in Tam
+
Dox
-
 treated animals 
(Figures 24I–24U). Importantly, a similar proportion, ~28% ± 7%, of neogenerated endocrine 
cells appeared to be β-galactosidase
+
, with such cells expressing insulin, glucagon, or 
somatostatin (Figures 24Q–24T). Hence, Pax4 misexpression in adult glucagon
+
 cells leads to 
their conversion into β-like cells. Subsequently, our data indicate a transient re-expression of 
Ngn3 in duct-lining cells (labeled and traced through HNF1β expression), most of these cells 
being, in turn, converted into endocrine cells. 
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Figure 22: Upon Pax4 misexpression in adult α-Cells, glucagon-expressing cells and 
HNF1β
+
 duct cells can adopt an insulin
+
 cell identity. 
(A–I) Immunofluorescence of pancreata of 6-month-old 4mDox
+
 Glu-rtTA::TetO-Pax4 mice outlines few cells 
positive for both insulin and glucagon (A–D), suggesting a putative glucagon
+
-to-β-like cell conversion. Glucagon
+
 
cell lineage tracing on 6-month-old 4mDox
+
 Glu-rtTA::TetO-Pax4::Glu-Cre::ROSA26-β-gal pancreata shows X-
gal staining in a number of cells located within the islet core where insulin
+
 cells are normally located (E). 
Immunohistochemistry reveals that most β-gal
+
 cells are, in fact, insulin
+
, indicating a conversion of glucagon
+
 cells 
into insulin
+
 cells (F and G). Smaller islets, most likely newly formed, are found almost uniformly positive for β-
gal (H and I).  
(J–U) The detection of cells expressing the ductal marker osteopontin together with insulin (J), glucagon (K), or 
somatostatin (L) suggests a potential involvement of duct-lining cells in endocrine cell neogenesis. Importantly, 
after their outcome using lineage tracing, we demonstrate the conversion of HNF1β
+
 duct-lining cells into 
endocrine cells and more specifically, insulin-producing cells (M–U). See also Figure 23.  
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Figure 23: Lineage tracing in induced Glu-rtTA::TetO-Pax4 pancreata. 
(A-G) Glu-Cre::ROSA26-β-gal animals were used to label glucagon-producing cells and follow their progeny. These animals were generated by 
crossing animals harboring the following transgenes: glucagon promoter driving the expression of the phage P1 Cre recombinase cDNA 
(Herrera, 2000); ROSA26 promoter upstream of a loxP-Neomycin resistance-STOP-loxP cassette followed by the β-galactosidase cDNA 
(Soriano, 1999). In addition to the results presented in Figure 22A-L, 6-month old Glu-Cre::ROSA26-β-gal control pancreatic sections were 
labeled using a combination of anti-insulin immuno-detection and X-Gal staining (A-C). Note that β-galactosidase activity is solely detected in 
the islet mantle and not in the islet core where β-cells are located. Sections of Glu-rtTA::TetO-Pax4::Glu-Cre::ROSA26-β-gal pancreata 
subjected to the same treatment demonstrate β-gal activity within insulin-producing cells both in hypertrophic islets (Figure 22E-I), but also in 
small islets (D-F). In Glu-Cre::ROSA26-β-gal and induced quadruple transgenic pancreata, quantitative analyses reveal that β-gal labels on 
average 82% and 73.8% of glucagon+ cells, respectively (G). Importantly, 45.1% of β-like cells of 2mDox+ Glu- rtTA::TetO-Pax4::Glu-
Cre::ROSA26-β-gal animals are found to be β-gal+. By factoring in the 153.9% increase in β-like cell numbers, these are found to represent 
(45.1X253.9)/153.9=74% of the supplementary β-like cells, a percentage in line with the proportion of initially labeled glucagon+ cells (G). 
Similar results were obtained in 2mDox+ and 4mDox+ Glu-rtTA::TetO-Pax4::TetO-Cre::ROSA26-β-gal mice allowing the sole labeling of 
glucagon+ Pax4+ cells, with a labeling of 74-76% of newly-formed β-like cells. This suggests that Pax4 does not exert a paracrine effect and 
does not induce the conversion of neighboring glucagon+ Pax4- cells (or the number of β-gal+ insulin+ cells would have been lower as compared 
to Glu-rtTA::TetO-Pax4::Glu-Cre::ROSA26-β-gal animals, or found decreasing with the induction time in Glu-rtTA::TetO-Pax4::TetO-
Cre::ROSA26-β-gal mice). (H-K) HNF1β-CreER::ROSA26-β-gal animals (Solar et al., 2009) were used for ductal cell lineage tracing. In 
addition to the results presented in Figure 22M-U, photographs of β-gal staining from representative sections of Tam+ HNF1β-
CreER::ROSA26-β-gal (H-I) and of Tam+ Dox+ Glu-rtTA::TetO-Pax4::HNF1β-CreER::ROSA26-β-gal (J) are presented: note the equivalent 
numbers of β-gal+ duct-lining cells in both conditions and the detection of β-gal+ endocrine cells solely in Tam+/Dox+ quadruple transgenic 
pancreata. Quantitative analyses indicate a labeling of 42% of duct cells, this percentage almost matching the proportion of β-gal+ supplementary 
endocrine cells (38%). Percentages ± SEM correspond to the quantification of hormone+, Pax6+ (endocrine cell quantification), or osteopontin+ 
(duct cell quantification) cells expressing β-galactosidase using cell counts (every 10th section) on at least 3 animals per genotype. 
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Figure 24: Assessment of cell proliferation and of the contribution of Ngn3-re-expressing 
cells to the supplementary endocrine cell Population of induced Glu-rtTA::TetO-Pax4 
mice. 
(A–H) The detection of proliferating cells in 4-month-old 1mDox
+
 Glu-rtTA::TetO-Pax4 animals, using a 10 day 
pulse of BrdU, outlines a 5.2-fold increase in BrdU
-
 labeled cell numbers (B–D), as compared to their nontreated 
counterparts (A). Importantly, these are mostly found outside of the islets, in the adjacent ductal lining. Ngn3 
detection reveals a reactivation of this developmental factor in the ductal lining, its expression persisting in a few 
insulin-labeled cells for a limited amount of time (D–H). 
(I–T) Lineage tracing experiments were undertaken by following the fate of adult Ngn3
+
 cells in 7.5-month-old 
2mDox
+
/2mTam
+
 Glu-rtTA::TetO-Pax4::Ngn3-CreER::ROSA26-β-gal. β-galactosidase activity assayed using X-
gal staining and immunohistochemistry is found in very few islet cells of 2mTam
+
 Ngn3-CreER::ROSA26-β-gal 
controls (I and J), but present in Dox
+
/Tam
+
 quadruple transgenic islets (K–N and P), ductal lining (O), and a 
number of insulin
+
 (K and L, and Q and R), glucagon
+
 (S), or somatostatin
+
 (T) cells, indicating that cells re-
expressing Ngn3 eventually adopt an endocrine cell identity. 
(U) In fact, quantitative analyses demonstrate a β-gal labeling of ~35% of duct cells. Importantly, ~16% of 
endocrine cells in induced Glu-rtTA::TetO-Pax4::Ngn3-CreER::ROSA26-β-gal pancreata also appear to be β-gal
+
. 
By factoring in the islet hypertrophy, these are found to represent ~28% of supplementary endocrine cells, a 
percentage in line with the proportion of labeled duct cells. The indicated percentages (±SEM) correspond to 
quantification of Pax6
+
 (endocrine cell quantification) or osteospontin
+
 (duct cell assessment) cells expressing β-
galactosidase using cell counts (every tenth section) on at least three animals per genotype. For X-gal staining, the 
counting of β-galactosidase
+
 cells was reported to the number of islet cells assessed with DAPI staining.  
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Figure 25: Analysis of key players of ΕΜΤ in induced Glu-rtTA::TetO-Pax4 pancreata. 
(A-H) In addition to the results presented in Figure 27, the expression of key players of the EMT was analyzed by 
immunohistochemistry in WT/Dox
-
 controls and Dox-treated Glu-rtTA::TetO-Pax4 pancreata. Ngn3 labeling was 
found absent in controls (A), while strongly re-expressed in induced animals (B). Similarly, Vimentin was found 
lacking in controls (C) but strongly re-expressed in Pax4-misexpressing mice (D). An additional example of the 
loss of E-cadherin labeling in the mesenchyme-like continuum adjacent to ducts (E) or of Snail2 re-expression in 
the same location (F) are provided. Importantly, Ptf1a is not found ectopically expressed in the ductal epithelium or 
lining in Dox-treated Glu-rtTA::TetO-Pax4 pancreata. Note that, due to the strength of E-cadherin labeling in ducts, 
the overall brightness of E-cadherin staining was digitally diminished to allow for a clearer visualization.  
 
 
 
 Ngn3-mediated EMT in adult dox+ Glu-rtTA::TetO-Pax4 mice 6.
To gain a deeper insight into the molecular mechanisms underlying Pax4-mediated 
regeneration, transcriptome analyses were performed on pancreata of Glu-rtTA::TetO-Pax4 
mice that received Dox for increasing periods of time compared to age-/sex-matched Dox- 
controls. Interestingly, whereas the expression of the stem cell marker genes Oct4 and Nanog 
was unaltered (Table 7), the expression of Snail2, Vimentin, Ngn3, and Sox11, transcriptional 
regulators of the developmental epithelial-mesenchymal transition (EMT) (Hargrave et al., 
1997; Lioubinski et al., 2003; Rukstalis and Habener, 2007), was found dramatically increased 
(Table 7). These results were confirmed by real-time quantitative PCR (qPCR) (Table 7) and 
immunohistochemistry (Figure 26). Indeed, Vimentin, the canonical mesenchymal marker, was 
found widely re-expressed in the cell-dense clusters surrounding ducts (Figures 26A–26F, 26I, 
21, 25C, and 25D). Nestin+ cells were also found in the same location (Figures 26G and 26H). 
It is important to note that the expression of Vimentin is normally absent in this location in 
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WT/Dox
_ 
pancreas (Figures 26E and 25C). In fact, further examination outlined a few E-
cadherin+ Vimentin+ duct-lining cells (Figures 26A–26D); these cells most likely acquired a 
migratory phenotype as seen during embryonic EMT. Conversion from Vimentin+ to insulin+ 
cells was suggested by the presence of rare double-positive cells (Figure 26I). Due to technical 
limitations, we could not codetect β-gal+ and Vimentin+ cells in Glu-rtTA:: TetO-Pax4::HNF1β-
CreER::ROSA26-β-gal pancreata; however, numerous β-gal+ cells were found within the ductal 
lining where most Vimentin+ cells were detected (Figure 26J). Sox11 and Snail2 also appeared 
ectopically expressed in cells clustered around the ductal epithelium of Dox
+
 Glu-rtTA::TetO-
Pax4 pancreata (Figures 26L, 26N, and 25F), in contrast to control mice (Figures 26K and 
26M). Of note, Pan et al. (2013) recently found that, upon pancreatic duct ligation (PDL), acinar 
cells could be converted into duct-like cells ectopically expressing Ptf1a, a fraction of which 
being further converted into endocrine cells. Interestingly, Ptf1a was not detected in ductal cells 
of Glu-rtTA::TetO-Pax4 pancreata (Figures 25G and 25H), indicating that acinar cells do not 
seem to contribute to the neogenerated endocrine cell population in our model. 
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Table 7: Real-time RT-PCR analysis of selected transcripts in induced Glu-rtTA::TetO-
Pax4 pancreata. 
Glu-rtTA::TetO-Pax4 mice were treated with Dox at 2 months of age and their pancreas was isolated 3 weeks later. 
RT-qPCR analyses were performed for the indicated genes. Note the dramatic increase in insulin, somatostatin, PP, 
Ngn3, Vimentin, Snail2, Sox11 transcripts in induced pancreata compared to WT/Dox
-
 controls. n>4, all values are 
depicted as mean ± SEM, ***p<0.001, **p<0.01, *p<0.05 using ANOVA comparison.  
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Figure 26: Reawakening of the EMT in Glu-rtTA::TetO-Pax4 pancreata. 
Immunohistochemical analyses reveal that key players of the developmental EMT are re-expressed in Dox
+
 Glu-
rtTA::TetO-Pax4 pancreata. In 6-month-old 3mDox
+
 animals, the mesenchymal markers Vimentin (A–F and I), 
Nestin (G and H), Sox11 (K and L), and Snail2 (M and N) are all found re-/ectopically expressed in the previously 
noted mesenchyme-like structures that surround a number of ducts (Figure 21). A coexpression of Vimentin and E-
cadherin is also observed in scattered cells (A–D); similarly, a number of cells are found to be positive for both 
insulin and Vimentin (I): these results suggest a putative transition from an epithelial to mesenchymal phenotype 
and, subsequently, from a mesenchymal to an endocrine identity. Due to technical limitations, we could not 
perform β-gal
+
 and Vimentin
+
 cell codetection in Glu-rtTA::TetO-Pax4::HNF1β-CreER::ROSA26-β-gal pancreata. 
Despite this issue, numerous β-gal
+
 cells were found located in the ductal lining (J) where most Vimentin
+
 cells are 
observed, supporting the notion that duct-lining cells pass through a Vimentin-expressing cell stage/EMT cycle 
prior to the acquisition of an endocrine cell identity. Note that, due to the strength of E-cadherin labeling in ducts, 
the overall brightness of E-cadherin staining was digitally diminished to allow for a clearer visualization. In 
selected photographs, islets are outlined in white dashed lines whereas the ductal lumen is outlined in yellow 
dashed lines. See also Figure 25.  
 
 
Since Ngn3 can induce the EMT during pancreas morphogenesis through the 
stabilization/activation of Snail2 (Gouzi et al., 2011), Ngn3 expression was inhibited by 
knockdown to assess its role in EMT reinduction and islet overgrowth upon Pax4 
misexpression. Glu-rtTA::TetO-Pax4 animals were therefore injected with GFP-encoding 
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lentiviruses containing either a small hairpin RNA (shRNA) targeting Ngn3 or a scrambled 
sequence (Collombat and Mansouri, 2009; Xu et al., 2008), subsequently treated with Dox, and 
examined 3 weeks later. Immunohisto-chemical analyses using antibodies raised against GFP, 
CK19, and synaptophysin confirmed previously published results (Collombat and Mansouri, 
2009; Xu et al., 2008) by demonstrating a targeting of 53% ± 8% of CK19+ ductal cells and of 
4% ± 3% of synaptophysin+ endocrine cells (Figure 27C). Similarly, using qPCR, we noted a 
45% ± 9% decrease in Ngn3 transcript contents in pancreata infected with the lentiviruses 
containing shRNAs targeting Ngn3, as compared to scrambled-infected pancreata (Figure 27C). 
Both islet size and number were found significantly decreased in Ngn3 knockdown pancreata 
compared to controls (Figures 27A–27C). Similarly, Ngn3+ and Snail2+ cell contents were also 
found diminished (Figures 27D and 27E), suggesting a causative role of Ngn3 in EMT. 
Interestingly, a similar prevention of islet hypertrophy was noted when Dox
+
 Glu-rtTA::TetO-
Pax4 animals were treated for 1 month with exogenous glucagon (Figures 27F–27K), 
suggesting that the shortage in the glucagon hormone caused by the Pax4-mediated glucagon+-
to-β-like conversion promotes such β-like cell neogenesis. Thus, in animals misexpressing Pax4 
in adult glucagon+ cells, our results support the notion of a glucagon shortage-dependent 
mobilization of duct-lining cells that re-express Ngn3 and adopt an endocrine cell identity 
through processes involving the reactivation of embryonic EMT. To our knowledge, this 
corresponds to the first demonstration of EMT reactivation in the adult context outside of 
pathological conditions. 
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Figure 27: Ngn3 knockdown or glucagon supplementation prevents EMT-driven islet 
hyperplasia/neogenesis. 
(A–E) Infection of 3-month-old Glu-rtTA::TetO-Pax4 animals using GFP-encoding lentiviruses producing either a 
shRNA targeting Ngn3 transcripts or a scrambled shRNA. After infection, the animals were administered Dox for 3 
weeks and sacrificed for examination: Ngn3 knockdown pancreata exhibit a 45% decrease in Ngn3 transcript 
content (C), but also a significant 38% diminution in insulin+ cell counts and a 39% decrease in islet numbers, as 
compared to their scramble-infected counterparts (A–C). A drastic reduction in Snail2-re-expressing cells is also 
noted in knockdown animals (D–E). For a better overview, photographs in (A) and (B) correspond to a composite 
regrouping 64 pictures.   (F–K) Examination of 5-month-old Glu-rtTA::TetO-Pax4 animals, injected with either a 
saline solution or glucagon, and concomitantly treated with Dox for 3 months. Although their glycaemia was found 
within normal ranges (data not shown), note the diminished size (F, J and K) and number of islets (G, J and K), as 
well as decreased insulin- (H, J and K), and glucagon- (I) producing cell counts in animals supplemented with 
glucagon as compared to genotype-matched Dox-treated animals injected with saline. n > 3. All values are depicted 
as mean ± SEM. **p < 0.01, *p < 0.05 using ANOVA comparison.  
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 Controlled Pax4 misexpression in adult glucagon+ cells can induce 7.
multiple cycles of β-cell-mass regeneration 
The β-cell phenotype and glucose responsiveness of Dox
+
 Glu-rtTA::TetO-Pax4 mice 
were examined in vivo. In addition to a normal basal glycaemia (Table 5), these animals 
responded better to glucose challenges performed at different ages or after various durations of 
Dox administration, with a lower peak in glycaemia and a faster normalization (Figure 28A; 
data not shown). As expected, circulating insulin levels were found normal under physiological 
conditions but dramatically increased in challenged Dox
+
 mice compared to controls (Figure 
28A), suggestive of an increased b-like cell mass. However, upon insulin challenge, the 
glycemic variations in induced Glu-rtTA::TetO-Pax4 mice remained similar to that of controls, 
indicating an unaltered response to insulin (data not shown). 
To determine whether neogenerated insulin+ cells in Dox
+
 Glu-rtTA::TetO-Pax4 mice 
were functional, 4-month-old 1mDox
+
 Glu-rtTA::TetO-Pax4 mice were injected with a high 
dose of streptozotocin (STZ) to eliminate endogenous insulin- producing cells (Mansford and 
Opie, 1968). Although control mice quickly became diabetic and died from massive 
hyperglycemia, all Dox
+
 Glu-rtTA::TetO-Pax4 mice displayed a short period of hyperglycemia 
but then steadily restored normoglycemia and survived (Figures 28B and 28C). 
Immunohistochemical analysis at different time points demonstrated that insulin
+
 cells were 
progressively regenerated after β cell loss (Figure 28D). Of note, in pancreata of 1mDox
+
 Glu-
rtTA::TetO-Pax4::Glu-Cre:: ROSA26-β-gal animals treated with STZ and examined 2 months 
later, the majority of insulin+ cells were found to be β-galactosidase
+
 (Figure 28E), further 
documenting that numerous newly generated β-like cells were derived from glucagon-
expressing cells. 
The surviving mice were then maintained on Dox for 1 month, and, subsequently, Dox 
treatment was either discontinued or prolonged. Five weeks later, another glucose challenge 
showed that solely the mice that were maintained on Dox during the entire procedure displayed 
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an improved response (Figure 28F). When these mice were subjected to another round of STZ, 
again only those that were kept on Dox during the whole process survived and showed a 
progressive normalization of their glycaemia (Figures 28G and 28H). This indicates that the 
newly formed β-like cells are sensitive to STZ but also that a second cycle of β-like cell 
regeneration can be induced (data similar to Figure 28D). In contrast, mice with discontinued 
Dox supply died of hyperglycemia (Figures 28G and 28H). To further test the robust capacity 
of this regeneration process, a third dose of STZ was administered to the surviving mice and 
resulted in a similar outcome (Figure 28I). The latter animals survived more than 7 months 
after the third injection of STZ (data not shown). These results provide evidence (1) that Pax4 is 
instrumental to glucagon
+
 cell-mediated β-like cell regeneration, (2) that the newly formed β-
like cells are functional and can counter chemically induced diabetes, and (3) that the functional 
β-cell mass can be repetitively replenished. 
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Figure 28: The whole β-cell mass can be replenished repeatedly in dox-treated Glu-
rtTA::TetO-Pax4 animals. 
(A) Three-month-old 1mDox Glu-rtTA::TetO-Pax4 (and controls corresponding to WT/Dox
_
 age-/sex-matched 
animals) were challenged with glucose. Induced animals perform better than controls with a lower peak in 
glycaemia and a faster return to euglycemia, suggestive of an increased β-like cell mass as outlined by circulating 
insulin measurements.  (B–E) One month after Dox administration, mice were subjected to streptozotocin 
treatment. Their glycaemia (B), survival (C), and pancreatic islet composition (D) were monitored. After a peak in 
glycaemia, a steady recovery is noted for induced mice (B), whereas controls die from massive hyperglycemia (C). 
Such recovery is associated with a clear regeneration of their β-cell mass monitored 5, 10, 30, and 80 days 
poststreptozotocin administration (D). The same experiments performed in Glu-rtTA::TetO-Pax4::Glu-
Cre::Rosa26-β-gal animals reveals that most regenerated β-like cells derive from cells that expressed the glucagon 
hormone (E). (F–H) At 5 months of age, Dox administration was either discontinued or prolonged for the surviving 
animals. Four weeks later, another glucose challenge was initiated and yet again, Dox-treated animals performed 
better than controls (F). Interestingly, Glu-rtTA::TetO-Pax4 animals for which Dox administration has been 
arrested react in a similar fashion to controls. Subsequently, these ‘‘survivors’’ were reinjected with streptozotocin 
resulting in Dox-treated mice seeing another increase in their glycaemia followed by a progressive return to normal 
ranges whereas all controls died displaying a massive hyperglycemia (G and H). Importantly, animals for which 
Dox treatment has been stopped also died presenting a massive increase in blood glucose levels (G and H).   (I) In 
addition, a third streptozotocin treatment leads to the same outcome, indicating that the β-cell mass can be replaced 
at least three times.   For all experiments, n > 3; all values are depicted as mean ± SEM. ***p < 0.001, **p < 0.01 
using ANOVA comparison (A, B and F). (C and H) Kaplan-Meier survival curve with ***p < 0.001 by log-rank 
test.  
 
 B. Discussion 
Our study demonstrates that the misexpression of Pax4 in adult α-cells promotes their 
conversion into β-like cells, but also induces a cycle of β-like cell neogenesis, resulting in an in- 
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crease in islet size and number. Importantly, these processes can be regulated and depend on the 
duration of Pax4 misexpression, but not on the age of induction. After the initial conversion of 
α-cells into β-like cells, increased proliferation and ectopic expression of Ngn3 are noted in the 
ductal lining, a subset of duct-lining/Ngn3-re-expressing cells eventually adopting a glucagon
+
 
cell identity and, subsequently, a β-like cell phenotype. Further analyses demonstrate that such 
endocrine cell neogenesis involves a Ngn3-mediated reactivation of the developmental EMT. 
Last, we provide evidence that Pax4 misexpression in adult glucagon
+
 cells is able to promote 
several cycles of replenishment of the β-like cell mass, and thereby to reverse several rounds of 
toxin-induced diabetes. 
 
 Pax4 promotes glucagon+ cell-mediated β-like cell neogenesis 1.
Our analysis indicates that, upon Pax4 misexpression, adult α cells can be converted into 
cells displaying most features of true β-cells independently of their age, maturation state, and 
microenvironment. Subsequently, the consistent detection of glucagon+ cells combined to 
lineage-tracing experiments show a cycle of glucagon+ cell neogenesis and conversion into β-
like cells, resulting in a limited increase in islet number and in a progressive, continuous, and 
controllable β-like cell hyperplasia. Interestingly, the continuous generation of β-like cells 
observed in these animals suggests an inherent capability of the adult pancreas to generate 
glucagon-producing cells in great numbers, these being turned into β-like cells upon Pax4 
misexpression and islets reaching up to ten times the size of control islets. As important was the 
observation of a limited increase in the number of islets: understanding the mechanisms 
involved in this islet neogenesis, but also in its restriction, would be of interest for diabetes 
research. 
Concomitantly to β-like cell neogenesis, an increase in the number of proliferating cells 
is noted in the ductal epithelium/ lining where Ngn3 expression is reactivated. These results are 
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in agreement with previous reports suggesting that, under specific conditions, facultative 
precursor cells may be induced to re-express Ngn3 and eventually adopt an endocrine cell 
phenotype (Collombat and Mansouri, 2009; Pan and Wright, 2011; Xu et al., 2008). Of interest 
was the recent detection of low levels of Ngn3 expression in adult endocrine cells but not in the 
ductal compartment (Wang et al., 2009). Under our experimental conditions, whereas we 
detected very low expression levels of Ngn3 in control islets by immunohistochemistry, a robust 
re-expression was noted in duct-lining cells of Dox
+
 Glu-rtTA::TetO-Pax4 mouse pancreas. 
Lineage-tracing experiments indicated that a number of adult Ngn3+ or HNF1β+  duct-lining cells 
could eventu- ally adopt a β-like cell identity. Interestingly, combining these quantitative 
analyses with glucagon+ cell lineage tracing, our data suggest that: (1) the large proportion of 
labeled glucagon+ cells matched the proportion of newly formed marked β-like cells, suggesting 
that, upon initial α-to-β-like cell conversion, glucagon+  cells are regenerated and further 
converted into β-like cells as long as Pax4 is misexpressed; (2) the proportion of labeled Ngn3+ 
or HNF1β+ cells also nearly matched the proportion of marked newly formed b-like cells, 
indicating that a majority of these β-like cells derived from Ngn3 re-expressing or HNF1β-
labeled cells. However, due to the incomplete labeling of these different cell subtypes (inherent 
to lineage tracing approaches), one cannot exclude that a fraction of neo-generated β-like cells 
could have an alternative origin. A possibility could be an acinar origin: indeed, a recent report 
from Pan et al. (2013) suggests that, upon PDL, Ptf1a+  acinar cells could adopt a Ptf1a+ HNF1β+ 
ductal cell identity, re-express Ngn3, and be further converted into endocrine cells. However, in 
Pax4-misexpressing animals, Ptf1a was not found ectopically produced in ductal or endocrine 
cells, and no evidence of acinar-to-duct or acinar-to-endocrine cell conversion was noted, 
suggesting that two different mechanisms operate. A likely explanation could lie in the 
differences between the approaches used. Indeed, with PDL corresponding to a fairly drastic 
model of acute pancre- atitis involving massive inflammation and cell death, it is therefore 
conceivable that additional/facultative cell-replacement mechanisms are activated as compared 
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to Pax4-misexpressing animals, which are mostly characterized by a glucagon+-to-β-like cell 
conversion. Thus, our data demonstrate that Pax4 misexpression can single-handedly promote 
several cycles of regeneration of the β-cell mass without requiring PDL. Additionally, these 
results also suggest that Ngn3+ or HNF1β+  cells are initially converted into glucagon+  cells and 
subsequently into β-like cells. The key role exerted by Ngn3 in these processes was further 
confirmed in knockdown experiments showing a strongly diminished β-like cell hyperplasia. 
Our analyses indicate a recapitulation of the Ngn3-mediated endocrine developmental 
program in this specific model of Pax4 misexpression in adult glucagon+  cells. However, unlike 
during pancreas morphogenesis, the proportion of the generated endocrine cell subtypes is 
clearly in favor of the glucagon+ cell lineage. One likely explanation could be the glucagon 
depletion provoked by the glucagon+-to-β-cell conversion. Indeed, it was previously found that 
alterations in glucagon signaling or glucagon shortage could trigger an α-like cell neogenesis 
(Furuta et al., 1997; Gelling et al., 2003; Longuet et al., 2013). It is conceivable that, in the 
present case, a similar α-like cell hyperplasia is induced, such cells subsequently misexpressing 
Pax4 and being turned into β-like cells. The decreased β-like cell hyperplasia observed after 
glucagon supplementation supports this notion. It should be noted that, in Pax4-misexpressing 
animals, the neo-generated glucagon+  cells detected prior to their conversion into β-like cells 
display a mature PC1/3-/GLP-1R_ α-like cell phenotype (and thereby not a pro-α-cell identity). 
However, due to the lack of well-characterized marker genes and in the absence of a more in-
depth analysis, one cannot ascertain that these correspond to true α-cells. 
Although the glucagon+  cell lineage is clearly favored in these regeneration processes, a 
few somatostatin+ or PP+ cells were also detected. However, technical limitations (lack of 
appropriate CreER mouse lines) prevented the tracing of their lineage. Given the systematic 
polarity of their distribution within islets and the fact that their number does not increase over 
time, it is conceivable that such cells correspond to Ngn3-derived cells (as demonstrated using 
lineage tracing) that have escaped the α-cell-lineage favoring. One could also postulate that such 
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cells could also acquire a β-like cell identity. However, the definitive validation of this postulate 
will require the generation of proper mouse lines. 
 
 Ngn3 re-expression reinduces the EMT in the adult pancreas 2.
The exploration of the molecular mechanisms underlying these endocrine cell 
regeneration processes outlined a Ngn3-mediated reawakening of the developmental EMT 
(Chiang and Melton, 2003; Cole et al., 2009; Gouzi et al., 2011; Rukstalis and Habener, 2007). 
Indeed, besides Ngn3 re-expression, the ectopic expression of epithelial/mesenchymal markers, 
such as Vimentin, Nestin, Snail2, and Sox11, is noted in our adult mice, with the knockdown of 
Ngn3 preventing their reactivation. 
Of note, the acquisition of a mesenchymal, migratory phenotype implies the subsequent 
and opposite conversion of mesenchyme-like cells to epithelial/endocrine ones. Despite an 
apparently rapid transition, we did indeed observe a few cells expressing Vimentin and 
insulin/glucagon. Together, our results thus support the concept that precursor cells localized in 
the ductal lining are mobilized and re-express Ngn3 prior to embarking on the EMT pathway 
leading to endocrine cell genesis and, at least, glucagon+-to-β-like cell conversion (see model in 
Figure 29). Whether all neo-generated islet cells pass through this cycle or whether a subset of 
duct-derived cells can expand prior to hormone expression or transactivate the dedifferen- 
tiation/proliferation/redifferentiation of endogenous islet cells remains to be determined. 
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Figure 29: Schematics depicting the consequences of Pax4 misexpression in adult α-cells.  
Upon ectopic expression of Pax4, α-cells are converted into β-like cells (1-3). Subsequently, the glucagon shortage 
provoked by such a conversion induces the mobilization of duct-lining cells (4), their proliferation (5), and the re-
expression of the proendocrine gene Ngn3 (5). Our results suggest that such cells undergo EMT (6) prior to 
preferentially acquiring glucagon
+
 cell identity (7). However, as soon as these initiate glucagon hormone 
expression, they misexpress Pax4 and are yet again converted into β-like cells (7). Such controllable cycles of 
neogenesis and conversion (3-7) results in hypertrophic islets displaying a β-like cell hyperplasia (8). Note the 
neogenesis of a few somatostatin
+
 or PP
+
 cells (7), their fate being unknown due to the lack of proper genetic tools 
(9). 
 
 Age-independent reversion of several rounds of toxin-induced 3.
diabetes 
In Dox-treated Glu-rtTA::TetO-Pax4 animals, hyperplastic insulin+ cells display a β-cell 
phenotype and are fully functional upon challenge. Interestingly, the newly formed β-like cells 
can repopulate the islets of STZ-treated animals and restore euglycemia. Importantly, these 
regenerative processes were responsive to at least two additional rounds of STZ injections. The 
capacity to repeatedly activate duct-to-β-like cell regeneration may therefore offer new 
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therapeutic strategies for type 1, but also type 2, diabetes where putatively regenerated β-like 
cells could, with time, be killed by the immune system. Taken together, our data indicate that 
(1) Pax4 misexpression is both necessary and sufficient for β-like cell neogenesis, (2) the newly 
formed β-like cells are functional, (3) Pax4 expression can be regulated, (4) the complete β-cell 
mass can be replaced at least three times, and (5) that several cycles of glucagon+ cell-mediated 
β-like cell regeneration can be successfully triggered in an age-independent manner. Based on 
these findings, we suggest that strategies controlling the expression of Pax4, Ngn3, or EMT 
induction, or of their molecular targets/cofactors, may pave new avenues for the treatment of 
diabetes. 
II. Chemical induction of α-cell-mediated β-like cell neogenesis 
The regenerative capacity of glucagon-producing cells and their potential of conversion 
into β-like cells are of great interest in the context of T1DM research. However, the transgenic 
approaches previously described would be difficult to apply to the development of human-
targeted therapies. We therefore performed a number of screens aiming at identifying small 
molecules/chemical compounds mimicking the effects of the ectopic expression of 
Pax4/inhibition of Arx. Herein, we report the identification of GABA as a putative -to--like 
cell inducer. Indeed, using lineage tracing, we provide evidence that long-term GABA treatment 
induces the conversion of glucagon-expressing -cells into functional insulin-producing -like 
cells. Interestingly, the continuous conversion of glucagon
+ 
cells leads to islet hypertrophy and 
this process is triggered by the reactivation of the pro-endocrine gene Ngn3. Lastly, following 
streptozotocin treatment and upon GABA addition, β-like cells are regenerated, these deriving 
from cells that expressed the glucagon hormone. 
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 A. GABA (γ-aminobutyric acid)  
 GABA biology 1.
γ-Aminobutyric acid (GABA), an amino acid not found in proteins, was initially 
identified as a major inhibitory neurotransmitter in the brain by Roberts and Frankel in 1950 
(Roberts and Frankel, 1950). GABA is indeed the predominant inhibitory neurotransmitter in 
the central nervous system (CNS). It is present in about 30% of all cerebral neurons, and affects 
almost all neuronal activities (Gladkevich et al., 2006). In neurons, GABA is synthesized in the 
cytosol from its precursor glutamate by the glutamate decarboxylase (GAD), transported into 
the synaptic vesicles, and released by exocytosis (Thomas-Reetz and De Camilli, 1994). GAD 
colocalizes with GABA (Reetz et al., 1991) in islets of rodents and humans, and the 
predominant isoform (GAD65 or GAD67) varies between species (Kim et al., 1993). The 
biological functions of GABA are mediated by the binding to and activation of the 
corresponding receptors (Thomas-Reetz and De Camilli, 1994). In the adult brain, the GABAA 
receptor (GABAAR) is the most prevalent receptor, and upon binding of GABA, it exerts an 
inhibitory effect manifested by a hyperpolarization of the cell membrane (Owens and 
Kriegstein, 2002). 
GABA is also present in peripheral nervous and endocrine systems, such as the testes, 
gastrointestinal tract, ovaries, placenta, uterus, adrenal medulla and the pancreas. GABA is 
largely produced by pancreatic islet cells (Adeghate and Ponery, 2002; Gerber and Hare, 1979; 
Okada et al., 1976; Reetz et al., 1991; Taniguchi et al., 1979; Vincent et al., 1983) and its 
concentration is comparable to that found in the CNS (Gerber and Hare, 1979; Gladkevich et al., 
2006). In accord with this, high levels of GAD have been detected in the islets of Langerhans 
(Sorenson et al., 1991). Moreover, it has been reported that both pancreatic α- and β-cells 
express a vesicular GABA transporter, which transports GABA into the intracellular vesicles for 
packaging before its release, and GAT3, which mediates cellular uptake of GABA 
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(Gammelsaeter et al., 2004). The abundance of GABA and the presence of the molecular 
machinery for GABA synthesis and release suggest an important role for this amino acid in 
pancreatic physiology.  
Once released, GABA is thought to serve as a functional regulator of pancreatic 
hormone secretion or as a fast-acting paracrine signaling molecule for the communication 
between β-cells and the other endocrine cells in the islets of Langerhans. The presence of 
GABA receptors in the pancreatic islets supports the putative autocrine/paracrine role of locally 
secreted GABA in islets. 
There are two basic types, A and B, receptors (GABAAR and GABABR, respectively):  
 GABAARs are composed of different subunits that form fast-acting chloride channels 
(Rudolph and Knoflach, 2011). There are 19 known GABAAR subunits: α1-6, β1-3, γ1-
3, δ, ε, θ, π and ρ1-3 (Luddens et al., 1995; Olsen and Tobin, 1990; Rudolph and 
Knoflach, 2011). GABAARs with different subunit combinations possess different 
pharmacological properties. Many of these subunits are found in islets or β-cell lines, 
and it appears that the αβγ configuration (two α-subunits, two β-subunits, and one γ-
subunit) represents a functional GABAAR in the islet cells.  
 GABABRs are composed of two invariable subunits: B1 and B2 (White et al., 2002). 
This slow-acting receptor is linked to K
+
 channels. These channels are opened by the 
activation of GABABR, leading to hyperpolarization of the membrane potential 
(Hashimoto and Kuriyama, 1997).  
In the adult brain, GABA exerts inhibitory effects that are primarily due to activation of 
the GABAAR chloride (Cl
–
) ion channel, which leads to Cl
–
 influx and membrane 
hyperpolarization (Kittler and Moss, 2003; Owens and Kriegstein, 2002). The shift from 
depolarizing to hyperpolarizing effects of GABA is associated with the onset of K
+
 - Cl
−
 
cotransporter 2 (KCC2) expression (Ludwig et al., 2003).  The neuron-specific KCC2 is 
responsible for establishing the Cl
−
 gradient in neurons through the maintenance of low 
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intracellular Cl
−
 concentrations (Ludwig et al., 2003). In the islets, a functional KCC2 is found 
in α-cells, but not in β-cells (Davies et al., 2004) providing a molecular mechanism underlying 
the opposite actions of GABA in the islet β- and α-cells, that will be explain in the paragraph 
below. 
 
 GABA release and action in the endocrine system 2.
It was shown that GABA is present at high concentration in the pancreas by screening a 
selection of peripheral organs of rats (Gerber and Hare, 1979). The basal release of GABA from 
β-cells is relatively constant (Reetz et al., 1991; Rorsman et al., 1989; Smismans et al., 1997) 
but it is modulated depending on the metabolic state of these cells (Winnock et al., 2002). 
GABA is localized in synaptic-like microvesicles (Reetz et al., 1991) and localized to insulin-
containing granules (Gammelsaeter et al., 2004). Therefore, β-cells secrete GABA in a regulated 
manner by both a glucose-dependent (exocytosis of insulin-containing granules) and a glucose-
independent mechanism (Braun et al., 2007). It appears that GABA is part of the fine-tuning 
machinery that maintains islet-cell glucose competence. 
The signaling pathways activated by GABA in the islets are not fully elucidated, 
although some mechanisms of action are known in α- and in β-cells (Figure 30). In α-cells, 
GABA induces membrane hyperpolarization and suppresses glucagon secretion (Rorsman et al., 
1989; Xu et al., 2006), whereas in islet β-cells, it induces membrane depolarization and 
increases insulin secretion (Prud'homme et al., 2013; Purwana et al., 2014; Soltani et al., 2011).  
In response to increasing glucose levels, insulin released from β-cells activates the 
insulin receptor present on α-cells. Subsequent activation of Akt leads to the phosphorylation of 
GABAAR that causes rapid translocation of the receptor to the plasma membrane (Figure 9). 
The resulting membrane hyperpolarization (induced by GABA-mediated activation of the 
receptors) inhibits glucagon release (Figure 30) (Xu et al., 2006). An impaired 
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GABAAR/glucagon secretory pathway in the islet might be an underlying mechanism for 
unsuppressed glucagon secretion, despite hyperglycemia, in diabetic subjects. 
Signaling differs sharply in β-cells, where GABA induces membrane depolarization by 
activation of the GABAARs, increasing insulin secretion (Figure 30) (Braun et al., 2010; Dong 
et al., 2006; Soltani et al., 2011). In isolated rodent and human islets, GABA was shown to 
promote β-cell proliferation and survival by the GABAAR-mediated activation of the Ca2
+
-
PI3K/Akt pathway (Figure 30) (Purwana et al., 2014; Soltani et al., 2011). Other studies 
demonstrated that GABABRs convey the same trophic effects of GABA on β-cells (Ligon et al., 
2007; Purwana et al., 2014; Tian et al., 2013). Indeed, in vivo studies suggest an important role 
for GABABRs in regulating β-cell function and glucose homeostasis. For instance, the treatment 
of non-obese diabetic (NOD) mice with a GABABR agonist delayed onset of T1DM (Beales et 
al., 1995) and the constitutive absence of GABABRs (GABAB1R
-/-
 mice with full knockout of B1 
subunit) induces alterations in pancreatic histology, physiology, and insulin resistance.   
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Figure 30: GABA release and action in the pancreatic islets.  
In response to increasing glucose levels, insulin released from β-cells activates the insulin receptor present on α-
cells (1). Subsequent activation of Akt (2) leads to phosphorylation of GABAARs that causes rapid translocation of 
these receptors to the plasma membrane (3), whereby they are activated by GABA leading to membrane 
hyperpolarization (4) and inhibition of glucagon release (5). In β-cells, GABA induces membrane depolarization by 
activation of the GABAARs (6) promoting, through the activation of the Ca2+-PI3K/Akt pathway (7), β-cell 
proliferation and survival (8) and increase in insulin secretion (9). Of note, GABA is released by the β-cells by both 
a glucose-dependent (10) and a glucose-independent (11) mechanism.   
 
 
 GABA and diabetes therapy 3.
Over the past few decades, numerous studies have uncovered a role for GABA in 
diabetes mellitus. Indeed, GABA has multiple beneficial effects on β-cells, which include the 
stimulation of cell proliferation and anti-apoptotic activities making it an attractive agent for 
diabetes therapy (Prud'homme et al., 2013; Purwana et al., 2014; Soltani et al., 2011; Tian et al., 
2013). Importantly, it prevents insulitis to a remarkable degree in preclinical models suggesting 
applications in the prevention or in the treatment (particularly in the context of clinical islet 
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transplantation) of this disease (Prud'homme et al., 2013; Purwana et al., 2014; Soltani et al., 
2011; Tian et al., 2013). 
Interestingly, GAD65 (the enzyme involved in GABA synthesis) was found to be one of 
the major target antigens recognized by self-reactive T cells in T1DM (Kim et al., 1993), GABA 
levels being decreased in endocrine pancreatic tissue in experimental and human diabetes. The 
autoimmunity against GAD in the islet depletes this enzyme and hence reduces GABA levels, 
which may be one of the reasons behind the progression of this disease. Indeed, 
immunomodulation with GAD65 vaccination has been extensively investigated for the 
prevention or treatment of T1DM (Ryden et al., 2014).  
These findings clearly indicate that the GABA network is altered in T1DM but its role in this 
pathology remains to be clarified.  
In addition, several studies have demonstrated that GABA participates in maintaining the 
β-cell mass (Mendu et al., 2011; Soltani et al., 2011), inducing β-cell proliferation and 
protecting β-cells from apoptosis in vitro (Ligon et al., 2007; Soltani et al., 2011). Importantly, 
it was shown that GABA therapy could decrease blood glucose levels and prevent diabetes in 
two mouse models of T1DM: the MDSD (multiple low-dose streptozotocin-induced diabetes) 
model and wild-type NOD mice (Soltani et al., 2011). Remarkably, in severely diabetic mice 
(MDSD model), GABA therapy resulted in the regeneration of the -cell mass capable of 
completely reversing hyperglycemia. 
upon GABA treatment, associated with anti-inflammatory and immuno-regulatory events 
(Soltani et al., 2011; Tian et al., 2011). 
Moreover, it was shown that activation of both GABAAR and GABABR is important in 
mediating GABA’s trophic effects to promote β-cell replication and survival, in both rodents 
and humans (Purwana et al., 2014). To analyze whether GABA could exert therapeutic effects 
on human islet cells, an islet xenotransplantation model was used: human islets were 
transplanted into immuno-deficient NOD mice after induction of diabetes with streptozotocin 
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(Purwana et al., 2014). This in vivo approach revealed that oral GABA treatment increased 
graft-cell proliferation and decreased apoptosis, leading to a significantly enhanced β-cell mass. 
Furthermore, GABA lowered blood glucose levels and ameliorated glucose tolerance. Thus, 
similarly to rodent studies, GABA displayed trophic effects on human islets. This is important 
as, while a number of agents exert protective and proliferative effects on rodent islet cells, very 
few show similar activities on human islet cells. 
Combined islet-antigen and GABA therapy has proven effective in mice. Indeed, Tian et 
al. reported that combined therapy with proinsulin/alum and GABA synergizes to restore 
normoglycemia in newly diabetic NOD mice, sometimes with permanent remission of the 
disease, by inhibiting pathogenic T-cell responses and to promote β-cell proliferation (Tian et 
al., 2014). In another study, the combination of oral GABA treatment and immunization with a 
GAD/alum formulation was also found to be effective in a transplantation model (Tian et al., 
2011). In diabetic NOD mice receiving syngeneic pancreas grafts, combined therapy was much 
more effective than mono-therapy in prolonging the survival of β-cells. In addition, GABA 
appears to be beneficial to T2DM. Tian et al. demonstrated that oral treatment with GABA 
improves glucose tolerance and insulin sensitivity in high-fat diet fed mice. They concluded that 
this was due to the inhibition of obesity-related inflammation and up-regulation of Treg 
responses (Tian et al., 2014). 
 
 GABA administration to humans 4.
Orally administered GABA is safe for humans, and acts on peripheral GABA receptors 
but does not affect CNS function, as it does not cross the blood–brain barrier. It can be 
administered orally in large amounts (several grams/day) without serious adverse effects 
(Nurnberger et al., 1986). This chemical compound can be used in humans for its relaxing, anti-
anxiety and anti-convulsive effects. Several reports studied the effects of GABA on endocrine 
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pancreatic function in humans. In one study, a single oral dose of GABA significantly increased 
plasma insulin in 12 healthy subjects (Cavagnini et al., 1982). In other study, baclofen (a 
GABABR agonist) was administered orally to ten healthy subjects 1 hour prior to a glucose 
tolerance test, which revealed a significantly increased insulin response and increased basal 
glucagon levels (Passariello et al., 1982). Another study demonstrated that intravenous 
administration of GABA significantly reduced blood glucose levels in the majority of diabetic 
individuals, but not in the non-diabetic subjects (Khumarian and Mamikonian, 1967).  These 
human studies were quite limited but nevertheless suggest that GABA plays a role in regulating 
endocrine pancreatic function.  
 
The majority of research regarding the effect of GABA as a putative agent for treatment 
of T1DM reports a GABA-dependent regeneration of β-producing cells in T1DM mouse 
models. However, the cellular origin of the neo-generated insulin-producing cells still remains 
unclear. 
 
 B. Analysis of mice treated with GABA for different periods of time 
 Long-term treatment of WT mice with GABA induces an insulin-1.
producing cell hyperplasia, such cells displaying a β-cell phenotype  
Through the generation and analysis of Glu-rtTA::TetO-Pax4 double transgenic animals 
(Al-Hasani et al., 2013), we previously demonstrated that the misexpression of Pax4 in adult -
cells induces their continuous neo-genesis and subsequent conversion into -like cells, such -
to--like cell conversion being triggered by the Pax4-mediated down-regulation of Arx 
expression in -cells. Aiming to gain further insight into the molecular mechanisms underlying 
these processes, we performed transcriptomics analyses of Glu-rtTA::TetO-Pax4 treated for 3 
weeks with doxycycline as compared to untreated counterparts. Our results, sorted by fold 
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changes, outlined strong alterations in the expression of several genes involved in GABA 
signalling (manuscript in preparation). Indeed, when comparing doxycycline-treated versus 
untreated pancreata, the expression of the GABAB receptor was found 10 times increased. 
Similarly, a 2-fold augmentation in GABAA receptor transcripts, a 2.5-fold rise in GAB3 
transcripts and a 4.5-fold increase in the expression of the GABAA receptor target, Gephyrin, 
were outlined.  
Such alterations being suggestive of an activation of GABA pathways, we initially 
assayed its short-term role in vitro using the -TC1-6 -cell line (Hamaguchi and Leiter, 1990). 
These were daily treated (or not) with concentrations of GABA ranging from 5M to 1mM and 
kept in culture for up to six weeks. Interestingly, even using low GABA concentrations, a 
comparative analysis of Arx expression by qPCR outlined a rapid decrease in Arx transcript 
contents, with a maximum of 30%, as compared to controls (Figure 31).  
 
 
Figure 31: Relative Arx mRNA expression in α-TC1-6 treated with GABA. 
α-TC1-6 cells were treated with increasing GABA concentrations for different periods of time. Relative Arx 
mRNA expression was measured in the different conditions. A decrease in Arx expression was observed in the 
cells treated with GABA compared to non-treated cells. *p < 0.05, ** p< 0.01, *** p < 0.001; n≥3; data statistically 
analyzed by a one-way ANOVA, all data depicted as mean ± SEM.  
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Such encouraging results prompted us to test GABA activities in vivo by combining 
long-term GABA administration and immunohistochemical analyses. Thus, 2.5 to 10-month old 
wild-type animals were first subjected to a 1 to 6-month (GABA 1-6m) GABA treatment 
(50µM) using daily intra-peritoneal injections. These were found to be viable, healthy and 
fertile, their lifespan and basal glycaemia remaining within normal range (Figure 32A). 
Importantly, the examination of GABA-treated pancreata (Figure 32C-D, F-G, I-J), as 
compared to control mice (Figure 32B, E, H), outlined a dramatic islet hypertrophy, resulting 
from a massive increase in the insulin
+
 cell content. Such insulin
+
 cell hyperplasia was found to 
progress with the duration of GABA treatment (Figure 32K). Interestingly, we also observed an 
augmentation in the number of islets in GABA-treated mice as compared to controls, such 
increase appearing, however, independent of the duration of GABA exposure as it plateaus at 
twice the count found in controls (Figure 32A, K). In addition to the augmented numbers of 
islets and insulin
+
 cells, GABA-treated pancreata also displayed augmented contents of 
glucagon
+
 and somatostatin
+ 
cells as compared to their non-treated counterparts (Figure 32D-
K). It is also important to note the atypical location of these non-β-cells, these being detected in 
clusters close to ducts (Figure 32F-G, I-J) and not uniformly distributed within the islet mantle 
zone as in seen controls (Figure 32E, H). Additional experiments using different concentrations 
of GABA (200 to 1000μM) provided for two months demonstrated a dose-dependent increase in 
pancreatic hormones
+
 cell contents and islet counts (Figure 33A-J).  
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Figure 32: The treatment of WT mice with GABA induces an islet hypertrophy 
accompanied by islet neogenesis and an increase in islet cell numbers. 
(A and K) Quantitative comparison of the number/size of islets (A) and the number of insulin-, glucagon- or 
somatostatin-expressing cells (K) by pixel counting between GABA-treated animals and aged-matched controls (n 
= 3 for each group). *** p<0.001, ** p<0.01; data statistically analyzed by a one-way ANOVA; all data depicted as 
mean ± SEM. The examination of WT mice treated with GABA for 2 or 3 months revealed an increase in the 
number of hormone-expressing cells and in the number of islets. Life expectancy and basal glycaemia (monitored 
weekly) were found within normal ranges, as compared to controls, in all conditions analyzed. 
Immunohistochemical staining of different hormone combinations on control (B, E, H) and on GABA-treated 
pancreata (C-D, F-G, I-J). Note the misallocation of non-β-cells within the islets, these were found preferentially 
located at a pole of the islet, adjacent to neighboring ducts in GABA-treated animals. Ducts and islets are outlined 
in dashed white lines in selected pictures.  
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Figure 33: Dose-dependant increase in islet number and hormone-expressing cells in 
GABA-treated animals. 
Representative pictures of immunohistochemical analyses performed on islets of animals treated for 2 months with 
saline (A-B), GABA 200μM (C-D), GABA 500μM (E-F) and GABA 1000μM (G-H). Different concentrations of 
GABA (200 to 1000µM) provided for 2 months demonstrated a dose-dependent increase in number of islets (I) and 
of hormone
+
 cells (J).   
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In an effort to potentially discriminate supplementary insulin
+
 cells from their 
endogenous counterparts in GABA-treated pancreata, we assayed the expression of several 
endocrine cell marker genes (Figure 34C-D, G-H, K-L, O-P, S-T, W-X) compared to saline-
treated controls (Figure 34A-B, E-F, I-J, M-N, Q-R, U-V) by means of immunochemistry. 
These analyses revealed that all insulin-expressing cells in GABA-treated islets uniformly 
expressed the bona fide -cell markers, such as the prohormone convertase 1/3 (PC1/3) (Figure 
34A-D), the transcription factors Nkx6.1 (Figure 34E-H) and Pdx1 (Figure 34I-L), the -cell-
specific glucose transporter Glut 2 (Figure 34M-P), as well as the pan-endocrine marker Pax6 
(Figure 34Q-T) and NeuroD1 (Figure 34U-X). These cells were also found to lack the non-β-
cell labels, such as glucagon (Figure 32F-G compared 32E) and somatostatin (Figure 32I-J 
compared to 32H).  
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Figure 34: Phenotypical analyses of GABA-treated animals compared to controls. 
Representative pictures of immunohistochemical analyses performed on pancreas sections of controls (A-B, E-F, I-
J, M-N, Q-R, U-V) and of age-/sex-matched GABA-treated mice (C-D, G-H, K-L, O-P, S-T, W-X) using the 
indicated antibody combinations. Compared to controls, GABA-treated pancreata displayed an increase in islet size 
caused by an insulin
+
 cell hyperplasia, such cells uniformly expressing the bona fide β-cell markers PC1/3 (A-D), 
Nkx6.1 (E-H), Pdx1 (I-L), Glut-2 (M-P), NeuroD1 (U-X), but also Pax6 (Q-T). (Each photograph is representative 
of at least 3 independent animals). 
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Along the same line, we analyzed pancreata from 2m GABA treated (or not) animals 
combining electron microscopy and insulin immunogold labeling: a thorough examination of 
more than 200 photographs per pancreas (n = 3) indicated that all cells displaying a -cell 
ultrastructure expressed insulin and that all insulin-labeled cells presented a -cell ultrastructure 
in GABA-treated pancreata (Figure 35A-D). Altogether, our data demonstrate that the sole 
continued administration of GABA to WT mice leads to islet neogenesis accompanied by a 
progressive islet hypertrophy, this hypertrophy being mainly the consequence of a -like cell 
hyperplasia. 
 
 
Figure 35: Insulin-expressing cells in GABA-treated mice display a β-cell ultrastructure. 
Electron microscopy examination was combined to insulin detection using immuno-gold staining to examine 
pancreata of animals treated for 2 months with saline or GABA. In GABA-treated pancreata, all cells displaying a 
β-cell ultrastructure express insulin. Similarly, all cells labeled with insulin exhibit a typical β-cell ultrastructure 
(n=3, 200 photographs analyzed per sample). 
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 GABA induces the conversion of glucagon-expressing cells into 2.
insulin-producing cells 
To determine the origin of the hyperplastic endocrine cells observed in GABA-treated 
pancreata, further immunohistochemical analyses were performed. In very rare instances, we 
noticed cells co-expressing both insulin and glucagon hormones (Figure 36A-B). Aiming to 
determine whether these may not correspond to cells transitioning from an -cell identity to a -
cell phenotype, we treated (or not) Glu-Cre::Rosa26-lox-β-gal mice (harboring the following 
transgenes: the rat glucagon promoter upstream of the phage P1 Cre recombinase (Herrera, 
2000) ; the Rosa26 promoter upstream of a loxP-Stop-loxP--galactosidase cassette (Soriano, 
1999)) with GABA for two months. Using X-gal staining to follow cells having expressed or 
still expressing glucagon, β-gal
+
 cells were expectedly detected solely in the mantle zone of 
controls islets (treated with saline) where glucagon-expressing cells are located (Figure 36C-E). 
Importantly, in GABA-treated animals, β-gal
+
 cells were again found located in the islet mantle 
zone, but also within the core of the islets where insulin
+
 cells are classically detected (Figure 
36F-H). Indeed, using immunofluorescence, we confirmed the detection of numerous insulin-
producing cells positive for the -cell label, -galactosidase (Figure 36I-K, 37A-F). Together, 
our results provide conclusive evidence that, upon GABA administration, glucagon-expressing 
cells can be converted into insulin-producing cells.  
 
 
 
109 
 
  
 
 
Figure 36: Glucagon-expressing cells can be converted into insulin-producing cells upon 
GABA treatment. 
Immunofluorescence detection applied to pancreata of 2-month old WT animals treated for 2 months with GABA 
revealed a number of cells positive for both insulin and glucagon (A-B), indicative of a putative α-to-β-like cell 
conversion. Lineage tracing of α-cells using X-gal staining on GABA-treated Glu-Cre::ROSA pancreata showed β-
galactosidase activity in cells located within the islet core where insulin
+
 cells were normally located (F-H), while 
β-galactosidase activity was solely detected in the islet mantle of non-treated Glu-Cre::Rosa controls (C-E). Further 
immunohistochemical analyses (I-K) revealed that most β-gal
+
 cells were in fact insulin
+
, indicating a conversion 
of glucagon
+
 cells into insulin
+
 cells.   
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Figure 37: Lineage tracing in GABA-treated GluCre::ROSA animals. 
Glu-Cre::ROSA26-β-gal animals were used to label glucagon-producing cells and follow their progeny. These 
animals were treated with GABA for 2 months. Pancreatic sections were labeled using combination of anti-insulin 
and anti-β-gal immuno-detection (A-F). Note the presence of insulin and β-gal
 
co-expressing cells (inlets). 
 
 Increased duct-lining cell proliferation and reawakening of the 3.
epithelial-mesenchymal transition in GABA-treated mice 
While, upon GABA administration, glucagon
+
 cells are converted into β-like cells, 
glucagon
+
 cells are also consistently detected in higher number as compared to control pancreata 
(Figure 32F-G, I-K). Additionally, we did not detect any alteration in apoptosis rate in GABA-
treated animals (data not shown). These observations suggesting their continued neo-genesis 
upon GABA treatment, we used long-term 5-bromo-2'-deoxyuridine (BrdU) labeling to detect 
cells undergoing or having undergone replication. As expected, very few BrdU-marked cells 
(mostly insulin-expressing cells) were noted in control mice (Figure 38A, D, G, J). However, in 
GABA-treated animals, drastically increased numbers of BrdU
+
 cells were detected mainly 
within the ductal lining and epithelium, but also within the endocrine compartment (Figure 
38B-C, E-F, H-I, K-L).  
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Figure 38: Increased cell proliferation in the pancreatic ductal lining and in the islet cells 
upon GABA treatment. 
A 10-day BrdU pulse-chase was performed in controls (A, D, G, J) and in 2-month old WT animals subjected to a 
2-month GABA treatment (B-C, E-F, H-I, K-L). Proliferating cells were preferentially localized in the pancreatic 
ductal lining, adjacent to islets in GABA-treated animals compared to controls. Note also the presence of insulin-
/glucagon-/somatostatin-proliferating cells and Brdu
+
 cells in the acinar compartment. For the purpose of clarity, 
islets and ducts are outlined in dashed white lines in selected pictures. 
 
In addition to this augmented proliferation rate, we often noticed, in long-term GABA-
treated mice, a thickening of the ductal lining in a cell nuclei-dense area reminiscent of 
mesenchyme (Figure 39B compared to A). Indeed, closer examination revealed that these cells 
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widely re-expressed the canonical mesenchymal marker, Vimentin (Figure 39C). Similarly, 
Snai2
+
 cells were also found in this location in GABA-treated animals (Figure 39D-F). Note 
that these markers were only found expressed in scattered cells of control mice (Figure 39A, D 
and data not shown). Vimentin and Snai2 being transcriptional regulators of the developmental 
epithelium to mesenchymal transition (EMT), the data suggest that the neo-generated endocrine 
cells underwent EMT as seen during embryogenesis.  
 
 
Figure 39: Evidence of a mesenchymal to endocrine transition in GABA-treated mice. 
Immunohistochemical analyses revealed that in GABA-treated animals, the mesenchymal marker vimentin was re-
expressed in that region surrounding ducts and close to islets (B-C), as well as the transcription regulator of EMT, 
Snai2 (E-F). No vimentin and Snai2 were detected in control mice (A, D). 
 
 Ngn3 re-expression is required for endocrine cell neogenesis upon 4.
GABA administration 
To further investigate the putative reactivation of endocrine developmental processes 
upon daily GABA administration, we analyzed the expression of a number of developmental 
marker genes involved in endocrine cell genesis. Interestingly, we observed a reactivation of the 
expression of the pro-endocrine gene Ngn3 in cells located within the ductal compartment 
(ductal lining and/or epithelium) in GABA-treated pancreata (Figure 40B-C), while almost no 
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expression of Ngn3 could be found in control mice (Figure 40A). Of note, we also detected 
Ngn3 in few islet cells of GABA-treated animals, suggestive of a conversion of Ngn3-re-
expressing cells into endocrine cells (Figure 40B). Lineage tracing experiments were therefore 
performed to determine the contribution of these Ngn3-re-expressing cells to the supplementary 
endocrine cell mass. We used Ngn3-CreER
TM
 mice (harboring a transgene composed of the 
Ngn3 promoter upstream of the phage P1 Cre recombinase fused to a mutant oestrogen receptor 
(Gu et al., 2002)) crossed with Rosa26-lox-β-gal animals. In GABA and Tam-treated double 
transgenics, a large number of -Gal-labelled cells were observed in the ductal lining and, most 
importantly, within the islets (Figure 40E-I), while controls appeared negative for β-
galactosidase (Figure 40D). To further confirm the role of Ngn3 in the endocrine cell 
hyperplasia observed in GABA-treated animals, Ngn3 expression was inhibited in vivo by a 
knockdown approach. Following two days of GABA treatment, 2-month-old WT animals were 
injected into the pancreatic duct with GFP-encoding lentiviruses producing either a small 
hairpin RNA (shRNA) targeting Ngn3 transcripts (previously found to induce a 45% decrease in 
Ngn3 transcript contents (Al-Hasani et al., 2013)) or a scrambled shRNA. Subsequently, the 
animals were treated daily with GABA and examined 28 days later. While GABA-treated 
scrambled-infected pancreata displayed hypertrophic islets (Figure 40J, 41A-B), GABA-treated 
Ngn3 knockdown pancreata exhibited a 40.5% reduction in islet overgrowth and 69% decrease 
in insulin
+
 cell counts (Figure 40K-L, 41A-B), indicating that Ngn3 re-expression is required 
for endocrine cell neo-genesis upon GABA treatment. Importantly, we observed a massive 
accumulation of mesenchyme-like cells surrounding ducts in Ngn3 knockdown mice (Figure 
40K-O), suggestive of an endocrine cell neogenesis process that was stopped at the 
mesenchymal stage. Indeed, such cells were found to widely express Vimentin (Figure 40M-N) 
or Snai2 (Figure 40O). Altogether, our data suggest that long-term GABA treatment leads to 
the reawakening of the Ngn3-controlled endocrine developmental program, such cells 
undergoing EMT prior to the acquisition of an endocrine cell identity. 
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Figure 40: Re-expression of Ngn3 in the ductal lining of GABA-treated pancreata and the 
potential contribution of Ngn3
+
 cells to islet hypertrophy. 
Immunohistochemical stainings of Ngn3 in control (A) and in 3-month GABA-treated animals (B-C). Ngn3 re-expression was 
detected in the ductal lining of GABA-treated mice, while being absent in their control counterparts. Note that vimentin, the 
canonical mesenchymal marker was also found expressed in this region in GABA-treated mice unlike control animals. β-
galactosidase staining on GABA and Tamoxifen-treated Ngn3CreER::ROSA revealed β-galactosidase activity in islets and in 
the ductal lining (E-F) while found absent in control animals (D). Further immunohistochemical analyses (G-I) revealed that β-
gal+ cells were in fact insulin+ (inlets), indicating a conversion of Ngn3+ cells into insulin+ cells.  Note that β-gal+ cells were also 
found in the ductal lining. 2-month-old WT animals were infected using GFP-encoding lentiviruses producing either a shRNA 
targeting Ngn3 transcripts or a scrambled shRNA after two days of GABA treatment. After infection, the animals were daily 
injected with GABA for 30 days and sacrificed for examination: Ngn3 knockdown pancreata exhibit a decrease in islet size (K-
O) as compared to their scrambled-infected counterparts (J). Note the accumulation of several clusters of cells (these expressing 
Vimentin and Snai2) around the islets in Ngn3 knockdown animals (M-O). Altogether, these results indicate that cells re-
expressing Ngn3 eventually adopt an endocrine cell identity contributing to islet overgrowth. For the purpose of clarity, islets 
and ducts are outlined in dashed white lines in selected pictures.  
 
 
 
115 
 
  
 
 
 
Figure 41: Quantitative analysis of Ngn3 knock-down pancreata. 
Quantitative comparaison of the number (A) and size (B) of islets between Ngn3 knock-down (KD) mice and 
control animals (n=3 for each group).  
 
 A functional β-cell mass can be regenerated following chemically-5.
induced diabetes in GABA-treated animals, these cells deriving from 
glucagon-expressing cells 
To determine whether neo-formed insulin
+
 cells could functionally replace endogenous 
β-cells upon GABA administration, 2-month old WT animals were injected with a high dose of 
streptozotocin (STZ) to obliterate the pancreatic β-cell mass. Once these animals were readily 
diabetics, with a glycaemia of approximately 300mg/dl, they were treated (daily) either with 
GABA or saline (controls). While saline-treated control mice saw their glycaemia increase 
further and died from extreme hyperglycemia, a steady recovery was observed following a peak 
in glycaemia in their GABA-treated counterparts (Figure 42A). Immunohistochemical analyses 
were performed on sections of Saline-treated (Figure 42B-C) and GABA-treated (Figure 42D-
F) pancreata isolated 5 to 85 days post-second STZ administration. While STZ treatment 
induced a clear loss of insulin-producing cells in all conditions, animals treated daily with 
GABA displayed a progressive regeneration of their -cell mass (Figure 42D-F), so that the 
islets were reconstituted 60-85 days following -cell ablation. Of note, these surviving animals 
displayed a normal life expectancy and a normal glycaemia. The glucose responsiveness of 
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these surviving GABA-treated mice was examined 4.5 months post -cell ablation. Upon 
challenge with a high dose of glucose, these animals were found to display an improved 
response with a lower raise in glycaemia and a faster return to euglycemia as compared to 
controls (non treated with GABA or STZ - Figure 42G). Accordingly, a 2.1-fold increase in 
insulin secretion, reflecting the augmented content of -line cells, was noted in GABA-treated 
mice as compared to saline-administered animals. 
Aiming to further confirm the origin of neo-generated -like cells, similar -cell ablation 
experiments were performed in Glu-Cre::Rosa26-lox-β-gal mice allowing -cell lineage tracing. 
Importantly, using both X-Gal staining and immunohistochemical analyses (Figure 42H-K), a 
vast majority of insulin-producing cells were found to be labeled by -galactosidase (labeling 
cells that once expressed glucagon), demonstrating that most of regenerated -like cells went 
trough a glucagon expression transitional phase.  
To determine whether GABA could induce several cycles of replenishments of the 
whole -cell mass, mice that went through a first round of -cell ablation and -like cell 
regeneration were, yet again, subjected to a second round of streptozotocin treatment (one 
month after stopping GABA treatment) and subsequently administered GABA (or not) only 
when their glycaemia reached 300mg/dl. Importantly, as seen previously, while saline-treated 
mice died from a massive hyperglycemia, their GABA-treated counterparts saw, next to a peak, 
a normalization of their blood glucose level, as well as a normalization of their life expectancy 
(Figure 42L). Together, these results clearly demonstrate that GABA can induce several cycles 
of complete -cell mass neogenesis using -cells as a proxy.  
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Figure 42: The β-like cell mass can be regenerated following streptozotocin treatment in 
GABA-treated mice through the conversion of glucagon-expressing cells. 
WT mice were subjected to streptozotocin (STZ) treatment and 15 to 20 days after, they were treated with GABA 
or water. Following a peak in glycemia, a steady recovery is noted for GABA-treated animals while controls die 
from extreme hyperglycemia (A). Immunohistochemical analyses revealed a clear regeneration of the β-cell mass, 
monitored 5, 10, 25 and 45 days post-GABA administration in GABA and STZ-treated mice (C-F). Control 
animals were administered solely with sodium citrate (B). 85 days post-streptozotocin injection, GABA- and STZ-
treated WT and non-treated controls were subjected to a glucose tolerance test (GTT) (G). GABA-treated mice 
performed better than controls with a lower peak in glycaemia and a faster return to euglycemia, suggestive of an 
increased β-cell mass. Lineage tracing of α-cells using X-gal staining on GABA-treated Glu-Cre::ROSA pancreata 
isolated 40 days post streptozotocin showed β-galactosidase activity in cells located within the islet core where 
insulin
+
 cells were normally located (H-J). Further immunohistochemical analyses (K-M) revealed that most β-gal
+
 
cells were in fact insulin
+
, indicating a conversion of glucagon
+
 cells into insulin
+
 cells.   
(N) WT mice were subjected to STZ treatment and 25 days after, they were treated with GABA or water. At 4 
months of age, GABA daily administration was discontinued for 1 month for the surviving animals. A second 
streptozotocin injection was administered. Animals for which GABA administration has been stopped for 1 month 
responded to STZ and a recovery is noted after GABA treatment initiated 15 days post-second STZ injection.  
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 GABA induces the loss of human glucagon
+
 cells to the profit of -like 6.
cells.  
While the present mouse studies clearly establish the neogenesis and conversion of -
cells into functional -like cells upon GABA administration, whether the same could apply to 
human -cells is unclear. Aiming to first determine whether human -cells could be converted 
into insulin
+
 cells, we initiated heterologous transplantation experiments. 500 human islet 
equivalents were transplanted under the kidney capsule of SCID mice that were subsequently 
treated (or not) with GABA daily for a month. Closer examination of the kidney of these 
animals combined to a quantitative analysis outlined an almost complete loss of glucagon
+
 -
cells. Concomitantly, we notice an increase in the number of insulin-producing cells. 
Altogether, these data (not shown) indicate a putative conversion of human -cells into -like 
cells upon GABA administration. 
 
 C. Discussion 
In this study, we report an unsuspected role of GABA in promoting a cycle of -cell 
neogenesis and their subsequent conversion into -like cells, resulting in a massive increase in 
islet size and number. Such hyperplasia does depend on the dose and duration of treatment. 
Specifically, our results suggest that GABA acts via the GABAA receptor present on -cells and 
induces their conversion into cells displaying a -cell phenotype by inhibiting Arx expression. 
This triggers -cell replacement mechanisms involving the mobilisation of ductal precursor 
cells that re-enact the endocrine differentiation program as seen during pancreas development. 
Importantly, the regenerated -like cells are functional and can reverse several times the 
consequences of multiple -cell ablation cycles. As important is the finding that the treatment of 
transplanted human islets with GABA results in a loss of -cells and a concomitant increase in 
-like cells, suggestive of -to--like conversion processes. 
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 GABA induces -cell-mediated -like cell neogenesis 1.
Our analysis reveals that long-term GABA treatment results in a massive increase in 
insulin-producing cell content. Such augmentation results from a progressive insulin
+
 cell 
hyperplasia depending on the dose of GABA and on the duration of GABA administration. 
Interestingly, an increase in islet number is also noted but appears to plateau at twice the number 
of islets found in control pancreata. This suggests that GABA can also trigger limited islet 
neogenesis. Understanding the molecular mechanisms controlling this limitation would be of 
obvious interest in the context of -cell regeneration research.  
Combining lineage tracing, electron microscopy and immunohistochemical analyses, we 
demonstrate that -cells can be converted into cells displaying most features of true -cells. 
However, the continued detection of glucagon
+
 cells suggests a cycle involving their 
replacement and subsequent conversion into -like cells. Indeed, the monitoring GABA-treated 
animals over time outlines increasing numbers of insulin
+ 
cells that went through a phase of 
glucagon expression (as assayed using -cell lineage tracing), thereby confirming the notion of 
-cell neogenesis and subsequent conversion into -like cells.  
Aiming to determine the origin of regenerating -cells, we consistently noticed an 
important increase in proliferating cells in the ductal lining and epithelium. Concomitantly, we 
also observed numerous Ngn3-expressing cells in the same location. These results suggesting 
the presence of ductal precursor cells able to reactivate the Ngn3-controled endocrine 
developmental program, we used lineage tracing to trace the fate of such cells. Accordingly, we 
found that such Ngn3-reexpresing cells eventually adopt an endocrine cell identity. The role of 
Ngn3 in the endocrine cell hyperplasia observed in GABA-treated animals was further 
confirmed by the inhibition of Ngn3 expression in vivo by a knockdown approach. In addition to 
Ngn3 reactivation, we often noticed a thickening of the duct characterized by a cell nuclei dense 
area resembling mesenchyme. Since endocrine development during embryogenesis involves an 
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epithelial-to-mesenchymal transition (EMT), we tested EMT marked in this adult context and 
found that such cells indeed expressed Vimentin or Snai2, both hallmarks of EMT.  
The phenotypical alterations observed in WT mice treated with GABA for 1 to 3 months 
are reminiscent of those found in animals with the ectopic expression of Pax4 in glucagon-
expressing cells. Indeed, the treatment of WT mice with GABA induces an islet hypertrophy 
accompanied by an augmentation in hormone cell content and an increase in islet number. One 
possibility for the origin of the oversized islets could be the proliferation of the endogenous β-
cells, this hypothesis being supported by the reports of GABA increasing β-cell replication 
(Ligon et al., 2007; Soltani et al., 2011). However, the increase in β-cell proliferation in the 
GABA-treated mice relative to the size of the islets (data not shown) suggests that the increase 
in the β-cell population may arise from another source. Taking into account the fact that cells 
co-expressing insulin with glucagon were noted in GABA-treated WT, we used the Glu-
Cre::Rosa26-lox-β-gal mouse line to determine the fate of glucagon-producing cells upon 
GABA addition. Lineage tracing experiments provided evidence for GABA mediated α-to-β-
cell conversion in vivo, resulting in hypertrophic islets. In addition, the continued detection of 
glucagon
+
 cells despite their conversion suggests that compensatory mechanisms are triggered 
to regenerate these cells. Indeed, an α-cell renewal was observed as a result of alterations in 
glucagon signaling or glucagon shortage in previous studies (Collombat et al., 2003; Furuta et 
al., 1997; Gelling et al., 2003; Longuet et al., 2013). If, in our case, islet hypertrophy is the 
consequence of the glucagon depletion and the subsequent α-cell neogenesis, glucagon 
supplementation should hinder this process. To verify this theory, glucagon could be 
administrated to GABA-treated WT to observe whether this could diminish the increased 
number of hormone-expressing cells.  
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 Origin of the islet hypertrophy 2.
Concerning the origin of the neo-generated α-like-cells, the observation of a preferential 
location of those cells at a pole of islet, adjacent to ducts, re-expression of Ngn3 and increased 
cell proliferation in the ductal environment hints to a putative source of glucagon-expressing 
cells. In addition, we noted that few cells within the islets co-expressed Ngn3 and 
glucagon/insulin (data not shown) further suggesting that those cells passed through a potential 
Ngn3-re-expressing phase. The tracing of Ngn3
+ 
cells in GABA-treated animals supported this 
hypothesis. Indeed, β-galactosidase activity was detected within the islets in GABA-treated 
Ngn3-CreER::Rosa26-lox-β-gal mice unlike control animals. However, further 
immunohistochemical analyses using antibodies raised against endocrine hormones and β-
galactosidase should confirm the concept that glucagon-expressing cells (and subsequently 
insulin-producing cells) passed through a Ngn3
+ 
transitional phase. A lentivirus approach 
allowing the knockdown of Ngn3 provided more evidence. Indeed, Ngn3 knockdown pancreata 
treated with GABA showed a decrease in islet size and in islet number as compared to their 
scrambled-infected counterparts indicating that Ngn3 contributes to GABA-induced islet 
hyperptrophy. Furthermore, to confirm a putative ductal ontogeny of these cells, HNF1-
CreER
TM
/Sox9-CreER::Rosa26-lox-β-gal animals should be treated with GABA. The 
examination by X-gal staining of the pancreata of these double transgenic mice will then allow 
us to determine the contribution of duct-lining cells to the islet cell hyperplasia observed in 
animals treated with GABA. Interestingly, the increased cell proliferation observed in GABA-
treated animals is not localized only in the ductal environment but also in the acinar 
compartment. One could therefore wonder the involvement of such cells in the islet overgrowth. 
The pancreas analysis of Ptf1A-CreER::Rosa26-lox-β-gal mice administered with GABA will 
allow us to determine their putative commitment to the β-like cell hyperplasia.  
In addition to Ngn3 re-expression, we observed the expression of a mesenchymal 
marker, vimentin in the same ductal environment and a few vimentin
+
 glucagon
+
/insulin
+
 cells 
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within the islets. Together, our results suggest that the generation of new epithelial/endocrine 
cells may require the conversion of mesenchyme-like cells. However, whether the neogenesis of 
islet cells pass through the activation of a mesenchymal pathway remains to be determined. 
Furthermore, an increased number of somatostatin
+
 cells was observed in close proximity to 
ducts and we also noted the presence of vimentin
+
 somatostatin
+
 cells within the islets. One 
could therefore hypothesize that these cells were regenerated upon GABA treatment prior to 
their conversion into insulin-producing cells. The tracing of somatostatin
+
 cells should give us 
answers. 
 
 GABA treatment can reverse toxin-induced diabetes  3.
We showed that, following streptozotocin treatment, β-like cells can functionally and 
progressively replace their endogenous counterparts. The surviving GABA-treated mice were 
subjected to another round of streptozotocin however, those animals were found to be not 
sensitive to STZ (even though insulin-expressing cells expressed Glut2). A possible explanation 
is that GABA exerts a protective effect in the β-like cell mass as mentioned by Soltani et al. 
(Soltani et al., 2011), a protection that is time-dependant or that the neo-generated β-like cells 
still express some features of α-cells. The mechanisms involved will have to be further 
investigated.  
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General discussion  
I. Induction of Pax4 misexpression in adult α-cells 
Our results provide conclusive evidence that, upon Pax4 induction in α-cells of different 
age groups, these are continuously regenerated and converted into β-like cells in vivo. Upon 
continuous doxycycline administration, these regeneration processes provoked an insulin
+
 cell 
hyperplasia resulting not only in islet hypertrophy but also in islet neogenesis. Such a 
conversion of adult α-cells into β-like cells was found to promote a reawakening of processes 
normally solely detected during development, including: 
 An increase in cell proliferation in the ductal lining and/or epithelium, such cells 
undergoing epithelial-to-mesenchymal transition, as seen during pancreas 
morphogenesis 
 The re-expression of the developmental pro-endocrine gene Ngn3, which is normally 
solely expressed during embryogenesis, in the ductal compartment 
 The conversion of these Ngn3+ cells into endocrine cells 
 The conversion of neo-generated glucagon+ cells into β-like cells upon Pax4 
misexpression   
In addition to Ngn3 re-awakening, the re-expression of several regulators of the 
developmental EMT was also noted. It was therefore suggested that the acquisition of a 
mesenchymal, migratory phenotype upon Ngn3 re-awakening in duct-lining cells resulted in 
their migration and concomitant differentiation into endocrine cells. Hence, a recapitulation of 
the Ngn3-mediated endocrine developmental program was evidenced in this mouse model at 
adult age. However, unlike during embryonic pancreas morphogenesis, the proportion of 
generated endocrine cell subtypes was clearly in the favor of α-cells. Glucagon supplementation 
of Pax4 misexpressing mice was found able to strongly decrease the β-cell hyperplasia, 
suggesting the shortage in the glucagon hormone as a contributor of α-cell neogenesis. 
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Altogether, these data support the notion that, upon Pax4-mediated α-to-β-like cell conversion, 
duct-lining cells re-express the pro-endocrine gene Ngn3 and undergo an EMT prior to 
acquiring a glucagon
+
 cell identity, such cells being further converted into β-like cells upon 
Pax4 misexpression. Consequently, this continuous cycle of regeneration and conversion results 
in oversized islets of Langerhans as a result of β-like cell hyperplasia. Importantly, we provide 
evidence that Pax4 misexpression in adult α-cells, and the subsequent cyclic regeneration 
processes, are able to promote several cycles of regeneration of a complete and fully functional 
β-cell mass in diabetic mice. 
To determine the molecular mechanisms underlying the Pax4-mediated reprogramming 
of α-cells into β-cells, further work was performed: a successive study demonstrated that the 
conversion of glucagon
+
 cells into β-like cells mediated by the ectopic activation of Pax4 is, in 
fact, due to the subsequent repression of Arx gene activity (Collombat et al., 2007; Courtney et 
al., 2011). Indeed, in an animal model permitting the inducible deletion of Arx in adult β-cells, 
hypertrophic islets mainly composed of hyperplastic β-cells were observed. As previously 
reported in mice misexpressing Pax4, the selective loss of Arx in glucagon
+
 cells was found to 
induce their continued neogenesis and conversion into β-like cells. Again, the latter appeared 
fully functional and able to reverse chemically-induced diabetes. Remarkably, the additional 
deletion of Pax4 in adult α-cells did not impact this regeneration process.  
Surprisingly, an increase in the number of somatostatin-expressing δ-cells, abnormally 
located close to the ducts, was observed in the Glu-rtTa::TetO-Pax4 model. As these 
somatostatin
+
 cells were not accumulated over time, one may wonder about their outcome. Our 
laboratory is currently investigating whether δ-cells could also be converted into β-like cells 
upon Pax4 misexpression in α-cells by using Glu-rtTa::TetO-Pax4::Sst-Cre::ROSA26-βGal 
animals. Our recent data show that, indeed, somatostatin-expressing cells can adopt an insulin
+
 
cell identity. This represents the first demonstration of forced conversion of δ-cells into-insulin
+
 
cells. In a second approach, we generated and analyzed mice allowing the misexpression of 
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Pax4 directly in δ-cells. Our results demonstrate an islet hypertrophy provoked by an insulin
+
 
cell hyperplasia, this involving the re-expression of vimentin. These results suggest that adult δ-
cells retain the capacity to transdifferenciate into β-like cells, revealing their plasticity. Ongoing 
work involves the characterization of the molecular mechanisms underlying this δ-to-β-cell 
conversion and the determination of potential of these neo-generated β-like cells to counter 
chemically-induced diabetes. 
II. Chemical induction of -cell-mediated -like cell neogenesis. 
Aiming to gain further insight into the molecular mechanisms underlying the neogenesis 
and conversion of α-cell into β-like cells, we performed transcriptomics analysis of Glu-
rtTA::TetO-Pax4 double transgenic animals treated with doxycycline for increasing periods of 
time as compared to untreated counterparts. Our results showed the involvement of GABA in α-
cell-mediated β-like cell neogenesis. The examination of the GABA-treated animals outlined: 
 A dramatic islet hypertrophy, resulting from a dramatic augmentation in the number 
of insulin
+
 cells. Such insulin
+
 cell hyperplasia was found to progress with the 
duration of GABA treatment. 
 An augmentation in the number of islets. 
 Augmented contents of glucagon+ and somatostatin+ cells 
Taking advantage of our linage tracing tools, we showed that a majority of the additional 
cells observed following GABA treatment have passed through a glucagon and Ngn3-
expressing stage, this process possibly requiring the conversion of mesenchyme-like cells. To 
further ascertain the origin of the supplementary β-like cells, multiple lineage-tracing 
approaches will be used to monitor any cell conversion processes (analyses of animals allowing 
us to follow the progeny of HNF1β
+
 or Sox9
+
 duct cells, Ptf1a
+
 cells and somatostatin-
expressing cells).  In addition, the newly-formed cells are functional and can reverse 
chemically-induced diabetes upon GABA treatment. Taken together, these findings support the 
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notion that GABA can induce β-cell regeneration through an α-to-β-cell conversion process, 
which is similarly observed in the Pax4 model.  
GABA therapy was shown to preserve β-cell mass and prevents diabetes in two mouse 
models of T1DM, ie. In the MDSD mode and wild-type NOD mice (see Section II.A.3 of the 
Results). Remarkably, in severely diabetic mice (MDSD model), GABA therapy regenerated β-
cell mass and completely reversed hyperglycemia (Soltani et al., 2011). This was associated 
with a putative β-cell proliferation, anti-inflammatory and immunoregulatory events, which also 
appear to contribute to the success of therapy. However, the regeneration process of the β-cell 
mass in these models is not clearly understood. The possible involvement of α-to-β-cell 
conversion process will be investigated on NOD mice as we established it in our chemically-
induced diabetes model upon GABA treatment. Furthermore, it was shown that GABA 
suppresses insulitis and systemic inflammatory cytokine production. This holds promise for 
GABA therapy in the field of autoimmunity research, GABA not being only involved in the 
regeneration process of the β-cell.  
In addition, similarly to rodent studies, GABA shows trophic effects on human islets. 
Indeed, to determine whether human -cells could be converted into insulin
+
 cells, human islet 
equivalents were transplanted under the kidney capsule of SCID mice that were subsequently 
treated (or not) with GABA. We observed a clear decrease of human glucagon
+
 cells whereas 
insulin
+
 cells are increased upon GABA treatment. This approach used cannot directly show the 
potential conversion of human -cells into -like cells because of a lack of tracing tools in this 
human model. These results remain though encouraging in the context of T1DM research as this 
« conversion » does not need cell gene manipulating, like in the Pax4 model, and orally 
administered GABA is safe for humans, thus representing a promising new therapeutic agent for 
diabetes. 
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III. Molecular mechanisms involved in the conversion of α-cells to β-cells 
As previously mentioned, Arx and Pax4 are mutually inhibitory at the transcriptional 
level (Collombat et al., 2005) and we have shown that: 
 Upon Pax4 misexpression embryonic (Collombat et al., 2009) and adult (Al-
Hasani et al., 2013) glucagon-producing cells can be converted into β-like cells 
in mice.  
 The inactivation of Arx in glucagon-expressing cells can trigger this process 
(Courtney et al., 2013).  
GABA can induce a decrease in Arx mRNA expression in vitro in α-TC1-6 cell line. If 
Arx downregulation is shown in our in vivo system, one could wonder whether the reduction of 
Arx expression is sufficient to achieve this conversion (like in Arx mutant mice) or whether the 
subsequent increase in Pax4 expression is necessary for this process (like in Pax4-
misexpressing animals (Al-Hasani et al., 2013; Colasante et al., 2009). To differentiate between 
the role of these two transcription factors in this phenomenon, Glu-Cre::Rosa26-lox-β-gal 
animals will be crossed with a Pax4 conditional knockout mouse line. The generated animals 
will be then treated with GABA and analyzed to determine whether similar phenotypic 
alterations are observed.  
Furthermore, as it has been shown that GABAA receptors are expressed in α-cells. 
GABA may potentially mediate its regenerative effect most likely via its receptors (Bailey et al., 
2007; Rorsman et al., 1989; Wendt et al., 2004). To verify this theory, antagonists will be used 
to specifically block these receptors to observe whether this would stop α-to-β-cell conversion.  
The link between GABA/GABA receptors and Arx/Pax4 remains to be established and 
the signaling pathway activated in α-cells by GABA still needs to be determined in our model.   
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IV. Conclusion 
The manipulation of Pax4 and/or Arx expression can lead to the neogenesis and 
subsequent conversion of mature α-cells into β-like cells not only in newborn animals, but also 
in their adult counterparts. The inherent plasticity of mature endocrine cells and the possibility 
to regenerate the β-cell mass by inducing or repressing a single gene have generated significant 
expectation over the possibility of these processes being therapeutically manageable. For 
instance, if we could achieve the controlled activation of Pax4, glucagon
+
 cells may represent a 
cell source that could be used to replace lost β-cells in diabetic patients. In this context, the 
genetic reprogramming of endogenous and regenerating α-cells would open new therapeutic 
possibilities not only for T1DM, characterized by a progressive autoimmune-mediated loss of β-
cells, but also for TD2M, where a reduction of β-cell mass also occurs in the later stage of the 
disease (Karalliedde and Gnudi, 2014; Meier, 2008; Prentki and Nolan, 2006). 
Screening of small molecules (such as GABA) library could lead to the identification of 
chemical tools able to modulate Pax4 and/or Arx expression, as well as their targets in vivo. The 
determination of the molecular triggers implicated in the β-cell regeneration observed in our 
diabetic mice may lead to new findings, including new “drugable” targets of importance for 
human diabetic patients. Also, molecules able to provide protection of neogenerated β-like cells 
in type 1 diabetic patients would clearly represent a significant advance in the context of 
diabetes research. 
  
 
 
 
129 
 
  
Annexe 
Résumé de these 
Le diabète de type 1 (DT1) résulte de la destruction des cellules β productrices d’insuline 
par le système immunitaire. Cette condition représente un enjeu de santé publique majeur car, 
malgré les thérapies actuelles, les patients atteints développent trop souvent des complications 
cardio-vasculaires. Des thérapies alternatives se doivent donc d’être mises au point. Ainsi, 
diverses approches visent à reprogrammer/différencier (in vitro ou in vivo) différents types 
cellulaires pancréatiques afin de générer des cellules β (productrices d’insuline) fonctionnelles. 
Dans ce but, notre laboratoire a notamment montré que les cellules α (productrices de glucagon) 
embryonnaires peuvent être régénérées et converties en cellules β fonctionnelles par 
l’expression ectopique du seul gène Pax4 (un gène normalement impliqué dans la spécification 
embryonnaire du lignage β - (Collombat and Mansouri, 2009)). Dans la première partie de ce 
travail, nous démontrons que les cellules α à l’âge adulte (Al-Hasani et al., 2013) retiennent leur 
capacité de régénération et de conversion en cellules , celles-ci étant fonctionnelles et capable 
de remplacer plusieurs fois l’ensemble des cellules  du pancréas. Cependant, cette approche 
transgénique serait difficile à mettre en oeuvre chez l’homme. De nombreux cribles furent donc 
initiés dans le but de trouver des petites molécules/composés chimiques mimant les effets de 
Pax4. Un composé potentiel, GABA, fut ainsi identifié et caractérisé. Nos résultats démontrent 
que le traitement de souris WT avec GABA résulte en une importante augmentation du nombre 
et de la taille des îlots (provoqués par une hyperplasie en cellules insuline
+
). Par l’utilisation 
d’outils de traçage de lignage cellulaire, nos résultats indiquent que ces cellules « β-like » néo-
générées proviennent de cellules glucagon
+
. Spécifiquement, notre analyse des mécanismes 
d’action de GABA suggèrent une réactivation du programme développemental sous-tendant la 
genèse des cellules  celles-ci étant continuellement régénérées et converties en cellules . Il est 
à noter que ces processus sont capables de régénérer plusieurs fois la totalité de la masse de 
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cellules β après plusieurs cycles d’induction chimique du diabète. Ces résultats offrent ainsi des 
perspectives très prometteuses pour la conception de nouvelles stratégies thérapeutiques dans le 
contexte de la recherche sur le DT1. 
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